<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9280161</article-id><article-id pub-id-type="pmcid-ver">PMC9280161.1</article-id><article-id pub-id-type="pmcaid">9280161</article-id><article-id pub-id-type="pmcaiid">9280161</article-id><article-id pub-id-type="pmid">35847031</article-id><article-id pub-id-type="doi">10.3389/fphar.2022.915565</article-id><article-id pub-id-type="publisher-id">915565</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection</article-title><alt-title alt-title-type="left-running-head">Farooq et al.</alt-title><alt-title alt-title-type="right-running-head">Innate Immune Receptors and SARS-CoV-2</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Farooq</surname><given-names initials="M">Mariya</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1438368/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khan</surname><given-names initials="AW">Abdul Waheed</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/378805/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmad</surname><given-names initials="B">Bilal</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1075382/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="MS">Moon Suk</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/917265/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Choi</surname><given-names initials="S">Sangdun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/24767/overview"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Molecular Science and Technology</institution>, <institution>Ajou University</institution>, <addr-line>Suwon</addr-line>, <country>South Korea</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>S&amp;K Therapeutics, Ajou University</institution>, <addr-line>Suwon</addr-line>, <country>South Korea</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/427255/overview" ext-link-type="uri">Gerhard Wolber</ext-link>, Freie Universit&#228;t Berlin, Germany</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/129670/overview" ext-link-type="uri">Budheswar Dehury</ext-link>, Regional Medical Research Center (ICMR), India</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/653205/overview" ext-link-type="uri">Marko Jukic</ext-link>, University of Maribor, Slovenia</p></fn><corresp id="c001">*Correspondence: Sangdun Choi, <email>sangdunchoi@ajou.ac.kr</email></corresp><fn fn-type="other"><p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>6</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">400058</issue-id><elocation-id>915565</elocation-id><history><date date-type="received"><day>08</day><month>4</month><year>2022</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>06</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>15</day><month>07</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-26 08:25:17.773"><day>26</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Farooq, Khan, Ahmad, Kim and Choi.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Farooq, Khan, Ahmad, Kim and Choi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-13-915565.pdf"/><abstract><p>The innate immune system is the first line of host&#8217;s defense against invading pathogens. Multiple cellular sensors that detect viral components can induce innate antiviral immune responses. As a result, interferons and pro-inflammatory cytokines are produced which help in the elimination of invading viruses. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to Coronaviridae family, and has a single-stranded, positive-sense RNA genome. It can infect multiple hosts; in humans, it is responsible for the novel coronavirus disease 2019 (COVID-19). Successful, timely, and appropriate detection of SARS-CoV-2 can be very important for the early generation of the immune response. Several drugs that target the innate immune receptors as well as other signaling molecules generated during the innate immune response are currently being investigated in clinical trials. In this review, we summarized the current knowledge of the mechanisms underlying host sensing and innate immune responses against SARS-CoV-2 infection, as well as the role of innate immune receptors in terms of their therapeutic potential against SARS-CoV-2. Moreover, we discussed the drugs undergoing clinical trials and the FDA approved drugs against SARS-CoV-2. This review will help in understanding the interactions between SARS-CoV-2 and innate immune receptors and thus will point towards new dimensions for the development of new therapeutics, which can be beneficial in the current pandemic.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>innate immune receptor</kwd><kwd>toll-like receptor</kwd><kwd>RIG-like receptor</kwd><kwd>antiviral response</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Coronaviridae is a family of enveloped positive-sense single-stranded RNA viruses. In the last 19&#160;years, this virus family has been the cause of three different zoonotic outbreaks, and the latest one&#8212;caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#8212;resulted in the COVID-19 pandemic (<xref rid="B53" ref-type="bibr">Gorbalenya et al., 2020</xref>). The family of coronaviridae can be divided into four genera: alpha (<italic toggle="yes">&#945;</italic>), beta (<italic toggle="yes">&#223;</italic>), gamma (<italic toggle="yes">&#947;</italic>), and delta (&#916;) (<xref rid="B171" ref-type="bibr">Sheahan et al., 2020</xref>). <italic toggle="yes">Alpha-</italic> and <italic toggle="yes">Betacoronavirus</italic> members have been reported to infect humans. Being the seventh member of Coronaviridae involved in a zoonosis, SARS-CoV-2 belongs to the genus <italic toggle="yes">Betacoronavirus</italic> (<xref rid="B107" ref-type="bibr">Li X. et al., 2020</xref>). With a particle size of 125&#160;nm, this ball-shaped virus has club-shaped appendages; a spike protein embedded into the envelope, giving it a crown-like appearance in an electron micrograph, hence the name coronavirus (<xref rid="B5" ref-type="bibr">Anderson and Schneider, 2012</xref>).</p><p>The virus was first identified in China, and the World Health Organization (WHO) used a provisional nonspecific name: &#8220;2019 novel coronavirus&#8221; (2019-nCoV). Later, based on the phylogenetic analysis of the other coronaviruses, the Coronavirus Study Group of the International Committee on Virus Taxonomy suggested renaming it as SARS-CoV-2 (<xref rid="B8" ref-type="bibr">Awadasseid et al., 2020</xref>).</p><p>Coronaviruses have one of the largest RNA genomes, with a size ranging between 26 and 32&#160;kb. SARS-CoV-2 has a genome length of 30&#160;kbp, and the genome is flanked by 3&#8242; and 5&#8242; untranslated regions and contains 15 open reading frames (ORFs). The genome translates into a polyprotein of approximately 800&#160;kDa. There are 4 structural proteins that are encoded by 2&#8211;14 open reading frames: Nucleocapsid (N), envelope (E) and Spike (S) and Membrane protein (M). The structural proteins play their role in virion assembly and infection; and the non-structural proteins are involved in the replication cycle of the virus (<xref rid="B123" ref-type="bibr">Mirza and Froeyen, 2020</xref>). The shape of the virus is maintained by the M protein. The M protein binds to Nucleocapsid, which constitutes almost 1% of the expressed protein during infection, and it binds to the viral RNA genome through its two different subunits. It helps to package the genome inside the virion (<xref rid="B24" ref-type="bibr">Chen Y. et al., 2020</xref>; <xref rid="B76" ref-type="bibr">Jackson et al., 2021a</xref>; <xref rid="B189" ref-type="bibr">Tugaeva et al., 2021</xref>). E and M interact to form the envelope of the virus. Receptor Binding Domain (RBD) of Spike, that is glycoprotein in nature, is responsible for interaction between virus and the host cell receptors thus helps the virus to enter the cell (<xref rid="B113" ref-type="bibr">Luan et al., 2020</xref>).</p><p>The first two ORFs encode nonstructural proteins. There are 16 of these proteins, which are Nsp1 through Nsp16. Nsp1 (protein ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476805" ext-link-type="uri">YP_009725297.1</ext-link>) has a length of 180 amino acid residues (aa). Nsp2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="YP_009725298.1">YP_009725298.1</ext-link>) consists of 638 aa. Nsp3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476807" ext-link-type="uri">YP_009725299.1</ext-link>) consists of 1945 aa. It contains the following domains: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), and adenosine diphosphate-ribose 1&#8243;-phosphatase (ADRP). Nsp4 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476808" ext-link-type="uri">YP_009725300.1</ext-link>) has a length of 500 aa and contains transmembrane domain 2. Nsp5 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476809" ext-link-type="uri">YP_009725301.1</ext-link>) is 3C-like proteinase (3Cl-pro), and its length is 306 aa. Nsp6 (protein ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476810" ext-link-type="uri">YP_009725302.1</ext-link>) is a putative transmembrane domain having a length of 290 aa. Nsp7 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476811" ext-link-type="uri">YP_009725303.1</ext-link>) and Nsp8 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476812" ext-link-type="uri">YP_009725304.1</ext-link>) are proposed cofactors for the polymerase. Lengths of their genes are 249 and 339 nucleotides encoding an 83 aa protein and 198 aa proteins, respectively. Nsp9 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476813" ext-link-type="uri">YP_009725305.1</ext-link>) is a single-stranded RNA (ssRNA)-binding protein whose length is 113 aa. Nsp10 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476814" ext-link-type="uri">YP_009725306.1</ext-link>) has a length of 139 aa and is also called CysHis; it has previously been known as growth factor-like protein (GFL). The length of Nsp11 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/YP_009725295.1" ext-link-type="uri">YP_009725295.1</ext-link>) is 13 aa. Nsp12 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476815" ext-link-type="uri">YP_009725307.1</ext-link>), with a length of 932 aa, carries an RNA-dependent RNA polymerase (RdRp) domain and NIRAN domain. Nsp13 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476816" ext-link-type="uri">YP_009725308.1</ext-link>) is helicase, which contains a zinc-binding domain (NTPase/helicase domain (HEL)) and RNA 5&#8242;-triphosphatase domain and has a length of 601 aa. Nsp14 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476817" ext-link-type="uri">YP_009725309.1</ext-link>) is 3&#8242;-to-5&#8242; exonuclease and has a length of 521 aa. Nsp15 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476818" ext-link-type="uri">YP_009725310.1</ext-link>), with a length of 346 aa, is endoRNase. Nsp16 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="YP_009725311">YP_009725311</ext-link>) is 2&#8242;-O-ribose methyltransferase and is 298 aa long. Structural and nonstructural proteins and their details are summarized in <xref rid="T1" ref-type="table">Tables 1</xref> and <xref rid="T2" ref-type="table">2</xref> (extracted from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/gene/43740578" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/gene/43740578</ext-link>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Summary of the Non-structural proteins.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Sr No.</th><th align="center" rowspan="1" colspan="1">Protein</th><th align="center" rowspan="1" colspan="1">GenBank ID</th><th align="center" rowspan="1" colspan="1">Start point (nt)</th><th align="center" rowspan="1" colspan="1">End point (nt)</th><th align="center" rowspan="1" colspan="1">Length (nt)</th><th align="center" rowspan="1" colspan="1">Length (aa)</th><th align="center" rowspan="1" colspan="1">MW (kDa)</th><th align="center" rowspan="1" colspan="1">Crystal Structure</th><th align="center" rowspan="1" colspan="1">Stability</th><th align="center" rowspan="1" colspan="1">Function</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Nsp1</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476805" ext-link-type="uri">YP_009725297.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">266</td><td align="char" char="." rowspan="1" colspan="1">805</td><td align="char" char="." rowspan="1" colspan="1">540</td><td align="char" char="." rowspan="1" colspan="1">180</td><td align="char" char="." rowspan="1" colspan="1">19.9</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">Leader protein</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Nsp2</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476806" ext-link-type="uri">YP_009725298.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">806</td><td align="char" char="." rowspan="1" colspan="1">2719</td><td align="char" char="." rowspan="1" colspan="1">1914</td><td align="char" char="." rowspan="1" colspan="1">639</td><td align="char" char="." rowspan="1" colspan="1">70.5</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">Disruption of the host cell environment</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Nsp3</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476807" ext-link-type="uri">YP_009725299.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">2720</td><td align="char" char="." rowspan="1" colspan="1">8554</td><td align="char" char="." rowspan="1" colspan="1">5835</td><td align="char" char="." rowspan="1" colspan="1">1935</td><td align="char" char="." rowspan="1" colspan="1">217.2</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">Papain Like Protease</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Nsp4</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476808" ext-link-type="uri">YP_009725300.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">8555</td><td align="char" char="." rowspan="1" colspan="1">10054</td><td align="char" char="." rowspan="1" colspan="1">1500</td><td align="char" char="." rowspan="1" colspan="1">500</td><td align="char" char="." rowspan="1" colspan="1">56.2</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">Contains transmembrane domain 2</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Nsp5</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476809" ext-link-type="uri">YP_009725301.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">10055</td><td align="char" char="." rowspan="1" colspan="1">10972</td><td align="char" char="." rowspan="1" colspan="1">918</td><td align="char" char="." rowspan="1" colspan="1">306</td><td align="char" char="." rowspan="1" colspan="1">33.5</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">3C-like proteinase</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Nsp6</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476810" ext-link-type="uri">YP_009725302.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">10973</td><td align="char" char="." rowspan="1" colspan="1">11842</td><td align="char" char="." rowspan="1" colspan="1">870</td><td align="char" char="." rowspan="1" colspan="1">293</td><td align="char" char="." rowspan="1" colspan="1">33.7</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">Putative transmembrane domain</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Nsp7</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476811" ext-link-type="uri">YP_009725303.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">11843</td><td align="char" char="." rowspan="1" colspan="1">12091</td><td align="char" char="." rowspan="1" colspan="1">249</td><td align="char" char="." rowspan="1" colspan="1">83</td><td align="char" char="." rowspan="1" colspan="1">92.9</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unstable</td><td rowspan="1" colspan="1">Co-factor of Nsp12</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Nsp8</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476812" ext-link-type="uri">YP_009725304.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">12092</td><td align="char" char="." rowspan="1" colspan="1">12685</td><td align="char" char="." rowspan="1" colspan="1">339</td><td align="char" char="." rowspan="1" colspan="1">210</td><td align="char" char="." rowspan="1" colspan="1">23.2</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">Co-factor of Nsp12</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Nsp9</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476813" ext-link-type="uri">YP_009725305.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">12686</td><td align="char" char="." rowspan="1" colspan="1">13024</td><td align="char" char="." rowspan="1" colspan="1">339</td><td align="char" char="." rowspan="1" colspan="1">111</td><td align="char" char="." rowspan="1" colspan="1">11.9</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">ssRNA-binding protein</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Nsp10</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476814" ext-link-type="uri">YP_009725306.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">13025</td><td align="char" char="." rowspan="1" colspan="1">13441</td><td align="char" char="." rowspan="1" colspan="1">417</td><td align="char" char="." rowspan="1" colspan="1">145</td><td align="char" char="." rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">CysHis; formerly known as growth-factor-like protein (GFL)</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">Nsp11</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476820" ext-link-type="uri">YP_009725312.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">13442</td><td align="char" char="." rowspan="1" colspan="1">13480</td><td align="char" char="." rowspan="1" colspan="1">39</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">23.7</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">Not known</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">Nsp12</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476815" ext-link-type="uri">YP_009725307.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">13442</td><td align="char" char="." rowspan="1" colspan="1">16236</td><td align="char" char="." rowspan="1" colspan="1">2696</td><td align="char" char="." rowspan="1" colspan="1">932</td><td align="char" char="." rowspan="1" colspan="1">106.7</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">RNA-dependent RNA polymerase</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">Nsp13</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476816" ext-link-type="uri">YP_009725308.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">16237</td><td align="char" char="." rowspan="1" colspan="1">19039</td><td align="char" char="." rowspan="1" colspan="1">1803</td><td align="char" char="." rowspan="1" colspan="1">601</td><td align="char" char="." rowspan="1" colspan="1">66.9</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">Helicase</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">Nsp14</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476817" ext-link-type="uri">YP_009725309.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">18040</td><td align="char" char="." rowspan="1" colspan="1">19620</td><td align="char" char="." rowspan="1" colspan="1">1581</td><td align="char" char="." rowspan="1" colspan="1">527</td><td align="char" char="." rowspan="1" colspan="1">59.8</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">3&#8242;-to-5&#8242; exonuclease</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">Nsp15</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476818" ext-link-type="uri">YP_009725310.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">19621</td><td align="char" char="." rowspan="1" colspan="1">20658</td><td align="char" char="." rowspan="1" colspan="1">1038</td><td align="char" char="." rowspan="1" colspan="1">346</td><td align="char" char="." rowspan="1" colspan="1">38.8</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">EndoRNAse</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">Nsp16</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/1802476819" ext-link-type="uri">YP_009725311.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">20659</td><td align="char" char="." rowspan="1" colspan="1">21552</td><td align="char" char="." rowspan="1" colspan="1">894</td><td align="char" char="." rowspan="1" colspan="1">298</td><td align="char" char="." rowspan="1" colspan="1">33.3</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Stable</td><td rowspan="1" colspan="1">2&#8242;-O-ribose methyltransferase</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Summary of the Structural proteins.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Sr. No.</th><th align="center" rowspan="1" colspan="1">Protein</th><th align="center" rowspan="1" colspan="1">GenBank ID</th><th align="center" rowspan="1" colspan="1">Start point (nt)</th><th align="center" rowspan="1" colspan="1">End point (nt)</th><th align="center" rowspan="1" colspan="1">Length (nt)</th><th align="center" rowspan="1" colspan="1">Length (aa)</th><th align="center" rowspan="1" colspan="1">MW</th><th align="center" rowspan="1" colspan="1">Crystal structure</th><th align="center" rowspan="1" colspan="1">Stability</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="center" rowspan="1" colspan="1">GeneID:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/gene/43740568" ext-link-type="uri">43740568</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">21563</td><td align="char" char="." rowspan="1" colspan="1">25384</td><td align="char" char="." rowspan="1" colspan="1">3822</td><td align="char" char="." rowspan="1" colspan="1">1273</td><td align="char" char="." rowspan="1" colspan="1">141.2</td><td align="center" rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Stable</td></tr><tr><td rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Nucleocapsid phosphoprotein</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/YP_009724397.2" ext-link-type="uri">YP_009724397.2</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">28274</td><td align="char" char="." rowspan="1" colspan="1">29533</td><td align="char" char="." rowspan="1" colspan="1">1260</td><td align="char" char="." rowspan="1" colspan="1">419</td><td align="char" char="." rowspan="1" colspan="1">45.6</td><td align="center" rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Unstable</td></tr><tr><td rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Membrane protein</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/YP_009724393.1" ext-link-type="uri">YP_009724393.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">26523</td><td align="char" char="." rowspan="1" colspan="1">27191</td><td align="char" char="." rowspan="1" colspan="1">669</td><td align="char" char="." rowspan="1" colspan="1">222</td><td align="char" char="." rowspan="1" colspan="1">25.1</td><td align="center" rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Stable</td></tr><tr><td rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Envelop</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/protein/YP_009724392.1" ext-link-type="uri">YP_009724392.1</ext-link>
</td><td align="char" char="." rowspan="1" colspan="1">26245</td><td align="char" char="." rowspan="1" colspan="1">26472</td><td align="char" char="." rowspan="1" colspan="1">228</td><td align="char" char="." rowspan="1" colspan="1">75</td><td align="char" char="." rowspan="1" colspan="1">8.4</td><td align="center" rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Stable</td></tr></tbody></table></table-wrap><p>The virus primarily infects the lung cells that express angiotensin-converting enzyme 2 (ACE2, which is a virus receptor) and is thus responsible for a pneumonia-like disease. ACE2, the main receptor of SARS-CoV-2, is present on various types of cells in the human body, e.g., cells in the heart, kidneys, liver, gastrointestinal tract, nervous system, endocrine system, and some skin sites (<xref rid="B221" ref-type="bibr">Zheng YY. et al., 2020</xref>; <xref rid="B141" ref-type="bibr">Pandey et al., 2020</xref>). Other receptors which also mediate viral entry include neuropilin-1, AXL, and antibody-Fc&#947;R complexes (<xref rid="B217" ref-type="bibr">Zhang et al., 2021b</xref>). Neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, enhances SARS-CoV-2 infectivity. NRP1 is highly expressed in the respiratory and olfactory epithelium, with endothelial and epithelial cells expressing the most. The spike protein&#8217;s furin-cleaved S1 fragment binds directly to cell surface NRP1 and disrupting its interaction with a small-molecule inhibitor or monoclonal antibodies inhibited viral infection in cell culture (<xref rid="B18" ref-type="bibr">Cantuti-Castelvetri et al., 2020</xref>). The other coronaviruses cause an upper-respiratory-tract infection, whereas SARS-CoV-2 causes a lower-respiratory-tract disease by infecting ciliated cells and type 2 alveolar epithelial cells in the lungs (<xref rid="B7" ref-type="bibr">Astuti and Ysrafil, 2020</xref>). SARS-CoV-2 has been detected in the upper respiratory tract too, and these data indicate that the nasopharynx is a site of viral replication. The Spike protein of SARS-CoV and that of SARS-CoV-2 are 76.5% similar, and the binding between the Spike of SARS-CoV-2 and ACE2 is stronger than the binding between SARS-CoV Spike and ACE2 (<xref rid="B213" ref-type="bibr">Zhang et al., 2020</xref>).</p></sec><sec id="s2"><title>2 The Replication Cycle</title><p>Enveloped viruses either enter the cell through direct fusion with the cell membrane and inject their genome or use the alternative mechanism, which involves endocytic machinery. When viruses enter the cell by either of these mechanisms, an additional step of activation is required. For SARS-CoV-2, in the case of direct fusion, the activation is implemented by proteolytic cleavage of Spike, whereas in the endosomal pathway, acidic pH in the endosome is required for successful virus entry. Acidic pH helps the viral and endosomal membranes to fuse and activate proteases. Therefore, the entry of the virus through direct fusion is independent of cellular pH as opposed to the endosomal entry (<xref rid="B211" ref-type="bibr">Yuki et al., 2020</xref>).</p><p>SARS-CoV-2 is an RNA virus that carries the enzymes required for its replication, because host cells that do not contain enzymes for replicating and translating the RNA genome. Out of the 16 nonstructural proteins that the SARS-CoV-2 genome codes for, two proteins are viral proteases that are responsible for the cleavage of the polyprotein synthesized via translation of the viral genomic RNA. The virus then translates the nonstructural proteins that are required for the replication of the viral genome. After the synthesis of structural proteins, the virion assembly begins. RNA gets packaged inside the nucleocapsid, and the virions are released from the cell, which are now ready to infect other cells (<xref rid="B146" ref-type="bibr">Poduri et al., 2020</xref>).</p><p>SARS-CoV-2 spike is a homotrimeric glycoprotein of 150&#160;kDa. The receptor binding domain (RBD) of spike binds to its receptor called human ACE2 and facilitates the entry of the virus into the host cell (<xref rid="B66" ref-type="bibr">Hoffmann et al., 2020</xref>). The virus is activated by the cleavage of the spike glycoprotein into two subunits&#8212;S1 and S2&#8212;by host cellular proteases, particularly TMPRSS2 (or by lysosomal cathepsins if the virus enters via the endosomal pathway) (<xref rid="B169" ref-type="bibr">Shang et al., 2020a</xref>; <xref rid="B67" ref-type="bibr">H&#246;rnich et al., 2021</xref>). The first subunit determines cellular tropism, whereas the second one mediates the fusion of a host cell with the virus membrane. After the fusion, the virus enters the cell. Once the virus is inside the cell, it releases its genome into the cytoplasm, where the replication of the genome and its translation into the structural and nonstructural proteins take place (<xref rid="B170" ref-type="bibr">Shang et al., 2020b</xref>). SARS-CoV-2 assembly begins with the coating of genomic RNA by the nucleocapsid protein, forming nucleocapsid structures that bud into the endoplasmic reticulum-Golgi intermediate compartment, thereby giving rise to a lipid bilayer containing the viral spike, membrane, and envelope proteins resulting in the formation of the mature virion (<xref rid="B77" ref-type="bibr">Jackson et al., 2021b</xref>). The latter then leaves the cell through exocytosis as shown in <xref rid="F1" ref-type="fig">Figure 1</xref> (<xref rid="B122" ref-type="bibr">Mendon&#231;a et al., 2021</xref>; <xref rid="B205" ref-type="bibr">Yadav et al., 2021</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Replication cycle of SARS-CoV-2. SARS-CoV-2 enters the cell either by endocytosis or by receptor mediated membrane fusion. The genome of the virus is released and is subjected to replication and translation. Viral proteins are synthesized, and single stranded RNA is produced, both of which are assembled with the help of Endoplasmic reticulum and Golgi apparatus. The virions thus assembled are then transported outside the body by exocytosis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-915565-g001.jpg"/></fig><p>The virus downregulates ACE2, as a result of which, the renin angiotensin aldosterone system is dysregulated. This problem leads to tissue injury, vasoconstriction, and increased vascular permeability. Endothelial cells are damaged because of the virus and undergo apoptosis, which results in decreased fibrinolysis and elevated thrombin production. SARS-CoV-2 excessively activates innate immunity and inhibits interferon (IFN) signaling. Consequently, the host develops cytokine release syndrome, wherein excessive production of cytokines occurs, and interleukin 1 beta (IL-1&#946;), IL-6, and IL-10 levels increase. Lymphopenia, a typical condition in severe infections, has been detected in 60&#8211;70% of the patients (<xref rid="B54" ref-type="bibr">Gupta et al., 2020</xref>).</p><p>SARS-CoV-2 infection has a wide variety of clinical manifestations. They range from asymptomatic cases to mild and severe symptoms, and even death. Asymptomatic patients play an especially important role in the COVID-19 pandemic because they spread the infection further without showing any symptoms. It has been reported that 40&#8211;50% of the patients were asymptomatic (<xref rid="B139" ref-type="bibr">Oran and Topol, 2020</xref>; <xref rid="B195" ref-type="bibr">Wang et al., 2020</xref>). Five common clinical manifestations include fever, malaise, cough, sputum secretion, and dyspnea. Comparatively less common symptoms are neurological problems, myalgia, sneezing, sore throat, rhinitis, goosebumps, chest pain, diarrhea etc (<xref rid="B34" ref-type="bibr">da Rosa Mesquita et al., 2021</xref>). According to data published in 2020, only 5&#8211;10% of all infected individuals develop a severe disease, which includes pneumonia and acute respiratory failure (<xref rid="B152" ref-type="bibr">Raghu and Wilson, 2020</xref>). However, the rate of development of severe disease varies based on the age as well as gender (<xref rid="B147" ref-type="bibr">Poletti et al., 2021</xref>; <xref rid="B64" ref-type="bibr">Herrera-Esposito and de los Campos, 2022</xref>).</p></sec><sec id="s3"><title>3 Transmission routes</title><p>SARS-CoV-2 is a respiratory virus that primarily infects lower respiratory tract along with the upper respiratory tract and gastrointestinal tract (<xref rid="B114" ref-type="bibr">Ludwig and Zarbock, 2020</xref>). It was noticed that when human bronchial epithelial cells were infected with SARS-CoV-2 at a biosafety level 3 lab facility, a large number of virions being produced and released by the cells could be observed by scanning electron microscopy (<xref rid="B43" ref-type="bibr">Ehre, 2020</xref>). The main route of transmission in air but it can also be transmitted through the respiratory droplets as well (<xref rid="B148" ref-type="bibr">Port et al., 2022</xref>). The main route of transmission is air, but the virus can be transmitted through respiratory droplets as well (<xref rid="B148" ref-type="bibr">Port et al., 2022</xref>). Aerosols are also believed to be a possible means of transmission, especially in closed environment (<xref rid="B184" ref-type="bibr">Tellier, 2022</xref>; <xref rid="B198" ref-type="bibr">Wilson et al., 2022</xref>). Some authors reported that SARS-CoV-2 can survive and maintain its infectivity in an aerosol for hours (<xref rid="B191" ref-type="bibr">Van Doremalen et al., 2020</xref>).</p><p>Nonetheless, the virus has other transmission pathways in addition to the respiratory route. In a study on organoids, it was proved that the virus is capable of infecting enterocytes (gut cells) that abundantly express ACE2 (the virus receptor). Viral RNA was detected in rectal swabs, suggesting that the fecal-oral route is also a possible transmission pathway (<xref rid="B223" ref-type="bibr">Zhou et al., 2020</xref>). Individuals infected with SARS-CoV-2 exhibit gastrointestinal symptoms including diarrhea, nausea, vomiting, and abdominal pain. This observation also points to the possibility that SARS-CoV-2 is an enteric virus (<xref rid="B42" ref-type="bibr">Ding and Liang, 2020</xref>; <xref rid="B129" ref-type="bibr">Moura et al., 2022</xref>). There is a report of persistent virus shedding by children through feces after their nasopharyngeal swabs tested negative for viral RNA (<xref rid="B204" ref-type="bibr">Xu et al., 2020b</xref>). Another study revealed virus shedding through feces even after the disappearance of the virus from nasopharyngeal area (<xref rid="B20" ref-type="bibr">Chen C. et al., 2020</xref>). It has been found that the mucosal membrane may also be involved in the transmission of SARS-CoV-2. Close contact with the eyes, nose, or mouth, whether direct or indirect, can lead to COVID-19 transmission (<xref rid="B112" ref-type="bibr">Lu et al., 2021</xref>).</p></sec><sec id="s4"><title>4 Innate immune sensors and recognition of SARS-CoV-2</title><p>In order to maintain cell homeostasis and survival, all living organisms require immediate cellular responses to pathogen invasion (<xref rid="B13" ref-type="bibr">Buchmann, 2014</xref>). Pattern recognition receptors (PRRs) are germline-encoded cellular receptors that recognize certain patterns of &#8216;non-self&#8217; and &#8216;danger&#8217; molecules, referred to as &#8216;pathogen-associated molecular patterns&#8217; (PAMPs) and &#8216;danger-associated molecular patterns&#8217; (DAMPs) respectively (DAMPs). PAMPs or DAMPs activate PRRs in mammals, triggering innate immune responses and the production of numerous IFNs and proinflammatory cytokines (<xref rid="B59" ref-type="bibr">Hansen et al., 2011</xref>). Several PRRs have been discovered in recent decades, including Toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), C-type lectin receptors (CLRs), AIM2-like receptors (ALRs), cyclic GMP-AMP synthase (cGAS) and retinoic acid-inducible gene I (RIG-I)-like receptors (<xref rid="B130" ref-type="bibr">Mu&#241;oz-Wolf and Lavelle, 2016</xref>). TLRs and RLRs are two of the most important receptors for recognizing RNA virus infection and activating antiviral IFN programs (<xref rid="B22" ref-type="bibr">Chen et al., 2017</xref>) (<xref rid="F2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Important pattern recognition receptors and cellular proteins which can serve as potential therapeutic targets against SARS-CoV-2. Different cellular receptors can be activated by viral proteins and viral genome. Structural proteins of SARS-CoV-2 activate membrane bound toll-like receptors and they activate NF-&#954;B by MyD88 activation. Endosomal TLRs are activated by viral structural as well as non-structural proteins, which also activate NF-&#954;B and downstream signaling. Thus, proinflammatory cytokines are released from the cell. Proinflammatory cytokines further activate the NLRP3 inflammasome which leads to secretion of IL-1&#946; and IL-18. NLRP3 inflammasome is activated directly too by viral proteins including ORF3a and non-structural proteins. STING expression is also dysregulated by ORF3a, and 3CLpro. Nucleocapsid and Membrane protein blocks IRF3 phosphorylation and attenuates interferon response. It also interferes with RIG-1. Various SARS-CoV-2 proteins have been reported to interfere with RIG-like receptor signaling.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-915565-g002.jpg"/></fig><sec id="s4-1"><title>4.1 TLRs and SARS-CoV-2</title><p>
<italic toggle="yes">Toll</italic> was first identified as an antifungal gene that is key to the <italic toggle="yes">Drosophila</italic> immune system. Subsequent studies further elucidated the fundamental role of TLRs in innate immune sensing in mammals (<xref rid="B99" ref-type="bibr">Lemaitre et al., 1996</xref>; <xref rid="B181" ref-type="bibr">Takeda and Akira, 2005</xref>). To date, multiple TLRs have been discovered, and their functions have been elucidated. In humans, 10 TLRs (TLR1&#8211;TLR10) have been identified, whereas in mice, 12 TLRs (TLR1&#8211;TLR9 and TLR11&#8211;TLR13) have been discovered, and their functions have been studied (<xref rid="B85" ref-type="bibr">Kawasaki and Kawai, 2014</xref>). Each TLR can identify PAMPs that are composed of microbial components such as nucleic acids, lipoproteins, and lipids (<xref rid="B84" ref-type="bibr">Kawai and Akira, 2010</xref>). Cell surface TLRs (TLR1/2, 2/6, 4, 5) detect lipids, lipoproteins, and proteins present in microbial membranes as shown in <xref rid="T3" ref-type="table">table 3</xref>. Endosomal TLRs 3,7,8 and 9 recognize bacterial and viral genomic components; TLR7/TLR8 receptors detect ssRNA, TLR3 detect double-stranded RNA (dsRNA), TLR9 recognizes double stranded DNA in endosomal compartments and recognize viruses that enter through endocytosis (<xref rid="B83" ref-type="bibr">Kawai and Akira, 2007</xref>). RLRs and TLRs launch antiviral defense mechanisms as soon as these receptors are engaged by RNA ligands. TLRs bind to adapter proteins such as myeloid differentiation primary response 88 (MyD88; for TLR7 and TLR8) and TIR domain-containing adapter inducing IFN-&#946; (TRIF; for TLR3) to initiate downstream signaling cascades (<xref rid="B193" ref-type="bibr">Vidya et al., 2018</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>TLRs, their ligands, cellular localization, and the adaptor molecules.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">TLRs</th><th align="center" rowspan="1" colspan="1">Ligands</th><th align="center" rowspan="1" colspan="1">Primary localization</th><th align="center" rowspan="1" colspan="1">Adapter Molecule</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">TLR1</td><td rowspan="1" colspan="1">Triacyl lipopolypepties</td><td rowspan="1" colspan="1">Cell surface</td><td rowspan="1" colspan="1">MyD88</td><td rowspan="1" colspan="1">
<xref rid="B15" ref-type="bibr">Buwitt-Beckmann et al. (2006)</xref>; <xref rid="B174" ref-type="bibr">Shinkai et al. (2006)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR2</td><td rowspan="1" colspan="1">Lipoproteins, zymosan, Pam3CSK4</td><td rowspan="1" colspan="1">Cell surface</td><td rowspan="1" colspan="1">MyD88</td><td rowspan="1" colspan="1">
<xref rid="B174" ref-type="bibr">Shinkai et al. (2006)</xref>; <xref rid="B48" ref-type="bibr">Farhat et al. (2008)</xref>; <xref rid="B73" ref-type="bibr">Irvine et al. (2013)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR3</td><td rowspan="1" colspan="1">dsRNA</td><td rowspan="1" colspan="1">Intracellular</td><td rowspan="1" colspan="1">TRIF</td><td rowspan="1" colspan="1">
<xref rid="B101" ref-type="bibr">Leonard et al. (2008)</xref>; <xref rid="B98" ref-type="bibr">Lee et al. (2013)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR4</td><td rowspan="1" colspan="1">LPS, Viral envelope of glycoproteins</td><td rowspan="1" colspan="1">Cell surface and Intracellular</td><td rowspan="1" colspan="1">MyD88 and TRIF</td><td rowspan="1" colspan="1">
<xref rid="B196" ref-type="bibr">Wang et al. (2016)</xref>; <xref rid="B121" ref-type="bibr">McGettrick and O&#8217;Neill, (2010)</xref>; <xref rid="B26" ref-type="bibr">Cheng et al. (2015)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR5</td><td rowspan="1" colspan="1">Flagellin</td><td rowspan="1" colspan="1">Cell surface</td><td rowspan="1" colspan="1">MyD88</td><td rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">Crellin et al. (2005)</xref>; <xref rid="B71" ref-type="bibr">Huleatt et al. (2008)</xref>; <xref rid="B70" ref-type="bibr">Huh et al. (2014)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR6</td><td rowspan="1" colspan="1">Diacyl lipopeptides</td><td rowspan="1" colspan="1">Cell surface</td><td rowspan="1" colspan="1">MyD88</td><td rowspan="1" colspan="1">
<xref rid="B142" ref-type="bibr">Pandey et al. (2014)</xref>; <xref rid="B174" ref-type="bibr">Shinkai et al. (2006)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR7</td><td rowspan="1" colspan="1">ssRNA</td><td rowspan="1" colspan="1">Intracellular</td><td rowspan="1" colspan="1">MyD88</td><td rowspan="1" colspan="1">
<xref rid="B41" ref-type="bibr">Diebold et al. (2004)</xref>; <xref rid="B117" ref-type="bibr">Maeda and Akira, (2016)</xref>; <xref rid="B98" ref-type="bibr">Lee et al. (2013)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR8</td><td rowspan="1" colspan="1">ssRNA</td><td rowspan="1" colspan="1">Intracellular</td><td rowspan="1" colspan="1">MyD88</td><td rowspan="1" colspan="1">
<xref rid="B144" ref-type="bibr">Pelka et al. (2016)</xref>; <xref rid="B173" ref-type="bibr">Shimizu, 2017</xref>) (<xref rid="B74" ref-type="bibr">Ishii et al., 2014</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR9</td><td rowspan="1" colspan="1">Unmethylated CpG- rich DNA, mitochondrial DNA</td><td rowspan="1" colspan="1">Intracellular</td><td rowspan="1" colspan="1">MyD88</td><td rowspan="1" colspan="1">
<xref rid="B194" ref-type="bibr">Wagner, (2004)</xref>; <xref rid="B214" ref-type="bibr">Zhang et al. (2014)</xref>; <xref rid="B98" ref-type="bibr">Lee et al. (2013)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR10</td><td rowspan="1" colspan="1">Gp41</td><td rowspan="1" colspan="1">Cell surface</td><td rowspan="1" colspan="1">MyD88</td><td rowspan="1" colspan="1">
<xref rid="B63" ref-type="bibr">Henrick et al. (2019)</xref>; <xref rid="B60" ref-type="bibr">Hasan et al. (2005)</xref>
</td></tr></tbody></table></table-wrap><sec id="s4-1-1"><title>4.1.1 Membrane-Bound TLRs</title><p>Studies have revealed that TLR3<sup>&#8722;/&#8722;</sup>-, TLR4<sup>&#8722;/&#8722;</sup>-, and TRIF-related adaptor molecule (TRAM)<sup>&#8722;/&#8722;</sup>- deficient mice are more vulnerable to SARS-CoV infection and show greater transient weight loss when compared to wild-type mice. Mice lacking TRIF (the adaptor protein for TLR3 and TLR4) are more susceptible to SARS-CoV infection (<xref rid="B39" ref-type="bibr">Devarajan and Vaseghi, 2021</xref>). Various <italic toggle="yes">in silico</italic> and <italic toggle="yes">in vitro</italic> studies point to the involvement of TLRs in the pathogenesis of COVID-19 (<xref rid="B28" ref-type="bibr">Choudhury and Mukherjee, 2020a</xref>; <xref rid="B145" ref-type="bibr">Plan&#232;s et al., 2021</xref>). The injection of INNA-051 (a TLR2/6 agonist) dramatically lowers the amount of viral RNA in the nose and throat in a ferret model (<xref rid="B150" ref-type="bibr">Proud et al., 2021</xref>). Another paper indicated that the SARS-CoV-2 envelope protein can upregulate production of pro-inflammatory cytokine through TLR2-dependent signaling (<xref rid="B145" ref-type="bibr">Plan&#232;s et al., 2021</xref>). It is also reported that TLR2 and MyD88 expression affects the severity of the disease. Moreover, TLR2 recognizes the SARS-CoV-2 envelope protein as its ligand and then induces the production of pro-inflammatory cytokines (<xref rid="B165" ref-type="bibr">Sariol and Perlman, 2021</xref>; <xref rid="B220" ref-type="bibr">Zheng et al., 2021</xref>). Some studies found that the spike protein of SARS-CoV-2 induces a pro-inflammatory response through a TLR-2 mediated pathway (<xref rid="B87" ref-type="bibr">Khan et al., 2021</xref>).</p><p>TLR4 is expressed in both immune cells and tissue resident cells. The expression of TLR4 and TLR7 was found to be significantly upregulated in mucosal membrane cells in the children with COVID-19; same study reported expression of pro-inflammatory cytokines at both the transcriptional and translational levels (<xref rid="B51" ref-type="bibr">Gankovskaya et al., 2021</xref>). TLR4 mediated inflammatory cytokines were found to be upregulated in another study conducted by Sohn et al. (<xref rid="B176" ref-type="bibr">Sohn et al., 2020</xref>). It has been proposed that the spike protein of SARS-CoV-2 upregulates TLR4, which ultimately increases the expression of ACE2 on cells and facilitates the entry of SARS-CoV-2. This hypothesis is supported by the finding that ACE2 is expressed by 1&#8211;2% of cells in the lungs. Due to ACE2 upregulation mediated by TLR-4, SARS-CoV-2 is able to infect more heart and lung cells (<xref rid="B62" ref-type="bibr">Heads, 2020</xref>; <xref rid="B1" ref-type="bibr">Aboudounya et al., 2021</xref>; <xref rid="B58" ref-type="bibr">Han et al., 2021</xref>; <xref rid="B118" ref-type="bibr">Manik et al., 2022</xref>). TAK-242, an anti-inflammatory molecule which inhibits TLR4 mediated signaling, was found to reduce the level of TNF-&#945; and IL-6 in BV-2 mouse microglial cell line (<xref rid="B138" ref-type="bibr">Olajide et al., 2022</xref>).</p><p>In peripheral blood mononuclear cells, the spike protein is capable of upregulating TLR6 and MMP9 and downregulating SKAP1 and LAG3, which are involved in the control of T-cell function (<xref rid="B215" ref-type="bibr">Zhang et al., 2021a</xref>). One of the <italic toggle="yes">in silico</italic> studies suggested that a citrus flavonoid called rutin may be a promising antiviral therapeutic, binding to M-pro, TLR2, TLR6, and TLR7 (<xref rid="B69" ref-type="bibr">Hu et al., 2020</xref>). Another <italic toggle="yes">in silico</italic> study indicated that TLR4 has high affinity for the spike protein, and that TLR6 and TLR1 have comparatively lower affinity (<xref rid="B29" ref-type="bibr">Choudhury and Mukherjee, 2020b</xref>).</p></sec><sec id="s4-1-2"><title>4.1.2 Endosomal TLRs</title><sec id="s4-1-2-1"><title>4.1.2.1 TLR3</title><p>TLR3 is an endosomal receptor that recognizes viral dsRNA, thereby inducing the production of type I IFN and inflammatory cytokines (<xref rid="B120" ref-type="bibr">Matsumoto and Seya, 2008</xref>). An <italic toggle="yes">in silico</italic> study on the binding of all mRNAs to intracellular TLRs shows that the mRNAs of Nsp10, S2, and E SARS-CoV-2 proteins are potential virus-associated molecular patterns that bind to TLR3, TLR9, and TLR7, respectively, and trigger downstream cascades (<xref rid="B27" ref-type="bibr">Choudhury et al., 2021</xref>). Other investigations noticed that SARS-CoV-2 activates TLR3 and TLR7; nevertheless, TLR3 mainly acts through IRF3 activation, whereas TLR7 exerts its action mainly via NF-&#954;B activation (<xref rid="B11" ref-type="bibr">Bortolotti et al., 2021</xref>). It has been demonstrated that ORF9b of SARS-CoV-2 inhibits IFN production by targeting the TLR3-TRIF cascade, in addition to RIG-I/MDA-5 MAVS and cGAS-STING signaling pathways (<xref rid="B58" ref-type="bibr">Han et al., 2021</xref>). According to a recently published article, polyinosinic:polycytidylic acid (polyI:C; a synthetic TLR3 agonist) protects mice against COVID-19 (<xref rid="B182" ref-type="bibr">Tamir et al., 2022</xref>).</p></sec><sec id="s4-1-2-2"><title>4.1.2.2 TLR7</title><p>TLR7 recognizes ssRNA and synthetic oligoribonucleotide analogs such as imidazoquinoline, imiquimod, and R-848 (<xref rid="B180" ref-type="bibr">Sun and Reddy, 2013</xref>). TLR8 is an endosomal sensor of RNA degradation products in human phagocytes and facilitates the detection of viral and bacterial infections (<xref rid="B125" ref-type="bibr">Moen et al., 2019</xref>). In a comparative analysis via an immunoinformatic approach, it was revealed that SARS-CoV-2 has more fragments of ssRNA than SARS-CoV does; therefore, SARS-CoV-2 is capable of hyperactivating the innate immune system by triggering of TLR7/8, resulting in acute lung injury because of the induction of a pro-inflammatory response via the TLR7/8 engagement (<xref rid="B128" ref-type="bibr">Moreno-Eutimio et al., 2020</xref>). A loss-of-function mutation in TLR7 increases COVID-19 severity in young males (<xref rid="B128" ref-type="bibr">Moreno-Eutimio et al., 2020</xref>). TLR7 agonist imiquimod has been proposed as a possible therapeutic for COVID-19 (<xref rid="B149" ref-type="bibr">Poulas et al., 2020</xref>). TLR4 and TLR7 over-expression mediated by SARS-CoV-2 has been detected in adipose tissue-derived mesenchymal stromal cells in response to periodic thermomechanical manipulation (<xref rid="B203" ref-type="bibr">Xu et al., 2021</xref>). Due to loss-of-function mutations that suppress the antiviral response to SARS-CoV-2, TLR7 variants constitute a major risk factor for severe COVID-19 in men under the age of 50 (<xref rid="B44" ref-type="bibr">Englmeier and Subburayalu, 2022</xref>). In a nested case study, it was found that the loss-of-function mutation of TLR7 is present in 2.1% of the patients with severe COVID-19, but in none of the asymptomatic patients (<xref rid="B45" ref-type="bibr">Fallerini et al., 2021</xref>).</p><p>Women have higher levels of immune-cell activation than men do, which is linked to TLR7 activation and IFN production (<xref rid="B197" ref-type="bibr">Webb et al., 2019</xref>). TLR7 expression is higher in females than in males, and its biallelic expression leads to enhanced immune responses and viral-infection resistance (<xref rid="B177" ref-type="bibr">Spiering and de Vries, 2021</xref>). Furthermore, after a viral infection, a lower amount of inflammatory IL-6 is produced in women than in men, and this sign is often associated with a longer lifespan. In addition to this, there are loci on the X chromosome that contain genes implicated in immune-cell modulation (e.g., <italic toggle="yes">FOXP3</italic>) and a transcription factor for regulatory T cells important for viral pathogenesis. The X chromosome affects the immune system by expressing a variety of proteins, including TLR8, CD40L, and CXCR3, all of which can be over-expressed in women and alter the immune system&#8217;s response to viral infections and immunizations. That is why women are less susceptible to viral infections than men (<xref rid="B30" ref-type="bibr">Conti and Younes, 2020</xref>).</p><p>Several TLR7 agonists have been proposed as drugs and vaccine adjuvants against SARS-CoV-2. TLR7 agonists have been conjugated to CoVac501, a self-adjuvanting peptide vaccine. The vaccine is manufactured entirely chemically and incorporates immunodominant peptides identified in the RBD. CoVac501 generates robust and long-lasting titers of protective neutralizing antibodies against numerous RBD mutants, original SARS-CoV-2 strain, and variants in non-human primates (<xref rid="B111" ref-type="bibr">Long et al., 2022</xref>).</p></sec><sec id="s4-1-2-3"><title>4.1.2.3 TLR8</title><p>An <italic toggle="yes">in silico</italic> study on brain glial cells determined the ability of viral spike epitope peptides M1Lys60 and Ala240Glu300 to bind or interact with human TLR8, with the brain-targeted vascular cell adhesion molecule (VCAM1) protein, with zonula occludens, with glial-cell-specific protein NDRG2, and with apo-S100B. It was also found that a SARS-COV-2 spike peptide forms a heterodimeric complex with human TLR8 (<xref rid="B36" ref-type="bibr">Dasgupta and Bandyopadhyay, 2021</xref>). A bioinformatic analysis of the viral genome revealed hundreds of fragments that might activate TLR7/8, suggesting that products of endosomal processing of the virus can potently induce IFN-based and inflammatory responses downstream of these receptors. SARS-CoV-2 associated molecular patterns elicit MyD88-dependent lung inflammation in mice, which is characterized by over-expression of pro-inflammatory and cytotoxic mediators, immune-cell infiltration, and phenotypic maturation of splenic dendritic cells. Thus, TLR7/8 was discovered as a critical cellular sensor of SARS-CoV-2 ssRNAs that takes part in host resistance and in COVID-19 development (<xref rid="B163" ref-type="bibr">Salvi et al., 2021</xref>).</p><p>In another research article, it is demonstrated that in the absence of pyroptosis, GU-rich ssRNA (GU-rich RNA) derived from SARS-CoV-2, SARS-CoV-1, or HIV-1 launches a TLR8-dependent pro-inflammatory cytokine response in human macrophages, with GU-rich RNA from the SARS-CoV-2 spike gene triggering a pro-inflammatory response. Moreover, it was shown using genetic and pharmacological suppression that the production of mature IL-1&#946; is mediated by a non-classic pathway that is dependent on caspase 1, caspase 8, the NLRP3 inflammasome, potassium ion efflux, and autophagy while being independent of TRIF (TICAM1), vitamin D<sub>3</sub>, and pyroptosis (<xref rid="B17" ref-type="bibr">Campbell et al., 2021</xref>).</p><p>
<italic toggle="yes">TLR8</italic> mRNA has turned out to be more abundant than <italic toggle="yes">TLR7</italic> mRNA, which indicates the presence of monocyte-derived dendritic cells (MDDCs). In <italic toggle="yes">in vitro</italic> assays on MDDCs activated with ssRNA40 (a TLR8 agonist that is a positive-sense ssRNA similar to SARS-CoV-2 RNA), upregulation of sXBP1 and mRNA and protein expression of IL-1&#946;, IL-6, and TNF was noticed. An IRE1 ribonuclease inhibitor (MKC8866) suppressed these responses. Moreover, 1) the presence of sXBP1 in nasopharyngeal swabs and BAAs, 2) sXBP1 induction by ssRNA40 in MDDCs, 3) the effect of IRE1 RNase inhibition on the cytokine induction produced by ssRNA40, and 4) the demonstration of sXBP1 binding to <italic toggle="yes">IL1B</italic>, <italic toggle="yes">IL6</italic>, and <italic toggle="yes">TNF</italic> promoters, all suggest that TLR8-induced XBP1 splicing potentially contributes to the viral sepsis observed in severe cases of COVID-19 (<xref rid="B49" ref-type="bibr">Fern&#225;ndez et al., 2022</xref>).</p></sec><sec id="s4-1-2-4"><title>4.1.2.4 TLR9</title><p>It has been hypothesized that for COVID-19, TLR9 activation is a subtle but potent factor causing hyperinflammation and thrombotic complications in vulnerable patients. As a result, testing the efficacy of TLR9 agonists is recommended for the fight against SARS-CoV-2 (<xref rid="B136" ref-type="bibr">Oberemok et al., 2020</xref>).</p><p>Human mitochondrial DNA, which is derived from endosymbiont bacteria and contains unmethylated CpG motifs, is a model of a well-known DAMP that directly activates the inflammatory process via TLR9 upon tissue damage and infection (<xref rid="B216" ref-type="bibr">Zhang et al., 2010</xref>). In endothelial cells, SARS-CoV-2 infection affects mitochondrial function and promotes TLR9 signaling. TLR9 launches inflammatory responses that culminate in endothelial-cell dysfunction, which may contribute to the severity of COVID-19 symptoms. Targeting of mitochondrial metabolic pathways may help to devise new COVID-19 treatments (<xref rid="B31" ref-type="bibr">Costa et al., 2022</xref>).</p><p>CpG 1018, which is a T helper 1 (Th1)-biasing synthetic TLR9 agonist, has been chosen as an adjuvant candidate to improve immunogenicity and attenuate possible vaccine-induced immunopathology. Cytokines generated by splenocytes of mice vaccinated with CpG 1018 and alum show a strong Th1-dominant response. In a dose-ranging trial, rats subjected to single- or double-dose regimens of S-2P coupled with CpG 1018 alone or CpG 1018 plus alum manifested no vaccine-related significant adverse effects. These findings support the development of a COVID-19 vaccine candidate based on CHO-derived S-2P formulated with CpG 1018 and alum (<xref rid="B95" ref-type="bibr">Kuo et al., 2020</xref>).</p><p>In another study, several combinations of PRR agonists and aluminum hydroxide (AH) were compared, and it was discovered that combining CpG oligodeoxynucleotides (TLR9 agonists) with AH and RBD significantly improves immune responses to RBD in young mice on a prime-boost immunization schedule. In aged mice, the AH:CpG-adjuvanted RBD vaccination evoked a strong anti-RBD immune response, with an extra boost dose generating an anti-RBD antibody response comparable to that in young adult mice and conferring complete protection against a live-SARS-CoV-2 challenge. In addition, it was observed that the AH:CpG adjuvant formulation has unique immunological capabilities yielding human-leukocyte activation <italic toggle="yes">in vitro</italic>. Overall, the thorough adjuvant comparison analysis showed that co-adjuvanting AH:CpG can overcome both RBD immunogenicity and immunosenescence (<xref rid="B131" ref-type="bibr">Nanishi et al., 2021</xref>).</p><p>
<xref rid="B56" ref-type="bibr">Haabeth et al. (2021)</xref> looked into the development of a new mRNA vaccine that involves charge-altering releasable transporters as a delivery mechanism. It was proposed that vaccination immunogenicity could be customized by including co-formulated adjuvants such as oligodeoxynucleotides with CpG motifs (CpG-ODN) in these intrinsically nonimmunogenic vehicles. Mice given the mRNA-charge-altering-releasable transporter vaccine acquired therapeutically relevant levels of RBD-specific neutralizing antibodies in the blood and bronchial secretions. Furthermore, the vaccination induced RBD-specific Th1 T-cell responses, including CD4<sup>+</sup> and CD8<sup>+</sup> T-cell memory, that were strong and long-lasting (<xref rid="B56" ref-type="bibr">Haabeth et al., 2021</xref>).</p><p>Various drugs which target toll-like receptors are being evaluated in clinical trials. Some of them have been listed in <xref rid="T4" ref-type="table">table 4</xref>.</p><table-wrap position="float" id="T4" orientation="portrait"><label>TABLE 4</label><caption><p>Clinical trials of the drug targeting immune mediators against SARS-CoV-2.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">Molecular target or pathway involved</th><th align="center" rowspan="1" colspan="1">Identifier number</th><th align="center" rowspan="1" colspan="1">Last updated</th><th align="center" rowspan="1" colspan="1">Status</th><th align="center" rowspan="1" colspan="1">Phase</th></tr></thead><tbody valign="top"><tr><td rowspan="5" align="left" colspan="1">Melatonin</td><td rowspan="19" align="center" colspan="1">NLRP3 Inflammasome</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04353128">NCT04353128</ext-link></td><td align="left" rowspan="1" colspan="1">23 November 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04474483">NCT04474483</ext-link></td><td align="left" rowspan="1" colspan="1">11 June 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04784754">NCT04784754</ext-link></td><td align="left" rowspan="1" colspan="1">11 June 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04409522">NCT04409522</ext-link></td><td align="left" rowspan="1" colspan="1">1 June 2020</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470297">NCT04470297</ext-link></td><td align="left" rowspan="1" colspan="1">24 July 2020</td><td align="left" rowspan="1" colspan="1">Not recruiting yet</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td rowspan="6" align="left" colspan="1">Curcumin</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05150782">NCT05150782</ext-link></td><td align="left" rowspan="1" colspan="1">11 January 2022</td><td align="left" rowspan="1" colspan="1">Not recruiting yet</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05130671">NCT05130671</ext-link></td><td align="left" rowspan="1" colspan="1">28 January 2022</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04802382">NCT04802382</ext-link></td><td align="left" rowspan="1" colspan="1">29 June 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04382040">NCT04382040</ext-link></td><td align="left" rowspan="1" colspan="1">31 August 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05037162">NCT05037162</ext-link></td><td align="left" rowspan="1" colspan="1">8 September 2021</td><td align="left" rowspan="1" colspan="1">Not recruiting yet</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04844658">NCT04844658</ext-link></td><td align="left" rowspan="1" colspan="1">1 December 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="2" align="left" colspan="1">Indomethacin</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05007522">NCT05007522</ext-link></td><td align="left" rowspan="1" colspan="1">26 November 2021</td><td align="left" rowspan="1" colspan="1">Not recruiting yet</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04344457">NCT04344457</ext-link></td><td align="left" rowspan="1" colspan="1">1 July 2020</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 1; Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">Pioglitazone</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04500639">NCT04500639</ext-link></td><td align="left" rowspan="1" colspan="1">3 May 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="3" align="left" colspan="1">Metformin</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04604678">NCT04604678</ext-link></td><td align="left" rowspan="1" colspan="1">7 January 2021</td><td align="left" rowspan="1" colspan="1">Not recruiting yet</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04625985">NCT04625985</ext-link></td><td align="left" rowspan="1" colspan="1">8 April 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510194">NCT04510194</ext-link></td><td align="left" rowspan="1" colspan="1">26 January 2022</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td rowspan="2" align="left" colspan="1">Colchicine</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04322565">NCT04322565</ext-link></td><td align="left" rowspan="1" colspan="1">10 July 2020</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05118737">NCT05118737</ext-link></td><td align="left" rowspan="1" colspan="1">3 December 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Early phase 1</td></tr><tr><td rowspan="3" align="left" colspan="1">Statins</td><td rowspan="3" align="center" colspan="1">ox-LDL-mediated NLRP3 inflammasome activation</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05238402">NCT05238402</ext-link></td><td align="left" rowspan="1" colspan="1">14 February 2022</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04472611">NCT04472611</ext-link></td><td align="left" rowspan="1" colspan="1">2 March 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04904536">NCT04904536</ext-link></td><td align="left" rowspan="1" colspan="1">7 October 2021</td><td align="left" rowspan="1" colspan="1">Not yet recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td rowspan="2" align="left" colspan="1">Resveratrol</td><td rowspan="2" align="center" colspan="1">TLR4</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04799743">NCT04799743</ext-link></td><td align="left" rowspan="1" colspan="1">16 July 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04666753">NCT04666753</ext-link></td><td align="left" rowspan="1" colspan="1">14 December 2020</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">M5049</td><td align="center" rowspan="1" colspan="1">TLR7/8 antagonist</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04448756">NCT04448756</ext-link></td><td align="left" rowspan="1" colspan="1">8 September 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">Poly I:C</td><td align="center" rowspan="1" colspan="1">TLR3 agonist</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04672291">NCT04672291</ext-link></td><td align="left" rowspan="1" colspan="1">18 August 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 1</td></tr><tr><td rowspan="2" align="left" colspan="1">PUL-042</td><td rowspan="2" align="center" colspan="1">TLR2/6/9 agonist</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04312997">NCT04312997</ext-link></td><td align="left" rowspan="1" colspan="1">16 July 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04313023">NCT04313023</ext-link></td><td align="left" rowspan="1" colspan="1">2 September 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydroxychloroquine sulfate</td><td align="center" rowspan="1" colspan="1">TLR7/9 inhibitor</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04340349">NCT04340349</ext-link></td><td align="left" rowspan="1" colspan="1">29 June 2021</td><td align="left" rowspan="1" colspan="1">Enrolling by invitation</td><td align="left" rowspan="1" colspan="1">Early phase 1</td></tr><tr><td rowspan="9" align="left" colspan="1">Baricitinib</td><td rowspan="17" align="center" colspan="1">Janus kinase inhibitor</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05082714">NCT05082714</ext-link></td><td align="left" rowspan="1" colspan="1">30 November 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04390464">NCT04390464</ext-link></td><td align="left" rowspan="1" colspan="1">18 May 2020</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 4</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04421027">NCT04421027</ext-link></td><td align="left" rowspan="1" colspan="1">19 July 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04970719">NCT04970719</ext-link></td><td align="left" rowspan="1" colspan="1">27 August 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05056558">NCT05056558</ext-link></td><td align="left" rowspan="1" colspan="1">28 September 2021</td><td align="left" rowspan="1" colspan="1">Not yet recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04693026">NCT04693026</ext-link></td><td align="left" rowspan="1" colspan="1">5 January 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05074420">NCT05074420</ext-link></td><td align="left" rowspan="1" colspan="1">19 January 2022</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04832880">NCT04832880</ext-link></td><td align="left" rowspan="1" colspan="1">6 April 2021</td><td align="left" rowspan="1" colspan="1">Not yet recruiting</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04390464">NCT04390464</ext-link></td><td align="left" rowspan="1" colspan="1">18 May 2020</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 4</td></tr><tr><td rowspan="8" align="left" colspan="1">Ruxolitinib</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04362137">NCT04362137</ext-link></td><td align="left" rowspan="1" colspan="1">11 October 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04334044">NCT04334044</ext-link></td><td align="left" rowspan="1" colspan="1">7 July 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 1; Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04338958">NCT04338958</ext-link></td><td align="left" rowspan="1" colspan="1">13 August 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04348071">NCT04348071</ext-link></td><td align="left" rowspan="1" colspan="1">8 March 2021</td><td align="left" rowspan="1" colspan="1">Withdrawn</td><td align="left" rowspan="1" colspan="1">Phase 2; Phase 3</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04414098">NCT04414098</ext-link></td><td align="left" rowspan="1" colspan="1">4 June 2020</td><td align="left" rowspan="1" colspan="1">Not yet recruiting</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04359290">NCT04359290</ext-link></td><td align="left" rowspan="1" colspan="1">24 August 2021</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04348695">NCT04348695</ext-link></td><td align="left" rowspan="1" colspan="1">17 April 2020</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04581954">NCT04581954</ext-link></td><td align="left" rowspan="1" colspan="1">2 September 2021</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 1; Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">Secukinumab</td><td align="center" rowspan="1" colspan="1">IL-17A antagonist</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04403243">NCT04403243</ext-link></td><td align="left" rowspan="1" colspan="1">27 May 2020</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">Phase 2</td></tr></tbody></table></table-wrap></sec></sec></sec><sec id="s4-2"><title>4.2 RIG-Like Receptors (RLRs) and SARS-CoV-2</title><p>RLRs, unlike TLRs, are crucial cytoplasmic virus sensors that detect intracellular non-self RNAs with different secondary-structure patterns or metabolic changes (<xref rid="B97" ref-type="bibr">L&#228;ssig and Hopfner, 2017</xref>). RLRs are RNA helicases that include the Asp-Glu-Ala-Asp (DEAD) box, and this family includes three members: RIG-I, melanoma differentiation-associated gene 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2). All RLRs have an RNA helicase domain with a C-terminal domain, which is responsible for RNA binding. Although RIG-I and MDA5 both contain tandem caspase activation and recruitment domains (CARDs) for downstream signal transduction, LGP2 does not have a CARD and therefore acts as a modulator of RIG-I and MDA5 (<xref rid="B210" ref-type="bibr">Yoo et al., 2014</xref>). RIG-I and MDA5 have similar as well as separate mechanisms for recognizing non-self RNAs. As mammalian cells lack an RdRp, dsRNA is a characteristic non-self RNA that is normally absent in uninfected cells. An artificial dsRNA called polyI:C can activate both RIG-I and MDA5 (<xref rid="B166" ref-type="bibr">Schlee and Hartmann, 2016</xref>). Of note, RIG-I and MDA5 activation by dsRNA is regulated differently depending on the length of the dsRNA. The shortest dsRNA found to activate RIG-I is 13 bp, which is the same as the shortest length required for the assembly of a 2-RIG-I/dsRNA dimer (<xref rid="B12" ref-type="bibr">Brisse and Ly, 2019</xref>). Recent research uncovered several biochemical properties of RLR-activating RNA species, including 1) 5&#8242;-triphosphate in RNAs having a secondary structure, 2) 5&#8242;-diphosphate and the absence of a cap, and 3) the presence of an unmethylated 5&#8242;-end nucleotide at the 2&#8242;-O position; such RNAs are typically generated during the replication of RNA viruses, including coronaviruses (<xref rid="B157" ref-type="bibr">Rehwinkel and Gack, 2020</xref>).</p><p>RLRs undergo conformational changes driven by ATPase/helicase activity, from an inactive &#8220;closed&#8221; state to an active &#8220;open&#8221; state. The CARD-CARD interaction allows activated RLRs to release CARDs, which then come into contact with a signaling adaptor molecule called mitochondria antiviral signaling protein (MAVS) (<xref rid="B102" ref-type="bibr">Leung and Amarasinghe, 2012</xref>). Signaling adapters MyD88, TRIF, and MAVS then recruit several ubiquitin ligases, such as TNF receptor-associated factor (TRAF) 3 and TRAF6, which associate with antiviral kinases like TANK-binding kinase 1 (TBK1), I&#954;B kinase (IKK), and the IKK complex, to coordinate downstream signaling pathways. As a result of the activation of transcription factors IRF3 and IRF7 as well as NF-&#954;B, type I IFN and pro-inflammatory cytokines are produced, allowing host antiviral IFN systems to function freely (<xref rid="B91" ref-type="bibr">Konno et al., 2009</xref>; <xref rid="B85" ref-type="bibr">Kawasaki and Kawai, 2014</xref>). It was found <italic toggle="yes">in vitro</italic> experiments that IFNs inhibit the replication cycle of SARS-CoV-2 in a dose-dependent manner (<xref rid="B14" ref-type="bibr">Busnadiego et al., 2020</xref>; <xref rid="B192" ref-type="bibr">Vanderheiden et al., 2020</xref>).</p><p>
<xref rid="B209" ref-type="bibr">Yin et al. (2021)</xref> reported the involvement of MDA5 and LGP2 (members of the RLR family) in the induction of an IFN response as a consequence of SARS-CoV-2 infection. They also identified IRF3, IRF7, and NF-&#954;B as the key transcription factors responsible for the regulation of IFN production in lung epithelial cells during SARS-CoV-2 infection (<xref rid="B209" ref-type="bibr">Yin et al., 2021</xref>). Another group demonstrated that the MDA5 protein mediates IFN production in lung cells as a result of COVID-19; however, the enhanced IFN response could not control the viral replication in the lung cells (<xref rid="B155" ref-type="bibr">Rebendenne et al., 2021</xref>). Another research group proposed that the RNA sensing through MDA5 is the key driver of inflammation in lung cells. They also suggested that the inhibition of innate immune sensing of SARS-CoV-2 may alleviate the inflammation caused by COVID-19 (<xref rid="B187" ref-type="bibr">Thorne et al., 2021</xref>). Different research groups have reported that different proteins of SARS-CoV-2 interfere with RIG1 and MDA5 or with either RIG1 or MDA5 signaling. One group reported that PL-pro antagonizes ISG15-dependent activation of MDA5 by de-ISGylation. MDA5 oligomerization is triggered by ISGylation of CARDs, and this process triggers innate immunity against a variety of viruses such as coronaviruses, flaviviruses, and picornaviruses. Accordingly, this mechanism helps the virus to evade the immune response (<xref rid="B110" ref-type="bibr">Liu et al., 2021b</xref>). By contrast, other studies reported that the M protein of SARS-CoV-2 suppresses type I and type III IFN responses by preventing the phosphorylation and activation of IRF3 through interaction with RIG-I, MAVS, and TBK1 (<xref rid="B222" ref-type="bibr">Zheng Y. et al., 2020</xref>). The nucleocapsid protein inhibits IFN secretion by blocking IRF3 phosphorylation and by downregulating Tyk2 and STAT2 (<xref rid="B94" ref-type="bibr">Kumar et al., 2021</xref>).</p><p>Recently, it was observed that MDA5 is over-expressed in asymptomatic and mildly symptomatic patients. Type I IFN was also found to be significantly upregulated in nasopharyngeal cells of the asymptomatic patients. This result points to a protective role of MDA5 involving upregulation of type I IFN to protect the patient from possible severe tissue damage caused by SARS-CoV-2 (<xref rid="B126" ref-type="bibr">Mohanty et al., 2021</xref>). The nucleocapsid protein of SARS-CoV-2 has been reported to inhibit the interaction between tripartite motif protein 25 (TRIM25) and RIG-I, as well as to suppress nuclear translocation of IFN-regulatory factor 3, thereby attenuating IFN production (<xref rid="B137" ref-type="bibr">Oh and Shin, 2021</xref>). Other components of SARS-CoV-2 have also been found to inhibit the induction of an IFN response. ORF3b, ORF6, ORF7a, ORF8, and Nsp14 in addition to the Nucleocapsid protein of SARS-CoV-2 are potent inhibitors of an IFN response (<xref rid="B105" ref-type="bibr">Li JY. et al., 2020</xref>; <xref rid="B19" ref-type="bibr">Cao et al., 2021</xref>; <xref rid="B68" ref-type="bibr">Hsu et al., 2021</xref>; <xref rid="B156" ref-type="bibr">Redondo et al., 2021</xref>).</p></sec><sec id="s4-3"><title>4.3 NLRs and SARS-CoV-2</title><p>Inflammasomes are multiprotein complexes composed of members of the NLR family and of the pyrin and HIN domain (PYHIN) family. Inflammasomes&#8217; biochemical purpose is to trigger caspase 1, which induces the maturation of IL-1&#946; and IL-18 as well as the activation of pyroptosis, a type of cell death. The roles of the NLRP3 inflammasome in human immunity and pathologies have been proven extensively. The NLRP3 inflammasome is a crucial mediator of host immune responses because it activates caspase 1 and IL-1&#946; and/or IL-18 (<xref rid="B61" ref-type="bibr">He et al., 2016</xref>).</p><p>The NLRP3 inflammasome, unlike other inflammasomes, can be activated by a variety of stimuli. The NLRP3 inflammasome is thought to sense cellular homeostasis rather than directly recognize a common motif present in its inducers; many physiological signals, e.g., K<sup>+</sup> efflux, Ca<sup>2+</sup> signaling, mitochondrial malfunction, and lysosomal rupture, have been hypothesized to drive its activation (<xref rid="B61" ref-type="bibr">He et al., 2016</xref>). Infectious microorganisms such as the Sendai virus, influenza virus, adenovirus, fungi <italic toggle="yes">Saccharomyces cerevisiae</italic> and <italic toggle="yes">Candida albicans</italic>, and bacteria (such as <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Listeria monocytogenes</italic>, and <italic toggle="yes">Shigella flexneri</italic>) are also able to activate the NLRP3 inflammasome. In some cases, specific microbial components or products that activate the NLRP3 inflammasome have been identified, such as bacterial and viral RNA, malaria-causing parasite hemozoin crystals, and various bacterial pore-forming toxins (<xref rid="B79" ref-type="bibr">Chengcheng et al., 2010</xref>; <xref rid="B219" ref-type="bibr">Zhao N. et al., 2021</xref>). The ORF3a-encoded SARS-CoV-2 viroporin&#8212;a type of tiny hydrophobic protein encoded by viruses that oligomerizes in host cell membranes resulting in the formation of hydrophilic pores&#8212;activates the NLRP3 inflammasome (<xref rid="B134" ref-type="bibr">Nieva et al., 2012</xref>). ORF3a activates the inflammasome via either an ASC-dependent or ASC-independent mechanism by triggering IL-1&#946; expression. ORF3a-mediated inflammasome activation necessitates K<sup>+</sup> efflux and NEK7-NLRP3 oligomerization (<xref rid="B201" ref-type="bibr">Xu et al., 2022</xref>). MCC950, a small-molecule inhibitor of NLRP3&#8217;s ATPase activity, lowers the production of IL-18 in response to these viral proteins (<xref rid="B160" ref-type="bibr">Rousseau et al., 2021</xref>). It was observed in another study that MCC950 can block ORF3a-mediated inflammasome activation. ORF3a key residues needed for the virus release and inflammasome activation are conserved among SARS-CoV-2 isolates across continents, suggesting that ORF3a and NLRP3 are prime targets for a therapeutic intervention (<xref rid="B202" ref-type="bibr">Xu et al., 2020a</xref>).</p><p>Additionally, NLRP3 leads to the release of several biologically active DAMPs. This action sets off a chain of events that result in amplification of the innate immune system&#8217;s reaction and trigger the complement cascade (ComC). In addition to DAMPs, mannan-binding lectin (MBL), which binds to SARS-CoV-2 proteins, has been shown to directly launch the ComC. Notably, activation of the ComC via the MBL-MASP-2 protease complex also triggers the coagulation cascade (CoaC), and the launch of the latter is associated with a worse prognosis in patients infected with SARS-CoV-2. This observation explains why ComC and CoaC inhibition are individually being investigated as a therapeutic option (<xref rid="B154" ref-type="bibr">Ratajczak and Kucia, 2020</xref>). It has been demonstrated that NLRP3 is activated by SARS-CoV-2 at an early stage of the infection and induces cytokine release syndrome. These data suggest that NLRP3 can serve as an effective target for reducing organ damage (<xref rid="B119" ref-type="bibr">Marchetti et al., 2021</xref>).</p><p>
<xref rid="B206" ref-type="bibr">Yalcinkaya et al. (2021)</xref> reported that the E protein prevents inflammasome priming and NLRP3 inflammasome activation in cultured macrophages. Similarly, in animals transfected with the E protein and treated with polyI:C mimicking the effects of viral RNA, the E protein reduces pro-IL-1&#946; expression, IL-1&#946; and IL-18 levels in bronchoalveolar lavage fluid, and macrophage infiltration of the lungs in an NLRP3-dependent manner. Macrophages were treated with both LPS and polyI:C to simulate the consequences of a more advanced infection. Under these conditions, the E protein boosted the activation of the NLRP3 inflammasome in both murine and human macrophages. As a consequence, the SARS-CoV-2 E protein may reduce the host NLRP3 inflammasome response to viral RNA at early stages of the infection while possibly enhancing NLRP3 inflammasome responses later on. The mentioned study suggests that targeting the SARS-CoV-2 E protein, particularly in the early stages of the infection, may be a unique way to treat COVID-19 (<xref rid="B206" ref-type="bibr">Yalcinkaya et al., 2021</xref>).</p><p>Two non-structural proteins, Nsp1 and Nsp13, suppress caspase 1-mediated IL-1&#946; activation, according to a screening of a complementary DNA (cDNA) library containing 28 SARS-CoV-2 ORFs. Caspase 1 inhibition was attributed to Nsp1 amino acid residues involved in the silencing of host translation and to Nsp13 domains responsible for helicase activity. Both Nsp1 and Nsp13 attenuated NLRP3 inflammasome-induced caspase 1 activity and IL-1&#946; production in THP-1 cells. These data suggest that SARS-CoV-2 Nsp1 and Nsp13 are effective NLRP3 inflammasome antagonists (<xref rid="B89" ref-type="bibr">Kim et al., 2021b</xref>).</p><p>A recent mutational analysis of SARS-CoV-2 implies that Nsp6 is an important indicator of viral pathogenicity. Inflammasome-related NOD-like receptor signaling is activated in SARS-CoV-2-infected lung epithelial cells and COVID-19 patients&#8217; lung tissues, according to transcriptome analysis. The induction of inflammasomes/pyroptosis in patients with severe COVID-19 was validated by means of serological markers. Nsp6 over-expression resulted in NLRP3/ASC-dependent caspase 1 activation, maturation of IL-1&#946; and IL-18 or either IL-1&#946; or IL-18, and pyroptosis of lung epithelial cells. Nsp6 inhibited autophagic flux by impairing lysosome acidification, which was reversed by 1,25-dihydroxyvitamin D<sub>3</sub>, metformin, or polydatin, which prevented Nsp6-induced pyroptosis. Nsp6 interacts directly with ATP6AP1 (a proton pump component of vacuolar ATPase) and reduces its cleavage-mediated activation. Reduced binding to ATP6AP1 and a diminished ability to impede lysosome acidification for promoting pyroptosis were revealed in the L37F Nsp6 variant, which was linked with asymptomatic COVID-19. Infection of cultured lung epithelial cells with live SARS-CoV-2 caused autophagic-flux stagnation, inflammasome activation, and pyroptosis in a consistent manner. Overall, the mentioned research suggests that SARS-CoV-2 Nsp6 can cause inflammatory cell death of lung epithelial cells, and this effect could be exploited therapeutically through pharmacological correction of autophagic flux (<xref rid="B178" ref-type="bibr">Sun et al., 2022</xref>).</p><p>In a confocal immunofluorescence analysis, the SARS-CoV-2 nucleocapsid was found to co-localize with neurons, astrocytes, oligodendrocytes, and microglia. In cerebral cortical tissues, the viral nucleocapsid was discovered alongside ACE2 (cell entry receptor) and the NLRP3 inflammasome (<xref rid="B16" ref-type="bibr">Cama et al., 2021</xref>). In another study, it was reported that the N protein interacts directly with the NLRP3 protein and facilitates NLRP3 inflammasome assembly by promoting NLRP3 binding to ASC (<xref rid="B140" ref-type="bibr">Pan et al., 2021</xref>).</p><p>The spike protein of SARS-CoV-2 has also been found to activate the NLRP3 inflammasome (<xref rid="B93" ref-type="bibr">Kucia et al., 2020</xref>). In another research article, it is reported that in cultured murine alveolar macrophages, ultramicronized palmitoylethanolamide inhibits NLRP3 inflammasome expression and the pro-inflammatory response activated by the SARS-CoV-2 Spike protein (<xref rid="B37" ref-type="bibr">Del Re et al., 2021</xref>). It was also observed that the infected cells undergo pyroptosis mediated by inflammasome activation involving NLRP3 and AIM2. Moreover, tissue-resident macrophages show inflammasome activation, but this phenomenon is not observed in infected epithelial cells (<xref rid="B81" ref-type="bibr">Junqueira et al., 2021</xref>). The SARS-CoV-2 spike protein triggers inflammasome activation and an IL-1&#946; release in macrophages obtained from COVID-19 patients but not in macrophages from healthy SARS-CoV-2-naive controls. <italic toggle="yes">Ex vivo</italic>, chemical NLRP3 suppression inhibits spike protein-induced IL-1&#946; production (<xref rid="B185" ref-type="bibr">Theobald et al., 2021</xref>). Another study indicated that ORF3a is required for the assembly of the NLRP3 inflammasome and for the secretion of mature IL-18. Albeit to a lesser extent, Nsp2 and ORF3b (among 26 tested viral proteins) enhanced NLPR3 inflammasome activity and the production of mature IL-18. In human-<italic toggle="yes">ACE2</italic> transgenic mice, specific suppression of the NLRP3 inflammasome by MCC950 reduces excessive lung inflammation and hence COVID-19-like pathology (<xref rid="B212" ref-type="bibr">Zeng et al., 2022</xref>).</p><p>In infected human monocytes, SARS-CoV-2 infection activates the NLRP3 inflammasome and inhibits caspase 1, GSDMD cleavage, and pyroptosis. <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments, the SARS-CoV-2 nucleocapsid protein interacts with GSDMD in cells and suppresses GSDMD cleavage. The Nucleocapsid protein attaches to the GSDMD linker region, thus preventing caspase 1 from processing this protein (<xref rid="B116" ref-type="bibr">Ma et al., 2021</xref>). In human microglial cells, NLRP3 could be primed and activated by the Spike protein of SARS-CoV-2 in an NF-&#954;B-dependent as well as ACE2-dependent manner (<xref rid="B3" ref-type="bibr">Albornoz et al., 2022</xref>). Thus, it becomes very clear that NLRP3 is an attractive target to be probed against SARS-CoV-2. Drugs which are under clinical trials have been listed in <xref rid="T4" ref-type="table">table 4</xref>.</p></sec><sec id="s4-4"><title>4.4 CLRs and SARS-CoV-2</title><p>CLRs, which belong to the superfamily of membrane-bound phagocytic PRRs, recognize carbohydrates on the surface of pathogens in a Ca<sup>2+</sup>-dependent manner and hence are termed &#8220;C-type lectin receptors.&#8221; CLRs play a substantial part in the regulation of adaptive immune responses by managing the induction of signaling pathways. CLRs can regulate adaptive immunity on multiple levels by initiating signaling on their own, through interaction with other PRRs, or by triggering carbohydrate-specific signaling cascades (<xref rid="B52" ref-type="bibr">Geijtenbeek and Gringhuis, 2009</xref>; <xref rid="B103" ref-type="bibr">Li and Wu, 2021</xref>). They can either modulate TLR signaling or directly induce gene expression. CLRs can be soluble or transmembrane receptors (<xref rid="B86" ref-type="bibr">Kerrigan and Brown, 2010</xref>), and are expressed by antigen-presenting cells such as dendritic cells, macrophages, monocytes, and Langerhans cells (<xref rid="B9" ref-type="bibr">Bermejo-Jambrina et al., 2018</xref>). The participation of CLRs in virus recognition is complicated. They can detect and respond efficiently to a wide spectrum of viruses and thus can shape antiviral immune responses (<xref rid="B127" ref-type="bibr">Monteiro and Lepenies, 2017</xref>).</p><p>Several C-type lectins (DC-SIGN, L-SIGN, LSECtin, ASGR1, and CLEC10A) serve as glycan-dependent binding partners of the spike protein of SARS-CoV-2. These substances interact with spike through the region around the RBD (<xref rid="B112" ref-type="bibr">Lu et al., 2021</xref>). Recently, it was demonstrated that attachment to such receptors as CLRs, DC-SIGN, L-SIGN, and sialic-acid-binding immunoglobulin-like lectin 1 (SIGLEC1) enhances ACE2-mediated infection and modulates the neutralizing activity of distinct types of spike-specific antibodies (<xref rid="B153" ref-type="bibr">Rahimi, 2020</xref>; <xref rid="B4" ref-type="bibr">Amraei et al., 2021</xref>; <xref rid="B100" ref-type="bibr">Lempp et al., 2021</xref>). Another study revealed that DC-SIGN, L-SIGN, langerin, and macrophage galactose-type C-type lectin can interact with the spike protein of SARS-CoV-2, and that DC/L-SIGN facilitates the virus entry into the cell through ACE2. Nonetheless, by means of a glycol-mimetic compound designed against DC-SIGN, <italic toggle="yes">trans</italic>-infection between different cell types can be inhibited (<xref rid="B186" ref-type="bibr">Th&#233;paut et al., 2021</xref>). Human liver sinusoidal endothelial cells and lymph node lymphatic endothelial cells express L-SIGN abundantly, whereas blood endothelial cells do not. SARS-CoV-2 proteins have been found within liver sinusoidal endothelial cells in liver autopsy samples from COVID-19 patients by high-resolution confocal microscopy. In comparison with control cells, both a pseudo-typed virus wrapped in the SARS-CoV-2 spike protein and the genuine SARS-CoV-2 virus infect L-SIGN-expressing cells. Furthermore, inhibition of L-SIGN function reduces SARS-CoV-2 infection. These findings suggest that L-SIGN is a receptor mediating SARS-CoV-2 infection (<xref rid="B90" ref-type="bibr">Kondo et al., 2021</xref>).</p></sec><sec id="s4-5"><title>4.5 cGAS-STING Pathway</title><p>Cyclic GMP-AMP (cGAMP) synthase (cGAS) cytosolic DNA sensor triggers innate immune responses by producing cGAMP, the second messenger, which activates the interferon gene adaptor stimulator (STING). The cGAS-STING system mediates protective immune protection against a wide range of DNA-containing pathogens (<xref rid="B21" ref-type="bibr">Chen et al., 2016</xref>). Increasing data suggest that RNA viruses can elicit cGAS-STING responses and be blocked by cGAS-STING activation in general (<xref rid="B75" ref-type="bibr">Ishikawa and Barber, 2008</xref>). Bats are believed to be a natural host for many coronaviruses, and all bats studied so far have STING molecules that are faulty in inducing type-I IFN and have limited antiviral efficacy (<xref rid="B200" ref-type="bibr">Xie et al., 2018</xref>). The duration of coronavirus infection in bats has been associated with faulty STING activation. During cross-species transmission, SARS-CoV-2 appears to have retained or regained its ability to block the STING function. SARS-CoV-2 inhibits cGAS-STING activity with at least two viral proteins. SARS-CoV-2 3CLpro and ORF3a can antagonize various vertebrate STING functions, including those of humans, mice, and chickens, which is consistent with the fact that SARS-CoV-2 can infect a wide spectrum of species (<xref rid="B161" ref-type="bibr">Rui et al., 2021</xref>).</p><p>Through transcriptome analysis, SARS-CoV-2 was found to be responsible for the activation of the cGAS-STING pathway and NF-&#954;B activation. This suggests that inhibition of STING can ameliorate the upregulated cytokine production (<xref rid="B133" ref-type="bibr">Neufeldt et al., 2022</xref>). Furthermore, within cells expressing ACE2 and the SARS-CoV-2 spike protein, viral infection can cause the development of syncytia, resulting in the creation of micronuclei. Micronucleus translocation cGAS, as well as overexpression of their downstream target genes, revealed that these micronuclei had a high level of activation of both the DNA damage response and cGAS-STING signaling. (<xref rid="B158" ref-type="bibr">Ren et al., 2021</xref>). The STING small-molecule agonist has been tested against SARS-Cov-2 infection in vitro and preclinical studies and has been found to stimulate interferon signaling and antiviral state against the virus. Intranasal delivery of diABZI-4, small molecule agonist of STING, was found to activate STING and proinflammatory cytokines (<xref rid="B72" ref-type="bibr">Humphries et al., 2021</xref>). In another study, diABZI significantly inhibited SARS-CoV-2 infection by inducing interferon signaling both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments (<xref rid="B106" ref-type="bibr">Li et al., 2021</xref>). These studies suggest the importance of cGAS<bold>-</bold>STING pathway in interferon signaling in response to SARS-CoV-2 thus pointing out to the need of conducting clinical trials for further validation of using STING agonist as a clinical drug.</p></sec></sec><sec id="s5"><title>5 Inflammatory Cytokines and the Cytokine storm in COVID-19</title><p>Immunopathological manifestations of COVID-19 include lymphopenia, dysregulated macrophages and monocytes, neutrophilia, antibody-dependent enhancement, a reduced or delayed IFN response, and a cytokine storm (<xref rid="B208" ref-type="bibr">Yang et al., 2021</xref>). The latter is defined as an immunological state marked by rapid proliferation and over-activation of T cells, macrophages, and natural killer cells as well as over-production of more than 150 inflammatory cytokines and chemical mediators released by the immune cells and nonimmune cells (<xref rid="B151" ref-type="bibr">Rabaan et al., 2021</xref>) The term &#8220;cytokine storm&#8221; was first used in 1933, in reference to acute graft-versus-host disease in the context of hematopoietic stem cell transplantation (<xref rid="B88" ref-type="bibr">Kim et al., 2021a</xref>). After the successful recognition of a virus by the immune system in the human body, the virus is presented to natural killer cells and CD8<sup>+</sup> cells in the form of viral antigens by antigen-presenting cells, which subsequently activate immune responses (<xref rid="B108" ref-type="bibr">Liskova et al., 2021</xref>). Cytokine and chemokine responses are a part of innate as well as adaptive immune responses because they play a crucial role in communication between different cells (<xref rid="B96" ref-type="bibr">Lacy, 2015</xref>). It has been reported that in a large proportion of cases, the severity of COVID-19 is explained mainly by hyper-inflammation and the cytokine storm (<xref rid="B88" ref-type="bibr">Kim et al., 2021a</xref>). The latter also contributes to deterioration of the health condition in a large number of COVID-19 patients by promoting acute respiratory distress syndrome, multiple organ dysfunction, and coagulation deficits (<xref rid="B23" ref-type="bibr">Chen et al., 2021</xref>).</p><p>Secretion of multiple cytokines, also known as cytokine release syndrome, is linked with the emergence of clinical symptoms. For example, IFN-&#947; can cause fever, chills, headache, dizziness, and fatigue. TNF can induce not only flu-like symptoms such as fever, general malaise, and fatigue, but also can cause vascular leakage, cardiomyopathy, lung injury, and acute-phase protein synthesis. IL-6, a key target in adoptive-cell therapy-induced cytokine release syndrome, can cause vascular leakage, complement activation, and triggering of the coagulation cascade, leading to severe symptoms of cytokine release syndrome such as diffuse intravascular coagulation and multiple organ failure (<xref rid="B172" ref-type="bibr">Shimabukuro-Vornhagen et al., 2018</xref>). It is worth noting that IL-6 may cause cardiomyopathy by promoting cardiac dysfunction, which is common in patients with cytokine release syndrome (<xref rid="B179" ref-type="bibr">Sun et al., 2020</xref>). It is reported that patients with COVID-19 symptoms have higher levels of cytokines and inflammatory markers such as IL-6, IL-8, IL-1&#946;, IL-10, IL-12, and IFN-&#947; (<xref rid="B32" ref-type="bibr">Costela-Ruiz et al., 2020</xref>). At present, there is a strong link between higher levels of pro-inflammatory cytokines&#8212;as potential markers of a cytokine storm&#8212;and the severity of COVID-19 as well as poor outcomes in hospitalized patients (<xref rid="B38" ref-type="bibr">Del Valle et al., 2020</xref>). Elevated IL-6 concentration is recognized as one of the most important markers of unfavorable outcomes and serves as an indicator of disease progression (<xref rid="B164" ref-type="bibr">Santa Cruz et al., 2021</xref>).</p><p>A stressed or infected cell activates a vast number of white blood cells, including B cells, T cells, natural killer cells, macrophages, dendritic cells, and monocytes, through receptor-ligand interactions. Inflammatory cytokines are released, which stimulate additional white blood cells in a positive feedback loop. After a primary infection, a cytokine storm begins locally and spreads throughout the body via systemic circulation. Calour (heat), dolour (pain), rubor (redness), tumor (swelling or edema), and loss of function (functio laesa) are all classic indicators of inflammation (<xref rid="B46" ref-type="bibr">Fara et al., 2020a</xref>). Initially, the localized response involves defensive mechanisms such as increased blood flow, facilitation of leucocyte extravasation and supply of plasma proteins to the site of injury, an increase in body temperature (advantageous in the case of bacterial infections), and pain triggering (<xref rid="B6" ref-type="bibr">Askenase and Sansing, 2016</xref>). Soon after the pathogenic trigger, repair mechanisms are initiated. There are two likely outcomes of these events: 1) organ function is progressively restored and 2) healing occurs via fibrosis, which can lead to chronic organ dysfunction (<xref rid="B47" ref-type="bibr">Fara et al., 2020b</xref>).</p><p>Several drugs that act via the blockade of the upregulated cytokines are currently in clinical trials against COVID-19. Some of them are listed in <xref rid="T5" ref-type="table">Table 5</xref>.</p><table-wrap position="float" id="T5" orientation="portrait"><label>TABLE 5</label><caption><p>Clinical trials of the drugs targeting cytokines different signaling molecules involved in the immune response against SARS-CoV-2.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">Molecular target or pathway involved</th><th align="center" rowspan="1" colspan="1">Identifier number</th><th align="center" rowspan="1" colspan="1">Last updated</th><th align="center" rowspan="1" colspan="1">Status</th><th align="center" rowspan="1" colspan="1">Phase</th></tr></thead><tbody valign="top"><tr><td rowspan="6" align="left" colspan="1">Tocilizumab</td><td rowspan="19" align="center" colspan="1">IL-6 inhibitor</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04730323">NCT04730323</ext-link></td><td align="center" rowspan="1" colspan="1">29 January 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 4</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445272">NCT04445272</ext-link></td><td align="center" rowspan="1" colspan="1">2 June 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04479358">NCT04479358</ext-link></td><td align="center" rowspan="1" colspan="1">2 December 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04924829">NCT04924829</ext-link></td><td align="center" rowspan="1" colspan="1">14 June 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04412772">NCT04412772</ext-link></td><td align="center" rowspan="1" colspan="1">17 November 2020</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04332094">NCT04332094</ext-link></td><td align="center" rowspan="1" colspan="1">6 May 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td rowspan="8" align="left" colspan="1">Sarilumab</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04386239">NCT04386239</ext-link></td><td align="center" rowspan="1" colspan="1">20 July 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Early phase 1</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04357808">NCT04357808</ext-link></td><td align="center" rowspan="1" colspan="1">11 February 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04315298">NCT04315298</ext-link></td><td align="center" rowspan="1" colspan="1">23 September 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2; Phase 3</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04661527">NCT04661527</ext-link></td><td align="center" rowspan="1" colspan="1">16 December 2020</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04359901">NCT04359901</ext-link></td><td align="center" rowspan="1" colspan="1">8 March 2021</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04357860">NCT04357860</ext-link></td><td align="center" rowspan="1" colspan="1">7 July 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04327388">NCT04327388</ext-link></td><td align="center" rowspan="1" colspan="1">13 May 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04322773">NCT04322773</ext-link></td><td align="center" rowspan="1" colspan="1">9 October 2020</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td rowspan="5" align="left" colspan="1">Clazakizumab</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04348500">NCT04348500</ext-link></td><td align="center" rowspan="1" colspan="1">2 December 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04381052">NCT04381052</ext-link></td><td align="center" rowspan="1" colspan="1">23 September 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04494724">NCT04494724</ext-link></td><td align="center" rowspan="1" colspan="1">31 July 2020</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1">NCT04363502</td><td align="center" rowspan="1" colspan="1">14 June 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04343989">NCT04343989</ext-link></td><td align="center" rowspan="1" colspan="1">15 February 2022</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td rowspan="11" align="left" colspan="1">Anakinra</td><td rowspan="11" align="center" colspan="1">IL-1 Receptor antagonist</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04443881">NCT04443881</ext-link></td><td align="center" rowspan="1" colspan="1">1 June 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2; Phase 3</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04603742">NCT04603742</ext-link></td><td align="center" rowspan="1" colspan="1">25 January 2022</td><td align="center" rowspan="1" colspan="1">Withdrawn</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04594356">NCT04594356</ext-link></td><td align="center" rowspan="1" colspan="1">30 August 2021</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04366232">NCT04366232</ext-link></td><td align="center" rowspan="1" colspan="1">16 December 2020</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04412291">NCT04412291</ext-link></td><td align="center" rowspan="1" colspan="1">18 February 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04357366">NCT04357366</ext-link></td><td align="center" rowspan="1" colspan="1">15 February 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04424056">NCT04424056</ext-link></td><td align="center" rowspan="1" colspan="1">23 June 2020</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04643678">NCT04643678</ext-link></td><td align="center" rowspan="1" colspan="1">10 February 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 2; Phase 3</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04341584">NCT04341584</ext-link></td><td align="center" rowspan="1" colspan="1">1 February 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04362943">NCT04362943</ext-link></td><td align="center" rowspan="1" colspan="1">28 July 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04339712">NCT04339712</ext-link></td><td align="center" rowspan="1" colspan="1">11 January 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">Emapalumab</td><td align="center" rowspan="1" colspan="1">IFN-&#947; blocking antibody</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324021">NCT04324021</ext-link></td><td align="center" rowspan="1" colspan="1">14 December 2020</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">Phase 2; Phase 3</td></tr><tr><td rowspan="2" align="left" colspan="1">Berberine</td><td rowspan="2" align="center" colspan="1">Cytokine storm</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05228626">NCT05228626</ext-link></td><td align="center" rowspan="1" colspan="1">8 February 2022</td><td align="center" rowspan="1" colspan="1">Not recruiting yet</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04479202">NCT04479202</ext-link></td><td align="center" rowspan="1" colspan="1">21 July 2020</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 4</td></tr><tr><td rowspan="4" align="left" colspan="1">
<bold>Canakinumab</bold>
</td><td rowspan="4" align="center" colspan="1">IL-1&#946;</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04362813">NCT04362813</ext-link></td><td align="center" rowspan="1" colspan="1">24 January 2022</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 3</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04348448">NCT04348448</ext-link></td><td align="center" rowspan="1" colspan="1">16 April 2020</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04365153">NCT04365153</ext-link></td><td align="center" rowspan="1" colspan="1">15 April 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510493">NCT04510493</ext-link></td><td align="center" rowspan="1" colspan="1">8 September 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 3</td></tr><tr><td rowspan="7" align="left" colspan="1">Quercetin</td><td rowspan="7" align="center" colspan="1">TNF-&#945; inhibition</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04377789">NCT04377789</ext-link></td><td align="center" rowspan="1" colspan="1">18 February 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04468139">NCT04468139</ext-link></td><td align="center" rowspan="1" colspan="1">13 July 2020</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Phase 4</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05037240">NCT05037240</ext-link></td><td align="center" rowspan="1" colspan="1">8 September 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05130671">NCT05130671</ext-link></td><td align="center" rowspan="1" colspan="1">28 January 2022</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04851821">NCT04851821</ext-link></td><td align="center" rowspan="1" colspan="1">27 July 2021</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04853199">NCT04853199</ext-link></td><td align="center" rowspan="1" colspan="1">28 July 2021</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Early phase 1</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04536090">NCT04536090</ext-link></td><td align="center" rowspan="1" colspan="1">23 August 2021</td><td align="center" rowspan="1" colspan="1">Not recruiting yet</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td rowspan="2" align="left" colspan="1">Berberine</td><td rowspan="2" align="center" colspan="1">Cytokine storm</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05228626">NCT05228626</ext-link></td><td align="center" rowspan="1" colspan="1">8 February 2022</td><td align="center" rowspan="1" colspan="1">Not recruiting yet</td><td align="center" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04479202">NCT04479202</ext-link></td><td align="center" rowspan="1" colspan="1">21 July 2020</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 4</td></tr><tr><td align="left" rowspan="1" colspan="1">Adalimumab</td><td align="center" rowspan="1" colspan="1">TNF-&#945;</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03464136">NCT03464136</ext-link></td><td align="center" rowspan="1" colspan="1">11 January 2022</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">Phase 3</td></tr></tbody></table></table-wrap></sec><sec id="s6"><title>6 Therapeutic targets involving viral proteins</title><p>As far as blocking the virus by inhibiting viral proteins is concerned, therapeutic targets can be generally divided into two main categories.<list list-type="simple"><list-item><p>&#10003; Inhibition of viral entry</p></list-item><list-item><p>&#10003; Inhibition of replication machinery</p></list-item></list>
</p><sec id="s6-1"><title>6.1 Inhibition of viral entry</title><p>As stated in <xref rid="s3" ref-type="sec">section 3</xref>, SARS-CoV-2 enters the cell through its spike protein by interacting with the host cell receptor (ACE2) and host cell proteases that are involved in the activation of spike. Inhibiting the viral entry may be an efficient way to stop further infection. Multiple strategies are being utilized to block the Spike protein (<xref rid="B35" ref-type="bibr">Dai and Gao, 2020</xref>). The most efficient among them is the use of convalescent plasma, which contains anti-SARS-CoV-2 antibodies produced by a recovered COVID-19 patient. Convalescent plasma is being used and tested in a clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04356534">NCT04356534</ext-link>). An anti-spike monoclonal antibody against SARS-CoV-2 is being assessed in a phase 3 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04452318">NCT04452318</ext-link>).</p><p>Blockage of TMRPSS2 is one of the best ways to inhibit the virus entry because this protein is indispensable for the viral pathogenesis. Camostat mesilate and enzalutamide have been reported to inhibit TMPRSS2 <italic toggle="yes">in vitro</italic>, and at present, they are in phase 2 clinical trials (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04455815">NCT04455815</ext-link></italic> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04475601">NCT04475601</ext-link>, respectively). Nafamostat mesilate also inhibits TMPRSS2 and is being tested in a phase 3 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04390594">NCT04390594</ext-link>).</p><p>Blocking ACE2 is another choice for blocking the virus entry. It has been demonstrated that ACE2 blockage through derivative peptides can inhibit the infectivity by up to 74% (<xref rid="B207" ref-type="bibr">Yang et al., 2020</xref>). Today, several drugs that block ACE2 are in clinical trials. Drugs which inhibit angiotensin receptor have also been evaluated to inhibit viral entry. One of them (losartan) is being evaluated in a phase 4 trial (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04394117">NCT04394117</ext-link></italic>
<bold>)</bold>. Another drug&#8212;telmisartan&#8212;which also blocks ACE2, has been tested in phase 4 clinical trial (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04355936">NCT04355936</ext-link></italic>
<bold>)</bold>. Other drugs that block ACE2 have been tested in clinical trials include bromhexine with or without hydroxychloroquine and valsartan (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04355026">NCT04355026</ext-link></italic> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04335786">NCT04335786</ext-link>, respectively). Furin inhibitors have been proved to inhibit viral entry and replication, and are further studied for their potential to be used as a therapeutic agent against SARS-CoV-2 (<xref rid="B25" ref-type="bibr">Cheng et al., 2020</xref>; <xref rid="B40" ref-type="bibr">Devi et al., 2022</xref>).</p></sec><sec id="s6-2"><title>6.2 Inhibition of Replication Machinery</title><sec id="s6-2-1"><title>6.2.1 3Cl-Pro</title><p>3Cl-pro, also known as Main protease (M-pro), is a chymotrypsin-like protease that is 306 aa long and has a molecular weight of 33.8&#160;kDa. Phylogenetic analysis of 3Cl-pro of SARS-CoV-2 revealed that it shares 96% structural similarity with that of SARS-CoV. 3Cl-pro is first cleaved from the polyprotein between Nsp4 and Nsp6 by autocleavage, and then it cleaves the polyprotein at 11 sites. It also participates in the maturation of the nonstructural proteins and thus gives rise to multiple proteins crucial for viral replication. These proteins include RdRp, helicase, exonuclease, and endoRNase. The fact that this protease is essential for the formation of proteins crucial for viral replication makes it an attractive drug target (<xref rid="B199" ref-type="bibr">Wu et al., 2020</xref>).</p><p>Lopinavir in combination with ritonavir has been approved by the FDA against HIV. Lopinavir is a protease inhibitor, whereas ritonavir inhibits metabolic inactivation of lopinavir by suppressing cytochrome P450 3A. Thus, ritonavir serves as a metabolic enhancer for lopinavir while lopinavir acts as a protease inhibitor and hence as the main antiviral in this combination (<xref rid="B188" ref-type="bibr">Tobaiqy et al., 2020</xref>). As for COVID-19, the main target of lopinavir is 3Cl-pro (<xref rid="B135" ref-type="bibr">Nukoolkarn et al., 2008</xref>). Currently, the combination is in a phase 4 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04255017">NCT04255017</ext-link>). Some toxic and adverse effects of lopinavir/ritonavir have been reported; therefore, these drugs need further research. PF-07321332 is a 3CLpro inhibitor with strong antiviral activity <italic toggle="yes">in vitro</italic> against SARS-CoV-2 and other coronaviruses and it has been tested by <italic toggle="yes">in silico</italic> studies and clinical trial as well (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04756531">NCT04756531</ext-link>) (<xref rid="B2" ref-type="bibr">Ahmad et al., 2021</xref>). Another protease inhibitor that is being evaluated in clinical trials is danoprevir in combination with ritonavir. Danoprevir was approved by China&#8217;s FDA in 2018 for the treatment of HCV infection. It targets the NS3 protease in HCV and has a half-maximal inhibitory concentration of 0.29&#160;&#181;M (Chen et al.). It has been tested against COVID-19 in a phase 4 trial (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04345276">NCT04345276</ext-link></italic>). Lately, it is being reported that sitagliptin and daclatasvir target PL-pro, whereas lycorine HCl and nelfinavir mesylate inhibit SARS-CoV-2 M-pro (<xref rid="B132" ref-type="bibr">Narayanan et al., 2022</xref>).</p><p>PL-pro is the papain-like protease encoded by the <italic toggle="yes">nsp3</italic> gene. It acts on the polyprotein at the N terminus and cleaves it into three nonstructural proteins that are indispensable for the replication cycle. Aside from functioning as the protease, it not only inhibits the innate immune response of the cell by suppressing IFN production but also recognizes the C terminus of ubiquitin and serves as deubiquitinase (<xref rid="B190" ref-type="bibr">Ullrich and Nitsche, 2020</xref>).</p><p>Therefore, being pivotal for viral replication, PL-pro is an appealing target for therapeutic regimens. Nevertheless, today, there is no FDA-approved drug that targets PL-pro. Possible adverse effects may be a reason for the absence of FDA approval because this drug mimics host deubiquitinases and hence may have a huge number of adverse effects and can be cytotoxic.</p></sec><sec id="s6-2-2"><title>6.2.2 RdRp</title><p>This is an enzyme that is most crucial for the viral life cycle and is the most conserved enzyme among various viruses including hepatitis C virus, Zika virus, and coronaviruses. Because RdRp structure is conserved among many species, its function and mechanism of action are conserved too. For successful replication of the virus, it first synthesizes RdRp so that positive-sense ssRNA can be produced. Owing to the similarity of structure and function among RdRps of different RNA viruses, it is believed that the broad-spectrum antivirals that act on RdRp may inhibit replication of many different RNA viruses.</p><p>RdRp is an essential enzyme catalyzing viral replication by means of the 3&#8242; polyA end of the positive-sense ssRNA as a template to synthesize the complementary strand. Two mechanisms have been proposed to explain the initiation of genome replication. The first one is primer-dependent initiation of synthesis, and the second mechanism is primer-independent synthesis also known as <italic toggle="yes">de novo</italic> synthesis. In case of primer-dependent synthesis, new nucleotides are added to the already present 3&#8242; hydroxyl end provided by the bound oligonucleotide or the protein primer. By contrast, in the case of the <italic toggle="yes">de novo</italic> synthesis, genomic-RNA synthesis is catalyzed by the polymerase itself or by co-factors of the polymerase without any pre-existing 3&#8242; hydroxyl end (<xref rid="B50" ref-type="bibr">Flint et al., 2009</xref>). As for SARS-CoV-2, Nsp7 and Nsp8 serve as these co-factors. Nsp8 can synthesize a primer of up to 6 nucleotides (<xref rid="B65" ref-type="bibr">Hillen et al., 2020</xref>). The elongation complex consists of 14 bases in the template strand and 11 bases in the primer strand, but for the initiation of the polymerization reaction, the first one or two nucleotides of the primer are very important (<xref rid="B159" ref-type="bibr">Romano et al., 2020</xref>).</p><p>Targeting RdRp by an antiviral can be effective because stopping this enzyme will inhibit viral replication, and thus the infection cycle will be blocked (<xref rid="B218" ref-type="bibr">Zhao J. et al., 2021</xref>; <xref rid="B80" ref-type="bibr">Juki&#269; et al., 2021</xref>). Moreover, RdRp has no host cell homolog. Nevertheless, the challenges associated with protein expression, purification, and catalytic activity in <italic toggle="yes">vitro</italic> systems tend to be limitations of RdRp as a target of an antiviral (<xref rid="B224" ref-type="bibr">Zhu et al., 2020</xref>).</p><p>To date, several drugs that target RdRp have been proposed as COVID-19 therapeutics, and many of them are being tested in clinical trials. At present, remdesivir, favipiravir, and maraviroc are such drugs. Remdesivir, an adenosine analog, has been found to be consistently effective against four families of viruses: Paramyxoviridae, Filoviridae, Pneumoviridae, and Coronaviridae (<xref rid="B143" ref-type="bibr">Pardo et al., 2020</xref>). It is reported to be effective against SARS-CoV-2 <italic toggle="yes">in vitro</italic> studies, and at present, it has been tested in phase 3 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04409262">NCT04409262</ext-link>).</p><p>Another promising drug is favipiravir. It is a guanine analog that inhibits RdRp. It was initially approved by the FDA in 2014 and is used against influenza A and B. It has been proposed as a drug against influenza strains that are resistant to neuraminidase inhibitors (<xref rid="B104" ref-type="bibr">Li H. et al., 2020</xref>). Favipiravir was recently tested against COVID-19 and was found effective, with an excellent half-maximal effective concentration of 61.88&#160;&#181;M. It has been tested in phase 3 clinical trial (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04464408">NCT04464408</ext-link></italic>).</p><p>Ribavirin has been employed in combination with IFN-&#945; against HCV (<xref rid="B57" ref-type="bibr">Hadziyannis et al., 2004</xref>). It is a guanosine analog and has been found to exert broad-spectrum antiviral action against various DNA and RNA viruses (<xref rid="B183" ref-type="bibr">Te et al., 2007</xref>). Today, ribavirin in combination with IFN-&#946;-1b is being assessed in a phase 2 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04494399">NCT04494399</ext-link>). Besides, ribavirin is being tested in combination with sofosbuvir in another clinical study currently in phase 3 trial (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04460443">NCT04460443</ext-link></italic>
<bold>).</bold>
</p></sec></sec><sec id="s6-3"><title>6.3 Accessory proteins</title><sec id="s6-3-1"><title>6.3.1 Exonuclease</title><p>Some of the most widely used antivirals are the nucleotide analogs that block viral replication by getting incorporated into the elongated genome, consequently leading to termination of the genome synthesis, thereby inhibiting the viral replication cycle. This approach is particularly useful against RNA viruses because RNA polymerase does not possess a proofreading activity. This drawback makes RNA viruses more susceptible to mutations and to nucleotide-based inhibitors (<xref rid="B124" ref-type="bibr">Modrow et al., 2013</xref>). Nonetheless, coronaviruses are an exception in this context because they possess exonuclease and endonuclease. The N terminus of Nsp14 serves as the exonuclease. A nucleotide analog incorporated in the growing strand is readily removed from the strand. Hence, the virus continues its replication without any hinderance (<xref rid="B55" ref-type="bibr">Gurung, 2020</xref>). Moreover, guanine-N7 methyltransferase, which is involved in the capping of SARS-CoV-2 is also being investigated for targeting in order to interfere with viral pathogenesis (<xref rid="B167" ref-type="bibr">Selvaraj et al., 2021</xref>). In an <italic toggle="yes">in</italic> silico study, Saquinavir, Hypericin, Baicalein and Bromocriptine have been found to interact with Nsp14 (<xref rid="B109" ref-type="bibr">Liu et al., 2021a</xref>). Therefore, Nsp14 can serve as a promising target, particularly when RdRp is being suppressed with nucleotide analogs.</p></sec><sec id="s6-3-2"><title>6.3.2 Helicase</title><p>Helicases are multifunctional proteins of Coronaviridae and have been conserved over the course of evolution. The helicase of SARS-CoV-2 belongs to helicase superfamily 1 (<xref rid="B175" ref-type="bibr">Shu et al., 2020</xref>). It contains three main domains: an N-terminal domain, metal-binding domain, and helicase domain. Helicase hydrolyzes nucleotides of DNA as well as RNA to unwind the helix in the 5&#8242;-to-3&#8242; direction and is a crucial component of viral replication machinery (<xref rid="B199" ref-type="bibr">Wu et al., 2020</xref>). Therefore, this enzyme has been suggested as an effective druggable target. Some authors reported that vapreotide and atazanavir are candidate drugs against the helicase of SARS-CoV-2 (<xref rid="B10" ref-type="bibr">Francis Borgio et al., 2020</xref>). Atazanavir is currently being evaluated in a clinical trial against COVID-19 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04468087">NCT04468087</ext-link>).</p></sec><sec id="s6-3-3"><title>6.3.3 Virulence Factors</title><p>Apart from participating in replication, viral proteins interfere with the host immune system and either antagonize or enhance the immune response depending upon the context. Such proteins can also be a target for drug design.</p><p>Nsp1, also known as the leader peptide, is encoded by the first nonstructural-protein gene in the SARS-CoV-2 genome. Nsp1 of SARS-CoV and that of SARS-CoV-2 are 100% similar in amino acid sequence. Some authors reported that Nsp1 of SARS-CoV inhibits IFN-&#946; expression; furthermore, it induces the degradation of host endogenous mRNAs (<xref rid="B82" ref-type="bibr">Kamitani et al., 2006</xref>). It has also been observed that SARS-CoV-2 ORF9b interacts with TOM70 and inhibits IFN-&#946; production, and hence no antiviral response from the host machinery is induced (<xref rid="B78" ref-type="bibr">Jiang et al., 2020</xref>). Moreover, viral protein ORF9b participates in immune evasion too, by influencing the interaction of MAVS with TOM70 (<xref rid="B92" ref-type="bibr">Konno et al., 2020</xref>; <xref rid="B162" ref-type="bibr">Ribero et al., 2020</xref>).</p></sec></sec></sec><sec id="s7"><title>7 Concluding Remarks</title><p>SARS-CoV-2 has been causing great harm since the beginning of the pandemic. As reviewed above, multiple innate-immunity receptors play a part in the pathogenicity of SARS-CoV-2. Despite the availability of vaccines and drugs, this virus still poses a great danger to humanity. Although it is not very common for RNA viruses to possess exonuclease activity, SARS-CoV-2 has the exonuclease activity as it belongs to <italic toggle="yes">Nidovirales</italic> order. Despite the exonuclease activity, the emergence of multiple variants has made it clear that the viral proteins can keep on mutating (thereby making the available drugs inefficacious against SARS-CoV-2). This phenomenon points to the importance of exploring the therapeutic potential of human endogenous immune receptors against COVID-19. Innate immune system is body&#8217;s first line of defense against any invading pathogen. A wide variety of innate-immunity receptors including TLRs, RLRs, CLRs, and their accessory signaling molecules play an important role in virus sensing and in the development of an optimal immune response. Once the viral components are detected by the cellular innate immune receptors, the body mounts an optimum immune response against SARS-CoV-2. The key features of the antiviral immune response include interferon generation, cytokine production and cell death. However, viral proteins interfere the immune response and create trouble for the body by hyperactivating the immune system which leads to cytokine storm. As a result of cytokine storm and other co-morbidities, the disease complications and severity increases, thus causing death of the host.</p><p>The present review has summarized current knowledge about innate-immunity receptors and about signaling molecules in relation to COVID-19 pathophysiology as well as the possibility of their use as druggable targets. Our review also summarizes the knowledge about currently available drugs as well as the drugs under clinical trials which are be being tested these days. Various drugs which target immune receptors and other signaling molecules have also been summarized in the review. Antibodies targeting cytokines and their receptors, including Canakinumab, Anakinra, Emapalumab, Sarilumab, and Tocilizumab, are under clinical trials. Although the success rate is relatively low when it comes to the application of innate-immunity receptors for the therapeutic purposes, the high mutation rate of RNA viruses makes these receptors a promising option.</p></sec></body><back><sec id="s8"><title>Author Contributions</title><p>MF, AK, and BA conceived the scope of the manuscript and wrote the manuscript. MF, AK, BA, and SC revised the manuscript. Project administration and funding acquisition is done by SC and MK. All authors read and approved the final manuscript.</p></sec><sec id="s9"><title>Funding</title><p>This research was supported by South Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (HN21C1058). This work was also supported by the National Research Foundation of Korea (NRF-2022M3A9G1014520, 2019M3D1A1078940 and 2019R1A6A1A11051471).</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aboudounya</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Heads</surname><given-names>R. J.</given-names></name></person-group> (<year>20212021</year>). <article-title>SARS-CoV-2 Spike S1 Glycoprotein Is a TLR4 Agonist, Upregulates ACE2 Expression and Induces Pro-inflammatory M1 Macrophage Polarisation</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2021.08.11.455921</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Batool</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ain</surname><given-names>Q. u.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations</article-title>. <source>Ijms</source><volume>22</volume>, <fpage>9124</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22179124</pub-id><pub-id pub-id-type="pmid">34502033</pub-id><pub-id pub-id-type="pmcid">PMC8430524</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albornoz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Amarilla</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X. X.</given-names></name><name name-style="western"><surname>Wijesundara</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>20222022</year>). <article-title>SARS-CoV-2 Drives NLRP3 Inflammasome Activation in Human Microglia through Spike-ACE2 Receptor Interaction</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2022.01.11.475947</pub-id><pub-id pub-id-type="pmcid">PMC10615762</pub-id><pub-id pub-id-type="pmid">36316366</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amraei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Napoleon</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Suder</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Berrigan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2</article-title>. <source>ACS Cent. Sci.</source><volume>7</volume>, <fpage>1156</fpage>&#8211;<lpage>1165</lpage>. <pub-id pub-id-type="doi">10.1021/ACSCENTSCI.0C01537/SUPPL_FILE/OC0C01537_SI_001.PDF</pub-id><pub-id pub-id-type="pmid">34341769</pub-id><pub-id pub-id-type="pmcid">PMC8265543</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>E.</given-names></name></person-group> (<year>2012</year>). <source>Coronaviruses</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Goldman&#8217;s Cecil Med.</publisher-name>, <fpage>2102</fpage>&#8211;<lpage>2104</lpage>. <pub-id pub-id-type="doi">10.1016/b978-1-4377-1604-7.00374-2</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Askenase</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Sansing</surname><given-names>L. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Stages of the Inflammatory Response in Pathology and Tissue Repair after Intracerebral Hemorrhage</article-title>. <source>Semin. Neurol.</source><volume>36</volume>, <fpage>288</fpage>&#8211;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1055/S-0036-1582132</pub-id><pub-id pub-id-type="pmid">27214704</pub-id><pub-id pub-id-type="pmcid">PMC4956485</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Astuti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ysrafil</surname></name></person-group> (<year>2020</year>). <article-title>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An Overview of Viral Structure and Host Response</article-title>. <source>Diabetes Metab. Syndr.</source><volume>14</volume>, <fpage>407</fpage>&#8211;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1016/j.dsx.2020.04.020</pub-id><pub-id pub-id-type="pmid">32335367</pub-id><pub-id pub-id-type="pmcid">PMC7165108</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awadasseid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>Initial Success in the Identification and Management of the Coronavirus Disease 2019 (COVID-19) Indicates Human-To-Human Transmission in Wuhan, China</article-title>. <source>Int. J. Biol. Sci.</source><volume>16</volume>, <fpage>1846</fpage>&#8211;<lpage>1860</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.45018</pub-id><pub-id pub-id-type="pmid">32398954</pub-id><pub-id pub-id-type="pmcid">PMC7211182</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermejo-Jambrina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Helgers</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Hertoghs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nijmeijer</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Stunnenberg</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>C-Type Lectin Receptors in Antiviral Immunity and Viral Escape</article-title>. <source>Front. Immunol.</source><volume>9</volume>, <fpage>590</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2018.00590/BIBTEX</pub-id><pub-id pub-id-type="pmid">29632536</pub-id><pub-id pub-id-type="pmcid">PMC5879224</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borgio</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Alsuwat</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Al Otaibi</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Almandil</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Al Asoom</surname><given-names>L. I.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>State-of-the-art Tools Unveil Potent Drug Targets Amongst Clinically Approved Drugs to Inhibit Helicase in SARS-CoV-2</article-title>. <source>Arch. Med. Sci.</source><volume>16</volume>, <fpage>508</fpage>&#8211;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.5114/aoms.2020.94567</pub-id><pub-id pub-id-type="pmid">32399096</pub-id><pub-id pub-id-type="pmcid">PMC7212215</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bortolotti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gentili</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schiuma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Beltrami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Strazzabosco</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Tlr3 and Tlr7 Rna Sensor Activation during Sars-Cov-2 Infection</article-title>. <source>Microorganisms</source><volume>9</volume>, <fpage>1820</fpage>. <pub-id pub-id-type="doi">10.3390/MICROORGANISMS9091820/S1</pub-id><pub-id pub-id-type="pmid">34576716</pub-id><pub-id pub-id-type="pmcid">PMC8465566</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brisse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>H.</given-names></name></person-group> (<year>2019</year>). <article-title>Comparative Structure and Function Analysis of the RIG-I-like Receptors: RIG-I and MDA5</article-title>. <source>Front. Immunol.</source><volume>10</volume>, <fpage>1586</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2019.01586/BIBTEX</pub-id><pub-id pub-id-type="pmid">31379819</pub-id><pub-id pub-id-type="pmcid">PMC6652118</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchmann</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Evolution of Innate Immunity: Clues from Invertebrates via Fish to Mammals</article-title>. <source>Front. Immunol.</source><volume>5</volume>, <fpage>459</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2014.00459/BIBTEX</pub-id><pub-id pub-id-type="pmid">25295041</pub-id><pub-id pub-id-type="pmcid">PMC4172062</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Busnadiego</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fernbach</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pohl</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Karakus</surname><given-names>U.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trkola</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2</article-title>. <source>MBio</source><volume>11</volume>, <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1128/MBIO.01928-20</pub-id><pub-id pub-id-type="pmcid">PMC7484541</pub-id><pub-id pub-id-type="pmid">32913009</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buwitt-Beckmann</surname><given-names>U.</given-names></name><name name-style="western"><surname>Heine</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wiesm&#252;ller</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>TLR1- and TLR6-independent Recognition of Bacterial Lipopeptides</article-title>. <source>J. Biol. Chem.</source><volume>281</volume>, <fpage>9049</fpage>&#8211;<lpage>9057</lpage>. <pub-id pub-id-type="doi">10.1074/JBC.M512525200</pub-id><pub-id pub-id-type="pmid">16455646</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cama</surname><given-names>V. F.</given-names></name><name name-style="western"><surname>Mar&#237;n-Prida</surname><given-names>J.</given-names></name><name name-style="western"><surname>Acosta-Rivero</surname><given-names>N.</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>E. F.</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>L. O.</given-names></name><name name-style="western"><surname>Casades&#250;s</surname><given-names>A. V.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The Microglial NLRP3 Inflammasome Is Involved in Human SARS-CoV-2 Cerebral Pathogenicity: A Report of Three Post-mortem Cases</article-title>. <source>J. Neuroimmunol.</source><volume>361</volume>, <fpage>577728</fpage>. <pub-id pub-id-type="doi">10.1016/J.JNEUROIM.2021.577728</pub-id><pub-id pub-id-type="pmid">34619427</pub-id><pub-id pub-id-type="pmcid">PMC8480138</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>To</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>S. A.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2, SARS-CoV-1, and HIV-1 Derived ssRNA Sequences Activate the NLRP3 Inflammasome in Human Macrophages through a Non-classical Pathway</article-title>. <source>iScience</source><volume>24</volume>, <fpage>102295</fpage>. <pub-id pub-id-type="doi">10.1016/J.ISCI.2021.102295</pub-id><pub-id pub-id-type="pmid">33718825</pub-id><pub-id pub-id-type="pmcid">PMC7939994</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cantuti-Castelvetri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pedro</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Djannatian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Franz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuivanen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity</article-title>. <source>Science</source><volume>370</volume>, <fpage>856</fpage>&#8211;<lpage>860</lpage>. <pub-id pub-id-type="doi">10.1126/SCIENCE.ABD2985/SUPPL_FILE/ABD2985_MDAR_REPRODUCIBILITY_CHECKLIST.PDF</pub-id><pub-id pub-id-type="pmid">33082293</pub-id><pub-id pub-id-type="pmcid">PMC7857391</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rajsbaum</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>P.-Y.</given-names></name></person-group> (<year>20212021</year>). <article-title>Ubiquitination of SARS-CoV-2 ORF7a Promotes Antagonism of Interferon Response</article-title>. <source>Cell. Mol. Immunol.</source><volume>18</volume> (<issue>18</issue>), <fpage>746</fpage>&#8211;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-00603-6</pub-id><pub-id pub-id-type="pmcid">PMC7815971</pub-id><pub-id pub-id-type="pmid">33473190</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>SARS-CoV-2-Positive Sputum and Feces after Conversion of Pharyngeal Samples in Patients with COVID-19</article-title>. <source>Ann. Intern. Med.</source><volume>172</volume>, <fpage>832</fpage>&#8211;<lpage>834</lpage>. <pub-id pub-id-type="doi">10.7326/M20-0991</pub-id><pub-id pub-id-type="pmid">32227141</pub-id><pub-id pub-id-type="pmcid">PMC7133055</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2016</year>). <source>First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Na&#239;ve and Experienced COVID-19 Patients</source>. <pub-id pub-id-type="doi">10.1101/2020.03.22.20034041</pub-id><pub-id pub-id-type="pmcid">PMC7710192</pub-id><pub-id pub-id-type="pmid">33235105</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>RNA Sensors of the Innate Immune System and Their Detection of Pathogens</article-title>. <source>IUBMB Life</source><volume>69</volume>, <fpage>297</fpage>&#8211;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1002/IUB.1625</pub-id><pub-id pub-id-type="pmid">28374903</pub-id><pub-id pub-id-type="pmcid">PMC7165898</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <fpage>1409</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2021.589095/BIBTEX</pub-id><pub-id pub-id-type="pmcid">PMC8115911</pub-id><pub-id pub-id-type="pmid">33995341</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D.</given-names></name></person-group> (<year>2020b</year>). <article-title>Emerging Coronaviruses: Genome Structure, Replication, and Pathogenesis</article-title>. <source>J. Med. Virol.</source><volume>92</volume>, <fpage>2249</fpage>&#8211;<lpage>2423</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.26234</pub-id><pub-id pub-id-type="pmid">32881013</pub-id><pub-id pub-id-type="pmcid">PMC7435528</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y. W.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects</article-title>. <source>Cell. Rep.</source><volume>33</volume>, <fpage>108254</fpage>. <pub-id pub-id-type="doi">10.1016/J.CELREP.2020.108254</pub-id><pub-id pub-id-type="pmid">33007239</pub-id><pub-id pub-id-type="pmcid">PMC7510585</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ourthiague</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Distinct Single-Cell Signaling Characteristics Are Conferred by the MyD88 and TRIF Pathways during TLR4 Activation</article-title>. <source>Sci. Signal.</source><volume>8</volume>. <pub-id pub-id-type="doi">10.1126/SCISIGNAL.AAA5208/SUPPL_FILE/</pub-id><pub-id pub-id-type="pmcid">PMC6764925</pub-id><pub-id pub-id-type="pmid">26175492</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>In Silico analyses on the Comparative Sensing of SARS-CoV-2 mRNA by the Intracellular TLRs of Humans</article-title>. <source>J. Med. Virol.</source><volume>93</volume>, <fpage>2476</fpage>&#8211;<lpage>2486</lpage>. <pub-id pub-id-type="doi">10.1002/JMV.26776</pub-id><pub-id pub-id-type="pmid">33404091</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group> (<year>2020a</year>). <article-title>In Silico studies on the Comparative Characterization of the Interactions of SARS-CoV-2 Spike Glycoprotein with ACE-2 Receptor Homologs and Human TLRs</article-title>. <source>J. Med. Virol.</source><volume>92</volume>, <fpage>2105</fpage>&#8211;<lpage>2113</lpage>. <pub-id pub-id-type="doi">10.1002/JMV.25987</pub-id><pub-id pub-id-type="pmid">32383269</pub-id><pub-id pub-id-type="pmcid">PMC7267663</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group> (<year>2020b</year>). <article-title>In Silico studies on the Comparative Characterization of the Interactions of SARS-CoV-2 Spike Glycoprotein with ACE-2 Receptor Homologs and Human TLRs</article-title>. <source>J. Med. Virol.</source><volume>92</volume>, <fpage>2105</fpage>&#8211;<lpage>2113</lpage>. <pub-id pub-id-type="doi">10.1002/JMV.25987</pub-id><pub-id pub-id-type="pmid">32383269</pub-id><pub-id pub-id-type="pmcid">PMC7267663</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Younes</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus COV-19/sars-CoV-2 Affects Women Less Than Men: Clinical Response to Viral Infection</article-title>. <source>J. Biol. Regul. Homeost. Agents</source><volume>34</volume>, <fpage>339</fpage>&#8211;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.23812/EDITORIAL-CONTI-3</pub-id><pub-id pub-id-type="pmid">32253888</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Potje</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Fraga-Silva</surname><given-names>T. F. C.</given-names></name><name name-style="western"><surname>da Silva-Neto</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Mitochondrial DNA and TLR9 Activation Contribute to SARS-CoV-2-Induced Endothelial Cell Damage</article-title>. <source>Vasc. Pharmacol.</source><volume>142</volume>, <fpage>106946</fpage>. <pub-id pub-id-type="doi">10.1016/J.VPH.2021.106946</pub-id><pub-id pub-id-type="pmcid">PMC8612754</pub-id><pub-id pub-id-type="pmid">34838735</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costela-Ruiz</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Illescas-Montes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Puerta-Puerta</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Melguizo-Rodr&#237;guez</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Infection: The Role of Cytokines in COVID-19 Disease</article-title>. <source>Cytokine Growth Factor Rev.</source><volume>54</volume>, <fpage>62</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/J.CYTOGFR.2020.06.001</pub-id><pub-id pub-id-type="pmid">32513566</pub-id><pub-id pub-id-type="pmcid">PMC7265853</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crellin</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>R. V.</given-names></name><name name-style="western"><surname>Hadisfar</surname><given-names>O.</given-names></name><name name-style="western"><surname>Allan</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Levings</surname><given-names>M. K.</given-names></name></person-group> (<year>2005</year>). <article-title>Human CD4+ T Cells Express TLR5 and its Ligand Flagellin Enhances the Suppressive Capacity and Expression of FOXP3 in CD4+CD25+ T Regulatory Cells</article-title>. <source>J. Immunol.</source><volume>175</volume>, <fpage>8051</fpage>&#8211;<lpage>8059</lpage>. <pub-id pub-id-type="doi">10.4049/JIMMUNOL.175.12.8051</pub-id><pub-id pub-id-type="pmid">16339542</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Rosa Mesquita</surname><given-names>R.</given-names></name><name name-style="western"><surname>Francelino Silva Junior</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Santos Santana</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Farias de Oliveira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Campos Alc&#226;ntara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Monteiro Arnozo</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Clinical Manifestations of COVID-19 in the General Population: Systematic Review</article-title>. <source>Wien. Klin. Wochenschr.</source><volume>133</volume>, <fpage>377</fpage>&#8211;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1007/S00508-020-01760-4/TABLES/2</pub-id><pub-id pub-id-type="pmid">33242148</pub-id><pub-id pub-id-type="pmcid">PMC7689634</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G. F.</given-names></name></person-group> (<year>20202020</year>). <article-title>Viral Targets for Vaccines against COVID-19</article-title>. <source>Nat. Rev. Immunol.</source><volume>21</volume>, <fpage>73</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-00480-0</pub-id><pub-id pub-id-type="pmcid">PMC7747004</pub-id><pub-id pub-id-type="pmid">33340022</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasgupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Molecular Docking of SARS-COV-2 Spike Epitope Sequences Identifies Heterodimeric Peptide-Protein Complex Formation with Human Zo-1, TLR8 and Brain Specific Glial Proteins</article-title>. <source>Med. Hypotheses</source><volume>157</volume>, <fpage>110706</fpage>. <pub-id pub-id-type="doi">10.1016/J.MEHY.2021.110706</pub-id><pub-id pub-id-type="pmid">34673372</pub-id><pub-id pub-id-type="pmcid">PMC8511551</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Re</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corpetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seguella</surname><given-names>L.</given-names></name><name name-style="western"><surname>Steardo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Palenca</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Ultramicronized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages</article-title>. <source>Metabolites</source><volume>202111</volume>, <fpage>592</fpage>. <comment><italic toggle="yes">Page 592</italic> 11</comment>. <pub-id pub-id-type="doi">10.3390/METABO11090592</pub-id><pub-id pub-id-type="pmcid">PMC8472716</pub-id><pub-id pub-id-type="pmid">34564408</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Valle</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Kim-Schulze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Nirenberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><etal/></person-group> (<year>20202020</year>). <article-title>An Inflammatory Cytokine Signature Predicts COVID-19 Severity and Survival</article-title>. <source>Nat. Med.</source><volume>26</volume>, <fpage>1636</fpage>&#8211;<lpage>1643</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-1051-9</pub-id><pub-id pub-id-type="pmcid">PMC7869028</pub-id><pub-id pub-id-type="pmid">32839624</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devarajan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vaseghi</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Hydroxychloroquine Can Potentially Interfere with Immune Function in COVID-19 Patients: Mechanisms and Insights</article-title>. <source>Redox Biol.</source><volume>38</volume>, <fpage>101810</fpage>. <pub-id pub-id-type="doi">10.1016/J.REDOX.2020.101810</pub-id><pub-id pub-id-type="pmid">33360293</pub-id><pub-id pub-id-type="pmcid">PMC7704069</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>K. P.</given-names></name><name name-style="western"><surname>Pourkarim</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Thijssen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sureda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khayatkashani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cismaru</surname><given-names>C. A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>A Perspective on the Applications of Furin Inhibitors for the Treatment of SARS-CoV-2</article-title>. <source>Pharmacol. Rep.</source><volume>74</volume>, <fpage>425</fpage>&#8211;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1007/S43440-021-00344-X/FIGURES/1</pub-id><pub-id pub-id-type="pmid">35031970</pub-id><pub-id pub-id-type="pmcid">PMC8760129</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diebold</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Kaisho</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hemmi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reis E Sousa</surname><given-names>C.</given-names></name></person-group> (<year>2004</year>). <article-title>Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA</article-title>. <source>Science</source><volume>303</volume>, <fpage>1529</fpage>&#8211;<lpage>1531</lpage>. <pub-id pub-id-type="doi">10.1126/SCIENCE.1093616/SUPPL_FILE/DIEBOLD.SOM.PDF</pub-id><pub-id pub-id-type="pmid">14976261</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T. J.</given-names></name></person-group> (<year>2020</year>). <article-title>Is SARS-CoV-2 Also an Enteric Pathogen with Potential Fecal-Oral Transmission? A COVID-19 Virological and Clinical Review</article-title>. <source>Gastroenterology</source><volume>159</volume>, <fpage>53</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.04.052</pub-id><pub-id pub-id-type="pmid">32353371</pub-id><pub-id pub-id-type="pmcid">PMC7184994</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehre</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Infection of Airway Cells</article-title>. <source>N. Engl. J. Med.</source><volume>383</volume>, <fpage>969</fpage>. <pub-id pub-id-type="doi">10.1056/NEJMicm2023328</pub-id><pub-id pub-id-type="pmid">32877585</pub-id><pub-id pub-id-type="pmcid">PMC7484746</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Englmeier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Subburayalu</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>What&#8217;s Happening where when SARS-CoV-2 Infects: Are TLR7 and MAFB Sufficient to Explain Patient Vulnerability?</article-title><source>Immun. Ageing</source><volume>19</volume>, <fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1186/S12979-022-00262-3/FIGURES/4</pub-id><pub-id pub-id-type="pmid">35065665</pub-id><pub-id pub-id-type="pmcid">PMC8783172</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallerini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Daga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Picchiotti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Francisci</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Association of Toll-like Receptor 7 Variants with Life-Threatening COVID-19 Disease in Males: Findings from a Nested Case-Control Study</article-title>. <source>Elife</source><volume>10</volume>. <pub-id pub-id-type="doi">10.7554/ELIFE.67569</pub-id><pub-id pub-id-type="pmcid">PMC7987337</pub-id><pub-id pub-id-type="pmid">33650967</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mitrev</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rosalia</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Assas</surname><given-names>B. M.</given-names></name></person-group> (<year>2020a</year>). <article-title>Cytokine Storm and COVID-19: a Chronicle of Pro-inflammatory Cytokines</article-title>. <source>Open Biol.</source><volume>10</volume>, <fpage>200160</fpage>. <pub-id pub-id-type="doi">10.1098/RSOB.200160</pub-id><pub-id pub-id-type="pmid">32961074</pub-id><pub-id pub-id-type="pmcid">PMC7536084</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mitrev</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rosalia</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Assas</surname><given-names>B. M.</given-names></name></person-group> (<year>2020b</year>). <article-title>Cytokine Storm and COVID-19: a Chronicle of Pro-inflammatory Cytokines</article-title>. <source>Open Biol.</source><volume>10</volume>, <fpage>200160</fpage>. <pub-id pub-id-type="doi">10.1098/RSOB.200160</pub-id><pub-id pub-id-type="pmid">32961074</pub-id><pub-id pub-id-type="pmcid">PMC7536084</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farhat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Riekenberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heine</surname><given-names>H.</given-names></name><name name-style="western"><surname>Debarry</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mages</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Heterodimerization of TLR2 with TLR1 or TLR6 Expands the Ligand Spectrum but Does Not Lead to Differential Signaling</article-title>. <source>J. Leukoc. Biol.</source><volume>83</volume>, <fpage>692</fpage>&#8211;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1189/JLB.0807586</pub-id><pub-id pub-id-type="pmid">18056480</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Mancebo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garcinu&#241;o</surname><given-names>S.</given-names></name><name name-style="western"><surname>March</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>S.</given-names></name><etal/></person-group> (<year>20222022</year>). <article-title>IRE1&#945;-XBP1 Activation Elicited by Viral Singled Stranded RNA via TLR8 May Modulate Lung Cytokine Induction in SARS-CoV-2 Pneumonia</article-title>. <source>medRxiv</source>. <pub-id pub-id-type="doi">10.1101/2022.01.26.22269752</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flint</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Enquist</surname><given-names>L. W.</given-names></name><name name-style="western"><surname>Racaniello</surname><given-names>V. R.</given-names></name><name name-style="western"><surname>Skalka</surname><given-names>A. M.</given-names></name></person-group> (<year>2009</year>). <source>Principles of Virology: Volume II</source>, <fpage>419</fpage>.<source>Pathogenesis Control</source></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gankovskaya</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Zinina</surname><given-names>E. V.</given-names></name><name name-style="western"><surname>Zinina</surname><given-names>E. V.</given-names></name><name name-style="western"><surname>Gankovskii</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Semushkin</surname><given-names>A. R.</given-names></name></person-group> (<year>2021</year>). <article-title>Changes in the Expression of Toll-like Receptors, Cytokines and Chemokines in the Cells of the Mucous Membrane of the Oropharynx in Children with COVID-19</article-title>. <source>Immunologiya</source><volume>42</volume>, <fpage>222</fpage>&#8211;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.33029/0206-4952-2021-42-3-222-231</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geijtenbeek</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Gringhuis</surname><given-names>S. I.</given-names></name></person-group> (<year>20092009</year>). <article-title>Signalling through C-type Lectin Receptors: Shaping Immune Responses</article-title>. <source>Nat. Rev. Immunol.</source><volume>9</volume>, <fpage>465</fpage>&#8211;<lpage>479</lpage>. <pub-id pub-id-type="doi">10.1038/nri2569</pub-id><pub-id pub-id-type="pmcid">PMC7097056</pub-id><pub-id pub-id-type="pmid">19521399</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorbalenya</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gulyaeva</surname><given-names>A. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and Naming it SARS-CoV-2</article-title>. <source>Nat. Microbiol.</source><volume>5</volume>, <fpage>536</fpage>&#8211;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id><pub-id pub-id-type="pmid">32123347</pub-id><pub-id pub-id-type="pmcid">PMC7095448</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Madhavan</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Sehgal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sehrawat</surname><given-names>T. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Extrapulmonary Manifestations of COVID-19</article-title>. <source>Nat. Med.</source><volume>26</volume>, <fpage>1017</fpage>&#8211;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0968-3</pub-id><pub-id pub-id-type="pmid">32651579</pub-id><pub-id pub-id-type="pmcid">PMC11972613</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurung</surname><given-names>A. B.</given-names></name></person-group> (<year>2020</year>). <article-title>In Silico structure Modelling of SARS-CoV-2 Nsp13 Helicase and Nsp14 and Repurposing of FDA Approved Antiviral Drugs as Dual Inhibitors</article-title>. <source>Gene Rep.</source><volume>21</volume>, <fpage>100860</fpage>. <pub-id pub-id-type="doi">10.1016/j.genrep.2020.100860</pub-id><pub-id pub-id-type="pmid">32875166</pub-id><pub-id pub-id-type="pmcid">PMC7452913</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haabeth</surname><given-names>O. A. W.</given-names></name><name name-style="western"><surname>Lohmeyer</surname><given-names>J. J. K.</given-names></name><name name-style="western"><surname>Sallets</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blake</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Sagiv-Barfi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Czerwinski</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory</article-title>. <source>ACS Cent. Sci.</source><volume>7</volume>, <fpage>1191</fpage>&#8211;<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1021/ACSCENTSCI.1C00361/SUPPL_FILE/OC1C00361_SI_001</pub-id><pub-id pub-id-type="pmid">34341771</pub-id><pub-id pub-id-type="pmcid">PMC8265720</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadziyannis</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Balan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Diago</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marcellin</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Peginterferon-alpha2a and Ribavirin Combination Therapy in Chronic Hepatitis C: a Randomized Study of Treatment Duration and Ribavirin Dose</article-title>. <source>Ann. Intern. Med.</source><volume>140</volume>, <fpage>346</fpage>&#8211;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-140-5-200403020-00010</pub-id><pub-id pub-id-type="pmid">14996676</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways</article-title>. <source>J. Med. Virol.</source><volume>93</volume>, <fpage>5376</fpage>&#8211;<lpage>5389</lpage>. <pub-id pub-id-type="doi">10.1002/JMV.27050</pub-id><pub-id pub-id-type="pmid">33913550</pub-id><pub-id pub-id-type="pmcid">PMC8242602</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Vojtech</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Laing</surname><given-names>K. J.</given-names></name></person-group> (<year>2011</year>). <article-title>Sensing Disease and Danger: A Survey of Vertebrate PRRs and Their Origins</article-title>. <source>Dev. Comp. Immunol.</source><volume>35</volume>, <fpage>886</fpage>&#8211;<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1016/J.DCI.2011.01.008</pub-id><pub-id pub-id-type="pmid">21241729</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>U.</given-names></name><name name-style="western"><surname>Chaffois</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saulnier</surname><given-names>V.</given-names></name><name name-style="western"><surname>Merck</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tancredi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Human TLR10 Is a Functional Receptor, Expressed by B Cells and Plasmacytoid Dendritic Cells, Which Activates Gene Transcription through MyD88</article-title>. <source>J. Immunol.</source><volume>174</volume>, <fpage>2942</fpage>&#8211;<lpage>2950</lpage>. <pub-id pub-id-type="doi">10.4049/JIMMUNOL.174.5.2942</pub-id><pub-id pub-id-type="pmid">15728506</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>H.</given-names></name><name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Mechanism and Regulation of NLRP3 Inflammasome Activation</article-title>. <source>Trends biochem. Sci.</source><volume>41</volume>, <fpage>1012</fpage>&#8211;<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.1016/J.TIBS.2016.09.002</pub-id><pub-id pub-id-type="pmid">27669650</pub-id><pub-id pub-id-type="pmcid">PMC5123939</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heads</surname><given-names>D. R.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 and Toll-like Receptor 4 (TLR4): SARS-CoV-2 May Activate TLR4 to Increase ACE2 Expression for Entry and Cause Abnormal Inflammatory Signalling: A Cardio-Respiratory Focus</article-title>. <source>Authorea Prepr.</source><pub-id pub-id-type="doi">10.22541/AU.160010865.58124057</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henrick</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X. D.</given-names></name><name name-style="western"><surname>Zahoor</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Abimiku</surname><given-names>A.</given-names></name><name name-style="western"><surname>Osawe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>K. L.</given-names></name></person-group> (<year>2019</year>). <article-title>TLR10 Senses HIV-1 Proteins and Significantly Enhances HIV-1 Infection</article-title>. <source>Front. Immunol.</source><volume>10</volume>, <fpage>482</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2019.00482/BIBTEX</pub-id><pub-id pub-id-type="pmid">30930906</pub-id><pub-id pub-id-type="pmcid">PMC6430187</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrera-Esposito</surname><given-names>D.</given-names></name><name name-style="western"><surname>de los Campos</surname><given-names>G.</given-names></name></person-group> (<year>2022</year>). <article-title>Age-specific Rate of Severe and Critical SARS-CoV-2 Infections Estimated with Multi-Country Seroprevalence Studies</article-title>. <source>BMC Infect. Dis.</source><volume>22</volume>, <fpage>311</fpage>&#8211;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1186/S12879-022-07262-0/TABLES/4</pub-id><pub-id pub-id-type="pmid">35351016</pub-id><pub-id pub-id-type="pmcid">PMC8962942</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hillen</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Kokic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Farnung</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dienemann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tegunov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure of Replicating SARS-CoV-2 Polymerase</article-title>. <source>Nature</source><volume>584</volume>, <fpage>154</fpage>&#8211;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2368-8</pub-id><pub-id pub-id-type="pmid">32438371</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>. <source>Cell.</source><volume>181</volume>, <fpage>271</fpage>&#8211;<lpage>e8</lpage>. <comment>e8</comment>. <pub-id pub-id-type="doi">10.1016/J.CELL.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;rnich</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Gro&#223;kopf</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Schlagowski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tenbusch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Neipel</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation</article-title>. <source>J. Virol.</source><volume>95</volume>, <fpage>2</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00002-21</pub-id><pub-id pub-id-type="pmcid">PMC8104116</pub-id><pub-id pub-id-type="pmid">33608407</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>J. C. C.</given-names></name><name name-style="western"><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pawlak</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Wilen</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Translational Shutdown and Evasion of the Innate Immune Response by SARS-CoV-2 NSP14 Protein</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>118</volume>. <pub-id pub-id-type="doi">10.1073/PNAS.2101161118/SUPPL_FILE/PNAS.2101161118.SAPP.PDF</pub-id><pub-id pub-id-type="pmcid">PMC8214666</pub-id><pub-id pub-id-type="pmid">34045361</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Possible SARS-Coronavirus 2 Inhibitor Revealed by Simulated Molecular Docking to Viral Main Protease and Host Toll-like Receptor</article-title>. <source>Future Virol.</source><volume>15</volume>, <fpage>359</fpage>&#8211;<lpage>368</lpage>. <pub-id pub-id-type="doi">10.2217/FVL-2020-0099/ASSET/IMAGES/LARGE/FIGURE5.JPEG</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huh</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>UNC93B1 Is Essential for the Plasma Membrane Localization and Signaling of Toll-like Receptor 5</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>111</volume>, <fpage>7072</fpage>&#8211;<lpage>7077</lpage>. <pub-id pub-id-type="doi">10.1073/PNAS.1322838111/-/DCSUPPLEMENTAL</pub-id><pub-id pub-id-type="pmid">24778236</pub-id><pub-id pub-id-type="pmcid">PMC4024908</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huleatt</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Nakaar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin</article-title>. <source>Vaccine</source><volume>26</volume>, <fpage>201</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/J.VACCINE.2007.10.062</pub-id><pub-id pub-id-type="pmid">18063235</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphries</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shmuel-Galia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Landis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>S.-L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A Diamidobenzimidazole STING Agonist Protects against SARS-CoV-2 Infection</article-title>. <source>Sci. Immunol.</source><volume>6</volume>. <pub-id pub-id-type="doi">10.1126/SCIIMMUNOL.ABI9002</pub-id><pub-id pub-id-type="pmcid">PMC8158975</pub-id><pub-id pub-id-type="pmid">34010139</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Gangloff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>C. E.</given-names></name></person-group> (<year>2013</year>). <article-title>The Molecular Basis for Recognition of Bacterial Ligands at Equine TLR2, TLR1 and TLR6</article-title>. <source>Vet. Res.</source><volume>44</volume>, <fpage>50</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1186/1297-9716-44-50/FIGURES/5</pub-id><pub-id pub-id-type="pmid">23826682</pub-id><pub-id pub-id-type="pmcid">PMC3716717</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishii</surname><given-names>N.</given-names></name><name name-style="western"><surname>Funami</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tatematsu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Endosomal Localization of TLR8 Confers Distinctive Proteolytic Processing on Human Myeloid Cells</article-title>. <source>J. Immunol.</source><volume>193</volume>, <fpage>5118</fpage>&#8211;<lpage>5128</lpage>. <pub-id pub-id-type="doi">10.4049/JIMMUNOL.1401375/-/DCSUPPLEMENTAL</pub-id><pub-id pub-id-type="pmid">25297876</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G. N.</given-names></name></person-group> (<year>20082008</year>). <article-title>STING Is an Endoplasmic Reticulum Adaptor that Facilitates Innate Immune Signalling</article-title>. <source>Nature</source><volume>455</volume>, <fpage>674</fpage>&#8211;<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1038/nature07317</pub-id><pub-id pub-id-type="pmcid">PMC2804933</pub-id><pub-id pub-id-type="pmid">18724357</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H.</given-names></name></person-group> (<year>2021a2021</year>). <article-title>Mechanisms of SARS-CoV-2 Entry into Cells</article-title>. <source>Nat. Rev. Mol. Cell. Biol.</source><volume>23</volume>, <fpage>3</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id><pub-id pub-id-type="pmcid">PMC8491763</pub-id><pub-id pub-id-type="pmid">34611326</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H.</given-names></name></person-group> (<year>2021b2021</year>). <article-title>Mechanisms of SARS-CoV-2 Entry into Cells</article-title>. <source>Nat. Rev. Mol. Cell. Biol.</source><volume>23</volume>, <fpage>3</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id><pub-id pub-id-type="pmcid">PMC8491763</pub-id><pub-id pub-id-type="pmid">34611326</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H. N.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q. F.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Orf9b Suppresses Type I Interferon Responses by Targeting TOM70</article-title>. <source>Cell. Mol. Immunol.</source><volume>17</volume>, <fpage>998</fpage>&#8211;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0514-8</pub-id><pub-id pub-id-type="pmid">32728199</pub-id><pub-id pub-id-type="pmcid">PMC7387808</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>R. A.</given-names></name></person-group> (<year>20102010</year>). <article-title>Molecular Mechanism of NLRP3 Inflammasome Activation</article-title>. <source>J. Clin. Immunol.</source><volume>30</volume>, <fpage>628</fpage>&#8211;<lpage>631</lpage>. <pub-id pub-id-type="doi">10.1007/S10875-010-9440-3</pub-id><pub-id pub-id-type="pmid">20589420</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juki&#269;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jane&#382;i&#269;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bren</surname><given-names>U.</given-names></name></person-group> (<year>2021</year>). <article-title>Potential Novel Thioether-Amide or Guanidine-Linker Class of SARS-CoV-2 Virus RNA-dependent RNA Polymerase Inhibitors Identified by High-Throughput Virtual Screening Coupled to Free-Energy Calculations</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume>. <pub-id pub-id-type="doi">10.3390/IJMS222011143</pub-id><pub-id pub-id-type="pmcid">PMC8540652</pub-id><pub-id pub-id-type="pmid">34681802</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junqueira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>&#194;.</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lewandrowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ingber</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Lacerda</surname><given-names>L. B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Infects Blood Monocytes to Activate NLRP3 and AIM2 Inflammasomes, Pyroptosis and Cytokine Release</article-title>. <source>Res. Sq.</source><pub-id pub-id-type="doi">10.21203/RS.3.RS-153628/V1</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamitani</surname><given-names>W.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lokugamage</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ikegami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Severe Acute Respiratory Syndrome Coronavirus Nsp1 Protein Suppresses Host Gene Expression by Promoting Host mRNA Degradation</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>103</volume>, <fpage>12885</fpage>&#8211;<lpage>12890</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0603144103</pub-id><pub-id pub-id-type="pmid">16912115</pub-id><pub-id pub-id-type="pmcid">PMC1568942</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Antiviral Signaling through Pattern Recognition Receptors</article-title>. <source>J. Biochem.</source><volume>141</volume>, <fpage>137</fpage>&#8211;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1093/JB/MVM032</pub-id><pub-id pub-id-type="pmid">17190786</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>20102010</year>). <article-title>The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-like Receptors</article-title>. <source>Nat. Immunol.</source><volume>11</volume> (<issue>11</issue>), <fpage>373</fpage>&#8211;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><pub-id pub-id-type="pmid">20404851</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Toll-like Receptor Signaling Pathways</article-title>. <source>Front. Immunol.</source><volume>5</volume>, <fpage>461</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2014.00461/BIBTEX</pub-id><pub-id pub-id-type="pmid">25309543</pub-id><pub-id pub-id-type="pmcid">PMC4174766</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerrigan</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G. D.</given-names></name></person-group> (<year>2010</year>). <article-title>Syk-coupled C-type Lectin Receptors that Mediate Cellular Activation via Single Tyrosine Based Activation Motifs</article-title>. <source>Immunol. Rev.</source><volume>234</volume>, <fpage>335</fpage>&#8211;<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1111/J.0105-2896.2009.00882.X</pub-id><pub-id pub-id-type="pmid">20193029</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shafiei</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Longoria</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schoggins</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Savani</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Spike Protein Induces Inflammation via TLR2-dependent Activation of the NF-&#922;b Pathway</article-title>. <source>Elife</source><volume>10</volume>. <pub-id pub-id-type="doi">10.7554/eLife.68563</pub-id><pub-id pub-id-type="pmcid">PMC8709575</pub-id><pub-id pub-id-type="pmid">34866574</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Effenberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szpirt</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Immunopathogenesis and Treatment of Cytokine Storm in COVID-19</article-title>. <source>Theranostics</source><volume>11</volume>, <fpage>316</fpage>&#8211;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.7150/THNO.49713</pub-id><pub-id pub-id-type="pmid">33391477</pub-id><pub-id pub-id-type="pmcid">PMC7681075</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>N.-E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-K.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.-J.</given-names></name></person-group> (<year>2021b2021</year>). <article-title>SARS-CoV-2 Nonstructural Proteins 1 and 13 Suppress Caspase-1 and the NLRP3 Inflammasome Activation</article-title>. <source>Microorganisms</source><volume>9</volume>, <fpage>494</fpage>. <pub-id pub-id-type="doi">10.3390/MICROORGANISMS9030494</pub-id><pub-id pub-id-type="pmcid">PMC7996899</pub-id><pub-id pub-id-type="pmid">33652815</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Larabee</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>L-SIGN Is a Receptor on Liver Sinusoidal Endothelial Cells for SARS-CoV-2 Virus</article-title>. <source>JCI Insight</source><volume>6</volume>. <pub-id pub-id-type="doi">10.1172/JCI.INSIGHT.148999</pub-id><pub-id pub-id-type="pmcid">PMC8410055</pub-id><pub-id pub-id-type="pmid">34291736</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gohda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Semba</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>TRAF6 Establishes Innate Immune Responses by Activating NF-kappaB and IRF7 upon Sensing Cytosolic Viral RNA and DNA</article-title>. <source>PLoS One</source><volume>4</volume>, <fpage>e5674</fpage>. <pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0005674</pub-id><pub-id pub-id-type="pmid">19479062</pub-id><pub-id pub-id-type="pmcid">PMC2682567</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Uriu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fukushi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koyanagi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant</article-title>. <source>Cell. Rep.</source><volume>32</volume>, <fpage>108185</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2020.108185</pub-id><pub-id pub-id-type="pmid">32941788</pub-id><pub-id pub-id-type="pmcid">PMC7473339</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kucia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bujko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ciechanowicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cymer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sielatycka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ratajczak</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The ACE2 Receptor for COVID-19 Entry Is Expressed on the Surface of Hematopoietic Stem/Progenitor Cells and Endothelial Progenitors as Well as Their Precursor Cells and Becomes Activated in Nlrp3 Inflammasome-dependent Manner by Virus Spike Protein - a Potential Pathway Leading to a "Cytokine Storm"</article-title>. <source>Blood</source><volume>136</volume>, <fpage>8</fpage>. <pub-id pub-id-type="doi">10.1182/BLOOD-2020-137083</pub-id>
32614959</mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>R.</given-names></name><name name-style="western"><surname>Strilets</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lopez-Orozco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fayad</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors</article-title>. <source>J. Virol.</source><volume>95</volume>. <pub-id pub-id-type="doi">10.1128/JVI.00266-21/ASSET/0F4B9D93-FCCC-415C-9A34-B4D699001681/ASSETS/IMAGES/LARGE/JVI.00266-21-F0008.JPG</pub-id><pub-id pub-id-type="pmcid">PMC8316110</pub-id><pub-id pub-id-type="pmid">34110264</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>T. Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Traquina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Development of CpG-Adjuvanted Stable Prefusion SARS-CoV-2 Spike Antigen as a Subunit Vaccine against COVID-19</article-title>. <source>Sci. Rep.</source><volume>10</volume>, <fpage>20085</fpage>&#8211;<lpage>20110</lpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-77077-z</pub-id><pub-id pub-id-type="pmid">33208827</pub-id><pub-id pub-id-type="pmcid">PMC7676267</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacy</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Editorial: Secretion of Cytokines and Chemokines by Innate Immune Cells</article-title>. <source>Front. Immunol.</source><volume>6</volume>, <fpage>1</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2015.00190</pub-id><pub-id pub-id-type="pmid">25954279</pub-id><pub-id pub-id-type="pmcid">PMC4406090</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#228;ssig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hopfner</surname><given-names>K.-P.</given-names></name></person-group> (<year>2017</year>). <article-title>Discrimination of Cytosolic Self and Non-self RNA by RIG-I-like Receptors</article-title>. <source>J. Biol. Chem.</source><volume>292</volume>, <fpage>9000</fpage>&#8211;<lpage>9009</lpage>. <pub-id pub-id-type="doi">10.1074/JBC.R117.788398</pub-id><pub-id pub-id-type="pmid">28411239</pub-id><pub-id pub-id-type="pmcid">PMC5454087</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>Z. R.</given-names></name><name name-style="western"><surname>Schekman</surname><given-names>R.</given-names></name><etal/></person-group> (<year>20132013</year>). <article-title>UNC93B1 Mediates Differential Trafficking of Endosomal TLRs</article-title>. <source>Elife</source><volume>2</volume>. <pub-id pub-id-type="doi">10.7554/ELIFE.00291</pub-id><pub-id pub-id-type="pmcid">PMC3576711</pub-id><pub-id pub-id-type="pmid">23426999</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemaitre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Michaut</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reichhart</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>J. A.</given-names></name></person-group> (<year>1996</year>). <article-title>The Dorsoventral Regulatory Gene Cassette sp&#228;tzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila Adults</article-title>. <source>Cell.</source><volume>86</volume>, <fpage>973</fpage>&#8211;<lpage>983</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80172-5</pub-id><pub-id pub-id-type="pmid">8808632</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lempp</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Soriaga</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Montiel-Ruiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benigni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Noack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.-J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Lectins Enhance SARS-CoV-2 Infection and Influence Neutralizing Antibodies</article-title>. <source>Nature</source><volume>598</volume>, <fpage>342</fpage>&#8211;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03925-1</pub-id><pub-id pub-id-type="pmid">34464958</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonard</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Ghirlando</surname><given-names>R.</given-names></name><name name-style="western"><surname>Askins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Margulies</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>D. R.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>The TLR3 Signaling Complex Forms by Cooperative Receptor Dimerization</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>105</volume>, <fpage>258</fpage>&#8211;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1073/PNAS.0710779105</pub-id><pub-id pub-id-type="pmid">18172197</pub-id><pub-id pub-id-type="pmcid">PMC2224197</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Amarasinghe</surname><given-names>G. K.</given-names></name></person-group> (<year>2012</year>). <article-title>Structural Insights into RNA Recognition and Activation of RIG-I-like Receptors</article-title>. <source>Curr. Opin. Struct. Biol.</source><volume>22</volume>, <fpage>297</fpage>&#8211;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/J.SBI.2012.03.011</pub-id><pub-id pub-id-type="pmid">22560447</pub-id><pub-id pub-id-type="pmcid">PMC3383332</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name></person-group> (<year>20212021</year>). <article-title>Pattern Recognition Receptors in Health and Diseases</article-title>. <source>Sig Transduct. Target Ther.</source><volume>6</volume>, <fpage>1</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1038/s41392-021-00687-0</pub-id><pub-id pub-id-type="pmcid">PMC8333067</pub-id><pub-id pub-id-type="pmid">34344870</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F. F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X. N.</given-names></name><name name-style="western"><surname>He</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Overview of Therapeutic Drug Research for COVID-19 in China</article-title>. <source>Acta Pharmacol. Sin.</source><volume>41</volume>, <fpage>1133</fpage>&#8211;<lpage>1140</lpage>. <pub-id pub-id-type="doi">10.1038/s41401-020-0438-y</pub-id><pub-id pub-id-type="pmid">32555446</pub-id><pub-id pub-id-type="pmcid">PMC7298161</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>The ORF6, ORF8 and Nucleocapsid Proteins of SARS-CoV-2 Inhibit Type I Interferon Signaling Pathway</article-title>. <source>Virus Res.</source><volume>286</volume>, <fpage>198074</fpage>. <pub-id pub-id-type="doi">10.1016/J.VIRUSRES.2020.198074</pub-id><pub-id pub-id-type="pmid">32589897</pub-id><pub-id pub-id-type="pmcid">PMC7309931</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferretti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>B.</given-names></name><name name-style="western"><surname>Descamps</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dittmar</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Pharmacological Activation of STING Blocks SARS-CoV-2 Infection</article-title>. <source>Sci. Immunol.</source><volume>6</volume>. <pub-id pub-id-type="doi">10.1126/SCIIMMUNOL.ABI9007</pub-id><pub-id pub-id-type="pmcid">PMC10021026</pub-id><pub-id pub-id-type="pmid">34010142</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name></person-group> (<year>2020c</year>). <article-title>Bat Origin of a New Human Coronavirus: There and Back Again</article-title>. <source>Sci. China Life Sci.</source><volume>63</volume>, <fpage>461</fpage>&#8211;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1007/s11427-020-1645-7</pub-id><pub-id pub-id-type="pmid">32048160</pub-id><pub-id pub-id-type="pmcid">PMC7088771</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liskova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Samec</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koklesova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Al-Ishaq</surname><given-names>R. K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Flavonoids against the SARS-CoV-2 Induced Inflammatory Storm</article-title>. <source>Biomed. Pharmacother.</source><volume>138</volume>, <fpage>111430</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111430</pub-id><pub-id pub-id-type="pmid">33662680</pub-id><pub-id pub-id-type="pmcid">PMC7906511</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name></person-group> (<year>2021a</year>). <article-title>Potential Treatment with Chinese and Western Medicine Targeting NSP14 of SARS-CoV-2</article-title>. <source>J. Pharm. Anal.</source><volume>11</volume>, <fpage>272</fpage>&#8211;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/J.JPHA.2020.08.002</pub-id><pub-id pub-id-type="pmid">32923004</pub-id><pub-id pub-id-type="pmcid">PMC7476502</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>Z. M.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>van Gent</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021b2021</year>). <article-title>ISG15-dependent Activation of the Sensor MDA5 Is Antagonized by the SARS-CoV-2 Papain-like Protease to Evade Host Innate Immunity</article-title>. <source>Nat. Microbiol.</source><volume>6</volume> (<issue>6</issue>), <fpage>467</fpage>&#8211;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-021-00884-1</pub-id><pub-id pub-id-type="pmcid">PMC8103894</pub-id><pub-id pub-id-type="pmid">33727702</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>T.-Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>CoVac501, a Self-Adjuvanting Peptide Vaccine Conjugated with TLR7 Agonists, against SARS-CoV-2 Induces Protective Immunity</article-title>. <source>Cell. Discov.</source><volume>8</volume> (<issue>8</issue>), <fpage>1</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1038/s41421-021-00370-2</pub-id><pub-id pub-id-type="pmid">35102138</pub-id><pub-id pub-id-type="pmcid">PMC8803929</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gomez Castro</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Exacerbates Proinflammatory Responses in Myeloid Cells through C-type Lectin Receptors and Tweety Family Member 2</article-title>. <source>Immunity</source><volume>54</volume>, <fpage>1304</fpage>&#8211;<lpage>e9</lpage>. <comment>e9</comment>. <pub-id pub-id-type="doi">10.1016/J.IMMUNI.2021.05.006</pub-id><pub-id pub-id-type="pmid">34048708</pub-id><pub-id pub-id-type="pmcid">PMC8106883</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Spike Protein Recognition of Mammalian ACE2 Predicts the Host Range and an Optimized ACE2 for SARS-CoV-2 Infection</article-title>. <source>Biochem. Biophys. Res. Commun.</source><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.03.047</pub-id><pub-id pub-id-type="pmcid">PMC7102515</pub-id><pub-id pub-id-type="pmid">32201080</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludwig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zarbock</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronaviruses and SARS-CoV-2: A Brief Overview</article-title>. <source>Anesth. Analg.</source><volume>131</volume>, <fpage>93</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1213/ANE.0000000000004845</pub-id><pub-id pub-id-type="pmid">32243297</pub-id><pub-id pub-id-type="pmcid">PMC7173023</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luwei</surname><given-names>C. W. L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X. F.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z. F.</given-names></name></person-group> (<year>2020</year>). <article-title>2019-nCoV Transmission through the Ocular Surface Must Not Be Ignored</article-title>. <source>Lancet</source><volume>395</volume>, <fpage>e39</fpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30313-5</pub-id><pub-id pub-id-type="pmid">32035510</pub-id><pub-id pub-id-type="pmcid">PMC7133551</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Nucleocapsid Suppresses Host Pyroptosis by Blocking Gasdermin D Cleavage</article-title>. <source>EMBO J.</source><volume>40</volume>, <fpage>e108249</fpage>. <pub-id pub-id-type="doi">10.15252/EMBJ.2021108249</pub-id><pub-id pub-id-type="pmid">34296442</pub-id><pub-id pub-id-type="pmcid">PMC8420271</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>TLR7 Structure: Cut in Z-Loop</article-title>. <source>Immunity</source><volume>45</volume>, <fpage>705</fpage>&#8211;<lpage>707</lpage>. <pub-id pub-id-type="doi">10.1016/J.IMMUNI.2016.10.003</pub-id><pub-id pub-id-type="pmid">27760331</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R. K.</given-names></name></person-group> (<year>2022</year>). <article-title>Role of Toll-like Receptors in Modulation of Cytokine Storm Signaling in SARS-CoV-2-Induced COVID-19</article-title>. <source>J. Med. Virol.</source><volume>94</volume>, <fpage>869</fpage>&#8211;<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1002/JMV.27405</pub-id><pub-id pub-id-type="pmid">34672376</pub-id><pub-id pub-id-type="pmcid">PMC8662021</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Marchetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mould</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tengesdal</surname><given-names>I. W.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Dinarello</surname><given-names>C. A.</given-names></name></person-group> (<year>2021</year>). <source>Targeting of the NLRP3 Inflammasome for Early COVID-19</source>. <publisher-loc>Cold Spring Harbor, New York</publisher-loc>: <publisher-name>bioRxiv</publisher-name>, <fpage>432734</fpage>. <pub-id pub-id-type="doi">10.1101/2021.02.24.432734</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seya</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>TLR3: Interferon Induction by Double-Stranded RNA Including poly(I:C)</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>60</volume>, <fpage>805</fpage>&#8211;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1016/J.ADDR.2007.11.005</pub-id><pub-id pub-id-type="pmid">18262679</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGettrick</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>O'Neill</surname><given-names>L. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Localisation and Trafficking of Toll-like Receptors: an Important Mode of Regulation</article-title>. <source>Curr. Opin. Immunol.</source><volume>22</volume>, <fpage>20</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/J.COI.2009.12.002</pub-id><pub-id pub-id-type="pmid">20060278</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendon&#231;a</surname><given-names>L.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>20212021</year>). <article-title>Correlative Multi-Scale Cryo-Imaging Unveils SARS-CoV-2 Assembly and Egress</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-24887-y</pub-id><pub-id pub-id-type="pmcid">PMC8324836</pub-id><pub-id pub-id-type="pmid">34330917</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirza</surname><given-names>M. U.</given-names></name><name name-style="western"><surname>Froeyen</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural Elucidation of SARS-CoV-2 Vital Proteins: Computational Methods Reveal Potential Drug Candidates against Main Protease, Nsp12 Polymerase and Nsp13 Helicase</article-title>. <source>J. Pharm. Anal.</source><volume>10</volume>, <fpage>320</fpage>&#8211;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpha.2020.04.008</pub-id><pub-id pub-id-type="pmid">32346490</pub-id><pub-id pub-id-type="pmcid">PMC7187848</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Modrow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Falke</surname><given-names>D.</given-names></name><name name-style="western"><surname>Truyen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <source>Molecular Virology</source>. <publisher-name>Springer-Verlag Berlin Heidelberg</publisher-name>. <pub-id pub-id-type="doi">10.1007/978-3-642-20718-1</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moen</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Ehrnstr&#246;m</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kojen</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Yurchenko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beckwith</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Afset</surname><given-names>J. E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Human Toll-like Receptor 8 (TLR8) Is an Important Sensor of Pyogenic Bacteria, and Is Attenuated by Cell Surface TLR Signaling</article-title>. <source>Front. Immunol.</source><volume>10</volume>, <fpage>1209</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2019.01209/BIBTEX</pub-id><pub-id pub-id-type="pmid">31214180</pub-id><pub-id pub-id-type="pmcid">PMC6554558</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohanty</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Varose</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>U. P.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>M. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Expression of Innate Immune Response Genes in Upper Airway Samples of SARS-CoV-2 Infected Patients: A Preliminary Study</article-title>. <source>Indian J. Med. Res.</source><volume>153</volume>, <fpage>677</fpage>&#8211;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.4103/IJMR.IJMR_131_21</pub-id><pub-id pub-id-type="pmid">34528526</pub-id><pub-id pub-id-type="pmcid">PMC8555587</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monteiro</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Lepenies</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Myeloid C-type Lectin Receptors in Viral Recognition and Antiviral Immunity</article-title>. <source>Viruses</source><volume>9</volume>. <pub-id pub-id-type="doi">10.3390/V9030059</pub-id><pub-id pub-id-type="pmcid">PMC5371814</pub-id><pub-id pub-id-type="pmid">28327518</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-Eutimio</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>L&#243;pez-Mac&#237;as</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pastelin-Palacios</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Bioinformatic Analysis and Identification of Single-Stranded RNA Sequences Recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV Genomes</article-title>. <source>Microbes Infect.</source><volume>22</volume>, <fpage>226</fpage>&#8211;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/J.MICINF.2020.04.009</pub-id><pub-id pub-id-type="pmid">32361001</pub-id><pub-id pub-id-type="pmcid">PMC7192074</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moura</surname><given-names>I. B.</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Wilcox</surname><given-names>M. H.</given-names></name></person-group> (<year>2022</year>). <article-title>Can SARS-CoV-2 Be Transmitted via Faeces?</article-title><source>Curr. Opin. Gastroenterol.</source><volume>38</volume>, <fpage>26</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1097/MOG.0000000000000794</pub-id><pub-id pub-id-type="pmid">34628417</pub-id><pub-id pub-id-type="pmcid">PMC8654121</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz-Wolf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Innate Immune Receptors</article-title>. <source>Methods Mol. Biol.</source><volume>1417</volume>, <fpage>1</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-3566-6_1</pub-id><pub-id pub-id-type="pmid">27221479</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nanishi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Borriello</surname><given-names>F.</given-names></name><name name-style="western"><surname>O&#8217;Meara</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>R. E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An Aluminum hydroxide:CpG Adjuvant Enhances Protection Elicited by a SARS-CoV-2 Receptor-Binding Domain Vaccine in Aged Mice</article-title>. <source>Sci. Transl. Med.</source><volume>14</volume>, <fpage>eabj5305</fpage>. <pub-id pub-id-type="doi">10.1126/SCITRANSLMED.ABJ5305/SUPPL_FILE/SCITRANSLMED.ABJ5305_MDAR_REPRODUCIBILITY_CHECKLIST.ZIP</pub-id><pub-id pub-id-type="pmcid">PMC10176044</pub-id><pub-id pub-id-type="pmid">34783582</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narayanan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Narwal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Majowicz</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Varricchio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Toner</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Ballatore</surname><given-names>C.</given-names></name><etal/></person-group> (<year>20222022</year>). <article-title>Identification of SARS-CoV-2 Inhibitors Targeting Mpro and PLpro Using In-Cell-Protease Assay</article-title>. <source>Commun. Biol.</source><volume>5</volume> (<issue>5</issue>), <fpage>1</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1038/s42003-022-03090-9</pub-id><pub-id pub-id-type="pmcid">PMC8881501</pub-id><pub-id pub-id-type="pmid">35217718</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neufeldt</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Cerikan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frankish</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Plociennikowska</surname><given-names>A.</given-names></name><etal/></person-group> (<year>20222022</year>). <article-title>SARS-CoV-2 Infection Induces a Pro-inflammatory Cytokine Response through cGAS-STING and NF-&#922;b</article-title>. <source>Commun. Biol.</source><volume>5</volume> (<issue>5</issue>), <fpage>1</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/s42003-021-02983-5</pub-id><pub-id pub-id-type="pmcid">PMC8755718</pub-id><pub-id pub-id-type="pmid">35022513</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieva</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>L.</given-names></name></person-group> (<year>20122012</year>). <article-title>Viroporins: Structure and Biological Functions</article-title>. <source>Nat. Rev. Microbiol.</source><volume>10</volume> (<issue>10</issue>), <fpage>563</fpage>&#8211;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2820</pub-id><pub-id pub-id-type="pmcid">PMC7097105</pub-id><pub-id pub-id-type="pmid">22751485</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nukoolkarn</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Malaisree</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aruksakulwong</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hannongbua</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Molecular Dynamic Simulations Analysis of Ritonavir and Lopinavir as SARS-CoV 3CL(pro) Inhibitors</article-title>. <source>J. Theor. Biol.</source><volume>254</volume>, <fpage>861</fpage>&#8211;<lpage>867</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2008.07.030</pub-id><pub-id pub-id-type="pmid">18706430</pub-id><pub-id pub-id-type="pmcid">PMC7094092</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberemok</surname><given-names>V. V.</given-names></name><name name-style="western"><surname>Laikova</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Yurchenko</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Marochkin</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Fomochkina</surname><given-names>I. I.</given-names></name><name name-style="western"><surname>Kubyshkin</surname><given-names>A. V.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Will Constantly Sweep its Tracks: a Vaccine Containing CpG Motifs in 'lasso' for the Multi-Faced Virus</article-title>. <source>Inflamm. Res.</source><volume>69</volume>, <fpage>801</fpage>&#8211;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1007/S00011-020-01377-3/TABLES/2</pub-id><pub-id pub-id-type="pmid">32656668</pub-id><pub-id pub-id-type="pmcid">PMC7354743</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>O. S.</given-names></name></person-group> (<year>20212021</year>). <article-title>SARS-CoV-2 Nucleocapsid Protein Targets RIG-I-like Receptor Pathways to Inhibit the Induction of Interferon Response</article-title>. <source>Cells</source><volume>10</volume>, <fpage>530</fpage>. <pub-id pub-id-type="doi">10.3390/CELLS10030530</pub-id><pub-id pub-id-type="pmcid">PMC7999926</pub-id><pub-id pub-id-type="pmid">33801464</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olajide</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Iwuanyanwu</surname><given-names>V. U.</given-names></name><name name-style="western"><surname>Adegbola</surname><given-names>O. D.</given-names></name><name name-style="western"><surname>Al-Hindawi</surname><given-names>A. A.</given-names></name></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia</article-title>. <source>Mol. Neurobiol.</source><volume>59</volume>, <fpage>445</fpage>&#8211;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1007/S12035-021-02593-6/FIGURES/9</pub-id><pub-id pub-id-type="pmid">34709564</pub-id><pub-id pub-id-type="pmcid">PMC8551352</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oran</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Topol</surname><given-names>E. J.</given-names></name></person-group> (<year>2020</year>). <article-title>Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review</article-title>. <source>Ann. Intern. Med.</source><volume>173</volume>, <fpage>362</fpage>&#8211;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.7326/M20-3012</pub-id><pub-id pub-id-type="pmid">32491919</pub-id><pub-id pub-id-type="pmcid">PMC7281624</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M.</given-names></name><etal/></person-group> (<year>20212021</year>). <article-title>SARS-CoV-2 N Protein Promotes NLRP3 Inflammasome Activation to Induce Hyperinflammation</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>1</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-25015-6</pub-id><pub-id pub-id-type="pmcid">PMC8329225</pub-id><pub-id pub-id-type="pmid">34341353</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rane</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Targeting SARS-CoV-2 Spike Protein of COVID-19 with Naturally Occurring Phytochemicals: an In Silico Study for Drug Development</article-title>. <source>J. Biomol. Struct. Dyn.</source><volume>1&#8211;11</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1796811</pub-id><pub-id pub-id-type="pmcid">PMC7441770</pub-id><pub-id pub-id-type="pmid">32698689</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Chandel</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Selvaraj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jha</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Pegylated Bisacycloxypropylcysteine, a Diacylated Lipopeptide Ligand of TLR6, Plays a Host-Protective Role against Experimental Leishmania Major Infection</article-title>. <source>J. Immunol.</source><volume>193</volume>, <fpage>3632</fpage>&#8211;<lpage>3643</lpage>. <pub-id pub-id-type="doi">10.4049/JIMMUNOL.1400672</pub-id><pub-id pub-id-type="pmid">25194056</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Chamarthi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gupte</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>The Journey of Remdesivir: from Ebola to COVID-19</article-title>. <source>Drugs Context</source><volume>9</volume>. <pub-id pub-id-type="doi">10.7573/dic.2020-4-14</pub-id><pub-id pub-id-type="pmcid">PMC7250494</pub-id><pub-id pub-id-type="pmid">32547625</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Nucleic Acid-Sensing TLRs and Autoimmunity: Novel Insights from Structural and Cell Biology</article-title>. <source>Immunol. Rev.</source><volume>269</volume>, <fpage>60</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/IMR.12375</pub-id><pub-id pub-id-type="pmid">26683145</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Plan&#232;s</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bert</surname><given-names>J.-B.</given-names></name><name name-style="western"><surname>Tairi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benmohamed</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bahraoui</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <source>SARS-CoV-2 Envelope Protein (E) Binds and Activates TLR2: A Novel Target for COVID-19 Interventions</source>. <publisher-loc>Cold Spring Harbor, New York</publisher-loc>: <publisher-name>bioRxiv</publisher-name>. <pub-id pub-id-type="doi">10.1101/2021.11.10.468173</pub-id><pub-id pub-id-type="pmcid">PMC9146335</pub-id><pub-id pub-id-type="pmid">35632741</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poduri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jagadeesh</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Drugs Targeting Various Stages of the SARS-CoV-2 Life Cycle: Exploring Promising Drugs for the Treatment of Covid-19</article-title>. <source>Cell. Signal.</source><volume>74</volume>, <fpage>109721</fpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109721</pub-id><pub-id pub-id-type="pmid">32711111</pub-id><pub-id pub-id-type="pmcid">PMC7375293</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poletti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tirani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cereda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Trentini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guzzetta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sabatino</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Association of Age with Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients with Confirmed SARS-CoV-2 Infection in Italy</article-title>. <source>JAMA Netw. Open</source><volume>4</volume>, <fpage>e211085</fpage>. <pub-id pub-id-type="doi">10.1001/JAMANETWORKOPEN.2021.1085</pub-id><pub-id pub-id-type="pmid">33688964</pub-id><pub-id pub-id-type="pmcid">PMC7948061</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Port</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Yinda</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Avanzato</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><etal/></person-group> (<year>20222022</year>). <article-title>Increased Small Particle Aerosol Transmission of B.1.1.7 Compared with SARS-CoV-2 Lineage A <italic toggle="yes">In Vivo</italic>
</article-title>. <source>Nat. Microbiol.</source><volume>7</volume> (<issue>7</issue>), <fpage>213</fpage>&#8211;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-021-01047-y</pub-id><pub-id pub-id-type="pmcid">PMC11218742</pub-id><pub-id pub-id-type="pmid">35017676</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poulas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Farsalinos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zanidis</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Activation of TLR7 and Innate Immunity as an Efficient Method against COVID-19 Pandemic: Imiquimod as a Potential Therapy</article-title>. <source>Front. Immunol.</source><volume>11</volume>, <fpage>1373</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2020.01373/BIBTEX</pub-id><pub-id pub-id-type="pmid">32612613</pub-id><pub-id pub-id-type="pmcid">PMC7307572</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proud</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Tsitoura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>B. Y.</given-names></name><name name-style="western"><surname>Aram</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Bewley</surname><given-names>K. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Prophylactic Intranasal Administration of a TLR2/6 Agonist Reduces Upper Respiratory Tract Viral Shedding in a SARS-CoV-2 Challenge Ferret Model</article-title>. <source>eBioMedicine</source><volume>63</volume>, <fpage>103153</fpage>. <pub-id pub-id-type="doi">10.1016/J.EBIOM.2020.103153</pub-id><pub-id pub-id-type="pmid">33279857</pub-id><pub-id pub-id-type="pmcid">PMC7711201</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabaan</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Al-Ahmed</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sule</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Tirupathi</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm</article-title>. <source>Vaccines</source><volume>9</volume>, <fpage>436</fpage>. <pub-id pub-id-type="doi">10.3390/VACCINES9050436</pub-id><pub-id pub-id-type="pmid">33946736</pub-id><pub-id pub-id-type="pmcid">PMC8145892</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Raghu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>K. C.</given-names></name></person-group> (<year>2020</year>). <source>COVID-19 Interstitial Pneumonia: Monitoring the Clinical Course in Survivors</source>. <pub-id pub-id-type="doi">10.1016/s2213-2600(20)30349-0</pub-id><pub-id pub-id-type="pmcid">PMC7398671</pub-id><pub-id pub-id-type="pmid">32758440</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimi</surname><given-names>N.</given-names></name></person-group> (<year>20202021</year>). <article-title>C-Type Lectin CD209L/L-SIGN and CD209/DC-SIGN: Cell Adhesion Molecules Turned to Pathogen Recognition Receptors</article-title>. <source>Biology</source><volume>10</volume>, <fpage>1</fpage>. <pub-id pub-id-type="doi">10.3390/BIOLOGY10010001</pub-id><pub-id pub-id-type="pmcid">PMC7822156</pub-id><pub-id pub-id-type="pmid">33375175</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratajczak</surname><given-names>M. Z.</given-names></name><name name-style="western"><surname>Kucia</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Infection and Overactivation of Nlrp3 Inflammasome as a Trigger of Cytokine "storm" and Risk Factor for Damage of Hematopoietic Stem Cells</article-title>. <source>Leukemia</source><volume>34</volume>, <fpage>1726</fpage>&#8211;<lpage>1729</lpage>. <pub-id pub-id-type="doi">10.1038/s41375-020-0887-9</pub-id><pub-id pub-id-type="pmid">32483300</pub-id><pub-id pub-id-type="pmcid">PMC7262681</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rebendenne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaves Valad&#227;o</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Tauziet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maarifi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bonaventure</surname><given-names>B.</given-names></name><name name-style="western"><surname>McKellar</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Triggers an MDA-5-dependent Interferon Response Which Is Unable to Control Replication in Lung Epithelial Cells</article-title>. <source>J. Virol.</source><volume>95</volume>. <pub-id pub-id-type="doi">10.1128/JVI.02415-20/ASSET/6D37141D-124F-4749-A48E-1968D7E81198/ASSETS/20-F0009.JPG</pub-id><pub-id pub-id-type="pmcid">PMC8103705</pub-id><pub-id pub-id-type="pmid">33514628</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redondo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zald&#237;var-L&#243;pez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <fpage>2698</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2021.708264/BIBTEX</pub-id><pub-id pub-id-type="pmcid">PMC8293742</pub-id><pub-id pub-id-type="pmid">34305949</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rehwinkel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gack</surname><given-names>M. U.</given-names></name></person-group> (<year>2020</year>). <article-title>RIG-I-like Receptors: Their Regulation and Roles in RNA Sensing</article-title>. <source>Nat. Rev. Immunol.</source><volume>20</volume>, <fpage>537</fpage>&#8211;<lpage>551</lpage>. <pub-id pub-id-type="doi">10.1038/S41577-020-0288-3</pub-id><pub-id pub-id-type="pmid">32203325</pub-id><pub-id pub-id-type="pmcid">PMC7094958</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Micronucleus Production, Activation of DNA Damage Response and cGAS-STING Signaling in Syncytia Induced by SARS-CoV-2 Infection</article-title>. <source>Biol. Direct</source><volume>16</volume>, <fpage>20</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1186/S13062-021-00305-7/FIGURES/4</pub-id><pub-id pub-id-type="pmid">34674770</pub-id><pub-id pub-id-type="pmcid">PMC8530504</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruggiero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Squeglia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maga</surname><given-names>G.</given-names></name><name name-style="western"><surname>Berisio</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping</article-title>. <source>Cells</source><volume>9</volume>, <fpage>1267</fpage>. <pub-id pub-id-type="doi">10.3390/cells9051267</pub-id><pub-id pub-id-type="pmcid">PMC7291026</pub-id><pub-id pub-id-type="pmid">32443810</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rousseau</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Figueroa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Massaccesi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chattergoon</surname><given-names>M.</given-names></name></person-group> . (<year>2021</year>). <article-title>SARS-CoV-2 ORF3A Activates the Nlrp3 Inflammasome | Topics in Antiviral Medicine</article-title>; <volume>29</volume>(<issue>1</issue>):<fpage>71</fpage>, <year>2021</year>. | <source>EMBASE. Top. Antivir. Med.</source>, <volume>71</volume>. </mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name><etal/></person-group> (<year>20212021</year>). <article-title>Unique and Complementary Suppression of cGAS-STING and RNA Sensing- Triggered Innate Immune Responses by SARS-CoV-2 Proteins</article-title>. <source>Sig Transduct. Target Ther.</source><volume>6</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/s41392-021-00515-5</pub-id><pub-id pub-id-type="pmcid">PMC7958565</pub-id><pub-id pub-id-type="pmid">33723219</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sa Ribero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jouvenet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dreux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nisole</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Interplay between SARS-CoV-2 and the Type I Interferon Response</article-title>. <source>PLoS Pathog.</source><volume>16</volume>, <fpage>e1008737</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1008737</pub-id><pub-id pub-id-type="pmid">32726355</pub-id><pub-id pub-id-type="pmcid">PMC7390284</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H. O.</given-names></name><name name-style="western"><surname>Sozio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schioppa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gaudenzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Laffranchi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2-associated ssRNAs Activate Inflammation and Immunity via TLR7/8</article-title>. <source>JCI Insight</source><volume>6</volume>. <pub-id pub-id-type="doi">10.1172/JCI.INSIGHT.150542</pub-id><pub-id pub-id-type="pmcid">PMC8492321</pub-id><pub-id pub-id-type="pmid">34375313</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santa Cruz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mendes-Frias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>L.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <fpage>263</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2021.613422/BIBTEX</pub-id><pub-id pub-id-type="pmcid">PMC7930905</pub-id><pub-id pub-id-type="pmid">33679753</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sariol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Takes its Toll</article-title>. <source>Nat. Immunol.</source><volume>22</volume>, <fpage>801</fpage>&#8211;<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-021-00962-w</pub-id><pub-id pub-id-type="pmid">34103714</pub-id><pub-id pub-id-type="pmcid">PMC8238877</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>G.</given-names></name></person-group> (<year>20162016</year>). <article-title>Discriminating Self from Non-self in Nucleic Acid Sensing</article-title>. <source>Nat. Rev. Immunol.</source><volume>16</volume>, <fpage>566</fpage>&#8211;<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.78</pub-id><pub-id pub-id-type="pmcid">PMC7097691</pub-id><pub-id pub-id-type="pmid">27455396</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvaraj</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dinesh</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Panwar</surname><given-names>U.</given-names></name><name name-style="western"><surname>Abhirami</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Structure-based Virtual Screening and Molecular Dynamics Simulation of SARS-CoV-2 Guanine-N7 Methyltransferase (Nsp14) for Identifying Antiviral Inhibitors against COVID-19</article-title>. <source>J. Biomol. Struct. Dyn.</source><volume>39</volume>, <fpage>4582</fpage>&#8211;<lpage>4593</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1778535/SUPPL_FILE/TBSD_A_1778535_SM4594.DOCX</pub-id><pub-id pub-id-type="pmid">32567979</pub-id><pub-id pub-id-type="pmcid">PMC7332868</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="book"><collab>Severe Acute Respiratory Syndrome</collab> (<year>2021</year>). <source>Health-Topics</source>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1" ext-link-type="uri">https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1</ext-link> (Accessed March 4, 2022)</comment>. </mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aihara</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Structural Basis of Receptor Recognition by SARS-CoV-2</article-title>. <source>Nature</source><volume>581</volume>, <fpage>221</fpage>&#8211;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2179-y</pub-id><pub-id pub-id-type="pmid">32225175</pub-id><pub-id pub-id-type="pmcid">PMC7328981</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aihara</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Structural Basis of Receptor Recognition by SARS-CoV-2</article-title>. <source>Nature</source><volume>581</volume>, <fpage>221</fpage>&#8211;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2179-y</pub-id><pub-id pub-id-type="pmid">32225175</pub-id><pub-id pub-id-type="pmcid">PMC7328981</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Pruijssers</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Agostini</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice</article-title>. <source>Sci. Transl. Med.</source><volume>12</volume>. <pub-id pub-id-type="doi">10.1126/scitranslmed.abb5883</pub-id><pub-id pub-id-type="pmcid">PMC7164393</pub-id><pub-id pub-id-type="pmid">32253226</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimabukuro-Vornhagen</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#246;del</surname><given-names>P.</given-names></name><name name-style="western"><surname>Subklewe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stemmler</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Schl&#246;&#223;er</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Schlaak</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Cytokine Release Syndrome</article-title>. <source>J. Immunother. Cancer</source><volume>6</volume>, <fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/S40425-018-0343-9</pub-id><pub-id pub-id-type="pmid">29907163</pub-id><pub-id pub-id-type="pmcid">PMC6003181</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>Structural Insights into Ligand Recognition and Regulation of Nucleic Acid-Sensing Toll-like Receptors</article-title>. <source>Curr. Opin. Struct. Biol.</source><volume>47</volume>, <fpage>52</fpage>&#8211;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/J.SBI.2017.05.010</pub-id><pub-id pub-id-type="pmid">28600980</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinkai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morozumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Eguchi-Ogawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Muneta</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Biased Distribution of Single Nucleotide Polymorphisms (SNPs) in Porcine Toll-like Receptor 1 (TLR1), TLR2, TLR4, TLR5, and TLR6 Genes</article-title>. <source>Immunogenetics</source><volume>58</volume>, <fpage>324</fpage>&#8211;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1007/S00251-005-0068-Z/FIGURES/4</pub-id><pub-id pub-id-type="pmid">16604477</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities that Can Be Inhibited by Bismuth Salts</article-title>. <source>Virol. Sin.</source><volume>35</volume>, <fpage>321</fpage>&#8211;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1007/s12250-020-00242-1</pub-id><pub-id pub-id-type="pmid">32500504</pub-id><pub-id pub-id-type="pmcid">PMC7271831</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohn</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling that Mimics Bacterial Sepsis</article-title>. <source>J. Korean Med. Sci.</source><volume>35</volume>, <fpage>e343</fpage>. <pub-id pub-id-type="doi">10.3346/JKMS.2020.35.E343</pub-id><pub-id pub-id-type="pmid">32989935</pub-id><pub-id pub-id-type="pmcid">PMC7521960</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spiering</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>T. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <fpage>756262</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2021.756262</pub-id><pub-id pub-id-type="pmid">34858409</pub-id><pub-id pub-id-type="pmcid">PMC8632002</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>L.</given-names></name><etal/></person-group> (<year>20222021</year>). <article-title>SARS-CoV-2 Non-structural Protein 6 Triggers NLRP3-dependent Pyroptosis by Targeting ATP6AP1</article-title>. <source>Cell. Death Differ.</source><volume>29</volume>, <fpage>1240</fpage>&#8211;<lpage>1254</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-021-00916-7</pub-id><pub-id pub-id-type="pmcid">PMC9177730</pub-id><pub-id pub-id-type="pmid">34997207</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Cytokine Storm Intervention in the Early Stages of COVID-19 Pneumonia</article-title>. <source>Cytokine Growth Factor Rev.</source><volume>53</volume>, <fpage>38</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/J.CYTOGFR.2020.04.002</pub-id><pub-id pub-id-type="pmid">32360420</pub-id><pub-id pub-id-type="pmcid">PMC7182527</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Intracellular Sensors of Immunity and Allogeneic Hematopoietic Stem Cell Transplantation</article-title>. <source>Immune Biol. Allogeneic hematop. Stem Cell. Transpl.</source>, <fpage>425</fpage>&#8211;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-416004-0.00018-5</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Toll-like Receptors in Innate Immunity</article-title>. <source>Int. Immunol.</source><volume>17</volume>, <fpage>1</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1093/INTIMM/DXH186</pub-id><pub-id pub-id-type="pmid">15585605</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Melamed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Politi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yahalom-Ronen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Achdout</surname><given-names>H.</given-names></name><etal/></person-group> (<year>20222022</year>). <article-title>Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection</article-title>. <source>Viruses</source><volume>14</volume>, <fpage>189</fpage>. <comment><italic toggle="yes">Page 189</italic> 14</comment>. <pub-id pub-id-type="doi">10.3390/V14020189</pub-id><pub-id pub-id-type="pmcid">PMC8878863</pub-id><pub-id pub-id-type="pmid">35215785</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Te</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>D. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Mechanism of Action of Ribavirin in the Treatment of Chronic Hepatitis C</article-title>. <source>Gastroenterol. Hepatol. (N Y)</source><volume>3</volume>, <fpage>218</fpage>&#8211;<lpage>225</lpage>. <comment>Available at:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http:///pmc/articles/PMC3099343/?report=abstract" ext-link-type="uri">/pmc/articles/PMC3099343/?report=abstract</ext-link></comment>. (<comment>Accessed September 18, 2020)</comment>. <pub-id pub-id-type="pmid">21960835</pub-id><pub-id pub-id-type="pmcid">PMC3099343</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tellier</surname><given-names>R.</given-names></name></person-group> (<year>2022</year>). <article-title>COVID-19: the Case for Aerosol Transmission</article-title>. <source>Interface Focus</source><volume>12</volume>, <fpage>20210072</fpage>. <pub-id pub-id-type="doi">10.1098/RSFS.2021.0072</pub-id><pub-id pub-id-type="pmid">35261731</pub-id><pub-id pub-id-type="pmcid">PMC8831082</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theobald</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Simonis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Georgomanolis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kreer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zehner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eisfeld</surname><given-names>H. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Long-lived Macrophage Reprogramming Drives Spike Protein-Mediated Inflammasome Activation in COVID-19</article-title>. <source>EMBO Mol. Med.</source><volume>13</volume>, <fpage>e14150</fpage>. <pub-id pub-id-type="doi">10.15252/EMMM.202114150</pub-id><pub-id pub-id-type="pmid">34133077</pub-id><pub-id pub-id-type="pmcid">PMC8350892</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Th&#233;paut</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luczkowiak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Viv&#232;s</surname><given-names>C.</given-names></name><name name-style="western"><surname>Labiod</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bally</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lasala</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>DC/L-SIGN Recognition of Spike Glycoprotein Promotes SARS-CoV-2 Trans-infection and Can Be Inhibited by a Glycomimetic Antagonist</article-title>. <source>PLOS Pathog.</source><volume>17</volume>, <fpage>e1009576</fpage>. <pub-id pub-id-type="doi">10.1371/JOURNAL.PPAT.1009576</pub-id><pub-id pub-id-type="pmid">34015061</pub-id><pub-id pub-id-type="pmcid">PMC8136665</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorne</surname><given-names>L. G.</given-names></name><name name-style="western"><surname>Reuschl</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Zuliani-Alvarez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>M. V. X.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Noursadeghi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Sensing by RIG-I and MDA5 Links Epithelial Infection to Macrophage Inflammation</article-title>. <source>EMBO J.</source><volume>40</volume>, <fpage>e107826</fpage>. <pub-id pub-id-type="doi">10.15252/EMBJ.2021107826</pub-id><pub-id pub-id-type="pmid">34101213</pub-id><pub-id pub-id-type="pmcid">PMC8209947</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tobaiqy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qashqary</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al-Dahery</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mujallad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hershan</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Therapeutic Management of Patients with COVID-19: a Systematic Review</article-title>. <source>Infect. Prev. Pract.</source><volume>2</volume>, <fpage>100061</fpage>. <pub-id pub-id-type="doi">10.1016/j.infpip.2020.100061</pub-id><pub-id pub-id-type="pmid">34316558</pub-id><pub-id pub-id-type="pmcid">PMC7162768</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tugaeva</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>D. E. D. P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J. L. R.</given-names></name><name name-style="western"><surname>Bayfield</surname><given-names>O. W.</given-names></name><name name-style="western"><surname>Ker</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Sysoev</surname><given-names>A. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The Mechanism of SARS-CoV-2 Nucleocapsid Protein Recognition by the Human 14-3-3 Proteins</article-title>. <source>J. Mol. Biol.</source><volume>433</volume>, <fpage>166875</fpage>. <pub-id pub-id-type="doi">10.1016/J.JMB.2021.166875</pub-id><pub-id pub-id-type="pmid">33556408</pub-id><pub-id pub-id-type="pmcid">PMC7863765</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ullrich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nitsche</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>The SARS-CoV-2 Main Protease as Drug Target</article-title>. <source>Bioorg Med. Chem. Lett.</source><volume>30</volume>, <fpage>127377</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127377</pub-id><pub-id pub-id-type="pmid">32738988</pub-id><pub-id pub-id-type="pmcid">PMC7331567</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Gamble</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>B. N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1</article-title>. <source>N. Engl. J. Med.</source><volume>382</volume>, <fpage>1564</fpage>&#8211;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2004973</pub-id><pub-id pub-id-type="pmid">32182409</pub-id><pub-id pub-id-type="pmcid">PMC7121658</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderheiden</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ralfs</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chirkova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Bedoya</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures</article-title>. <source>J. Virol.</source><volume>94</volume>. <pub-id pub-id-type="doi">10.1128/JVI.00985-20</pub-id><pub-id pub-id-type="pmcid">PMC7495371</pub-id><pub-id pub-id-type="pmid">32699094</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidya</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V. G.</given-names></name><name name-style="western"><surname>Sejian</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bagath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bhatta</surname><given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>Toll-like Receptors: Significance, Ligands, Signaling Pathways, and Functions in Mammals</article-title>. <source>Int. Rev. Immunol.</source><volume>37</volume>, <fpage>20</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1080/08830185.2017.1380200</pub-id><pub-id pub-id-type="pmid">29028369</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>H.</given-names></name></person-group> (<year>2004</year>). <article-title>The Immunobiology of the TLR9 Subfamily</article-title>. <source>Trends Immunol.</source><volume>25</volume>, <fpage>381</fpage>&#8211;<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1016/J.IT.2004.04.011</pub-id><pub-id pub-id-type="pmid">15207506</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>Asymptomatic Cases with SARS-CoV-2 Infection</article-title>. <source>J. Med. Virol.</source><volume>92</volume>, <fpage>1401</fpage>&#8211;<lpage>1403</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25990</pub-id><pub-id pub-id-type="pmid">32383171</pub-id><pub-id pub-id-type="pmcid">PMC7267605</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Morin</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Whitby</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Surakattula</surname><given-names>M. M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>TLR4/MD-2 Activation by a Synthetic Agonist with No Similarity to LPS</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>113</volume>, <fpage>E884</fpage>&#8211;<lpage>E893</lpage>. <pub-id pub-id-type="doi">10.1073/PNAS.1525639113/-/DCSUPPLEMENTAL</pub-id><pub-id pub-id-type="pmid">26831104</pub-id><pub-id pub-id-type="pmcid">PMC4763747</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webb</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peckham</surname><given-names>H.</given-names></name><name name-style="western"><surname>Radziszewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oliveri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate with Both X Chromosome Number and Serum Sex Hormone Concentration</article-title>. <source>Front. Immunol.</source><volume>9</volume>, <fpage>3167</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2018.03167/FULL</pub-id><pub-id pub-id-type="pmid">30705679</pub-id><pub-id pub-id-type="pmcid">PMC6345344</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Sleeth</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R. M.</given-names></name></person-group> (<year>2022</year>). <source>Transmission of Respiratory Viral Diseases to Health Care Workers: COVID-19 as an Example</source>. <pub-id pub-id-type="doi">10.1146/ANNUREV-PUBLHEALTH-052120-110009</pub-id><pub-id pub-id-type="pmid">34995130</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods</article-title>. <source>Acta Pharm. Sin. B</source><volume>10</volume>, <fpage>766</fpage>&#8211;<lpage>788</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2020.02.008</pub-id><pub-id pub-id-type="pmid">32292689</pub-id><pub-id pub-id-type="pmcid">PMC7102550</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Dampened STING-dependent Interferon Activation in Bats</article-title>. <source>Cell. Host Microbe</source><volume>23</volume>, <fpage>297</fpage>&#8211;<lpage>e4</lpage>. <comment>e4</comment>. <pub-id pub-id-type="doi">10.1016/J.CHOM.2018.01.006</pub-id><pub-id pub-id-type="pmid">29478775</pub-id><pub-id pub-id-type="pmcid">PMC7104992</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akinyemi</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Chitre</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Loeb</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Lednicky</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>M. T.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 Viroporin Encoded by ORF3a Triggers the NLRP3 Inflammatory Pathway</article-title>. <source>Virology</source><volume>568</volume>, <fpage>13</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/J.VIROL.2022.01.003</pub-id><pub-id pub-id-type="pmid">35066302</pub-id><pub-id pub-id-type="pmcid">PMC8762580</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chitre</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Akinyemi</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Loeb</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Lednicky</surname><given-names>J. A. 4</given-names></name><name name-style="western"><surname>Mcintosh</surname><given-names>M. T.</given-names></name><etal/></person-group> (<year>2020a2020</year>). <article-title>SARS-CoV-2 Viroporin Triggers the NLRP3 Inflammatory Pathway</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.27.35773110.1101/2020.10.27.357731</pub-id><pub-id pub-id-type="pmcid">PMC8762580</pub-id><pub-id pub-id-type="pmid">35066302</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lendlein</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Periodic Thermomechanical Modulation of Toll-like Receptor Expression and Distribution in Mesenchymal Stromal Cells</article-title>. <source>MRS Commun.</source><volume>11</volume>, <fpage>425</fpage>&#8211;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1557/S43579-021-00049-5/FIGURES/3</pub-id><pub-id pub-id-type="pmid">34258101</pub-id><pub-id pub-id-type="pmcid">PMC8265727</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Characteristics of Pediatric SARS-CoV-2 Infection and Potential Evidence for Persistent Fecal Viral Shedding</article-title>. <source>Nat. Med.</source><volume>26</volume>, <fpage>502</fpage>&#8211;<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0817-4</pub-id><pub-id pub-id-type="pmid">32284613</pub-id><pub-id pub-id-type="pmcid">PMC7095102</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Khanra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhamija</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Role of Structural and Non-structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19</article-title>. <source>Cells</source><volume>10</volume>, <fpage>821</fpage>. <pub-id pub-id-type="doi">10.3390/CELLS10040821</pub-id><pub-id pub-id-type="pmid">33917481</pub-id><pub-id pub-id-type="pmcid">PMC8067447</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yalcinkaya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Kotini</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Gusarova</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Fidler</surname><given-names>T. P.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Modulation of the NLRP3 Inflammasome by Sars-CoV-2 Envelope Protein</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>1</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-04133-7</pub-id><pub-id pub-id-type="pmid">34952919</pub-id><pub-id pub-id-type="pmcid">PMC8709866</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Petitjean</surname><given-names>S. J. L.</given-names></name><name name-style="western"><surname>Koehler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dumitru</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Molecular Interaction and Inhibition of SARS-CoV-2 Binding to the ACE2 Receptor</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>4541</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-18319-6</pub-id><pub-id pub-id-type="pmid">32917884</pub-id><pub-id pub-id-type="pmcid">PMC7486399</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group> (<year>20212021</year>). <article-title>The Signal Pathways and Treatment of Cytokine Storm in COVID-19</article-title>. <source>Sig Transduct. Target Ther.</source><volume>6</volume>, <fpage>1</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/s41392-021-00679-0</pub-id><pub-id pub-id-type="pmcid">PMC8261820</pub-id><pub-id pub-id-type="pmid">34234112</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Riva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Martin-Sancho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kanamune</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells</article-title>. <source>Cell. Rep.</source><volume>34</volume>, <fpage>108628</fpage>. <pub-id pub-id-type="doi">10.1016/J.CELREP.2020.108628</pub-id><pub-id pub-id-type="pmid">33440148</pub-id><pub-id pub-id-type="pmcid">PMC7832566</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Sensing Viral Invasion by RIG-I like Receptors</article-title>. <source>Curr. Opin. Microbiol.</source><volume>20</volume>, <fpage>131</fpage>&#8211;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1016/J.MIB.2014.05.011</pub-id><pub-id pub-id-type="pmid">24968321</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fujiogi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koutsogiannaki</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 Pathophysiology: A Review</article-title>. <source>Clin. Immunol.</source><volume>215</volume>, <fpage>108427</fpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2020.108427</pub-id><pub-id pub-id-type="pmid">32325252</pub-id><pub-id pub-id-type="pmcid">PMC7169933</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X. L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Specific Inhibition of the NLRP3 Inflammasome Suppresses Immune Overactivation and Alleviates COVID-19 like Pathology in Mice</article-title>. <source>eBioMedicine</source><volume>75</volume>, <fpage>103803</fpage>. <pub-id pub-id-type="doi">10.1016/J.EBIOM.2021.103803</pub-id><pub-id pub-id-type="pmid">34979342</pub-id><pub-id pub-id-type="pmcid">PMC8719059</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Penninger</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Slutsky</surname><given-names>A. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Angiotensin-converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target</article-title>. <source>Intensive Care Med.</source><volume>46</volume>, <fpage>586</fpage>&#8211;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-05985-9</pub-id><pub-id pub-id-type="pmid">32125455</pub-id><pub-id pub-id-type="pmcid">PMC7079879</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J. Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J. X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Mitochondrial DNA Induces Inflammation and Increases TLR9/NF-&#922;b Expression in Lung Tissue</article-title>. <source>Int. J. Mol. Med.</source><volume>33</volume>, <fpage>817</fpage>&#8211;<lpage>824</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2014.1650</pub-id><pub-id pub-id-type="pmid">24535292</pub-id><pub-id pub-id-type="pmcid">PMC3976143</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC9943536"/></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Inflammation and Antiviral Immune Response Associated with Severe Progression of COVID-19</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <fpage>631226</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2021.631226</pub-id><pub-id pub-id-type="pmid">33679778</pub-id><pub-id pub-id-type="pmcid">PMC7930228</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Raoof</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sursal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Junger</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Circulating Mitochondrial DAMPs Cause Inflammatory Responses to Injury</article-title>. <source>Nature</source><volume>464</volume>, <fpage>104</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1038/nature08780</pub-id><pub-id pub-id-type="pmid">20203610</pub-id><pub-id pub-id-type="pmcid">PMC2843437</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2021b2021</year>). <article-title>Molecular Mechanism of Interaction between SARS-CoV-2 and Host Cells and Interventional Therapy</article-title>. <source>Sig Transduct. Target Ther.</source><volume>6</volume>, <fpage>1</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1038/s41392-021-00653-w</pub-id><pub-id pub-id-type="pmcid">PMC8193598</pub-id><pub-id pub-id-type="pmid">34117216</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>A Cell-Based Assay to Discover Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase</article-title>. <source>Antivir. Res.</source><volume>190</volume>, <fpage>105078</fpage>. <pub-id pub-id-type="doi">10.1016/J.ANTIVIRAL.2021.105078</pub-id><pub-id pub-id-type="pmid">33894278</pub-id><pub-id pub-id-type="pmcid">PMC8059291</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Di</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L. L.</given-names></name></person-group> (<year>2021b</year>). <article-title>The NLRP3 Inflammasome and COVID-19: Activation, Pathogenesis and Therapeutic Strategies</article-title>. <source>Cytokine Growth Factor Rev.</source><volume>61</volume>, <fpage>2</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/J.CYTOGFR.2021.06.002</pub-id><pub-id pub-id-type="pmid">34183243</pub-id><pub-id pub-id-type="pmcid">PMC8233448</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>TLR2 Senses the SARS-CoV-2 Envelope Protein to Produce Inflammatory Cytokines</article-title>. <source>Nat. Immunol.</source><volume>22</volume>, <fpage>829</fpage>&#8211;<lpage>838</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-021-00937-x</pub-id><pub-id pub-id-type="pmid">33963333</pub-id><pub-id pub-id-type="pmcid">PMC8882317</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y. T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name></person-group> (<year>2020a</year>). <article-title>COVID-19 and the Cardiovascular System</article-title>. <source>Nat. Rev. Cardiol.</source><volume>17</volume>, <fpage>259</fpage>&#8211;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1038/s41569-020-0360-5</pub-id><pub-id pub-id-type="pmid">32139904</pub-id><pub-id pub-id-type="pmcid">PMC7095524</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>M.-W.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling</article-title>. <source>Sig Transduct. Target Ther.</source><volume>5</volume> (<issue>5</issue>), <fpage>1</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/s41392-020-00438-7</pub-id><pub-id pub-id-type="pmcid">PMC7768267</pub-id><pub-id pub-id-type="pmid">33372174</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Infection of Bat and Human Intestinal Organoids by SARS-CoV-2</article-title>. <source>Nat. Med.</source><volume>26</volume>, <fpage>1077</fpage>&#8211;<lpage>1083</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0912-6</pub-id><pub-id pub-id-type="pmid">32405028</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C. Z.</given-names></name><name name-style="western"><surname>Gorshkov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>RNA-dependent RNA Polymerase as a Target for COVID-19 Drug Discovery</article-title>. <source>SLAS Discov.</source><volume>25</volume>, <fpage>1141</fpage>&#8211;<lpage>1151</lpage>. <pub-id pub-id-type="doi">10.1177/2472555220942123</pub-id><pub-id pub-id-type="pmid">32660307</pub-id><pub-id pub-id-type="pmcid">PMC7684788</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Regulation and Function of the cGAS-STING Pathway of Cytosolic DNA Sensing</article-title>. <source>Nat. Immunol.</source><volume>17</volume>, <fpage>1142</fpage>&#8211;<lpage>1149</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3558</pub-id><pub-id pub-id-type="pmid">27648547</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>